

Fulminant Myocarditis with Combination Immune Che

New England Journal of Medicine

375, 1749-1755

DOI: [10.1056/nejmoa1609214](https://doi.org/10.1056/nejmoa1609214)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Integrating immunotherapy into chemoradiation regimens for medically inoperable locally advanced non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2007, 6, 113-118.	1.3	13
2	Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade. <i>Cell</i> , 2016, 167, 1540-1554.e12.	13.5	830
5	Myocarditis with Immune Checkpoint Blockade. <i>New England Journal of Medicine</i> , 2017, 376, 290-292.	13.9	41
6	Review: Immune-Related Adverse Events With Use of Checkpoint Inhibitors for Immunotherapy of Cancer. <i>Arthritis and Rheumatology</i> , 2017, 69, 687-699.	2.9	101
7	Medication-associated gastrointestinal tract injury. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 470, 245-266.	1.4	22
9	Cardiovascular Toxicities Associated with Cancer Immunotherapies. <i>Current Cardiology Reports</i> , 2017, 19, 21.	1.3	126
10	Potential of Oncocardiology. <i>JAMA Cardiology</i> , 2017, 2, 817.	3.0	2
11	Potential of Oncocardiology—Reply. <i>JAMA Cardiology</i> , 2017, 2, 818.	3.0	1
12	Immune checkpoint inhibitors in challenging populations. <i>Cancer</i> , 2017, 123, 1904-1911.	2.0	266
13	Biologic response modifiers: Indications, implications, and insights. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 1445-1456.	1.5	25
14	Multicenter Evaluation of the Tolerability of Combined Treatment With PD-1 and CTLA-4 Immune Checkpoint Inhibitors and Palliative Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 344-351.	0.4	143
15	Cardiovascular Complications Associated With Novel Cancer Immunotherapies. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2017, 19, 36.	0.4	75
16	The Role of Biomarkers in Detection of Cardio-toxicity. <i>Current Oncology Reports</i> , 2017, 19, 42.	1.8	19
17	Rare heart risk found with checkpoint inhibitors. <i>Cancer</i> , 2017, 123, 1483-1484.	2.0	0
18	Cancer in Solid Organ Transplant Recipients: There Is Still Much to Learn and Do. <i>American Journal of Transplantation</i> , 2017, 17, 1967-1969.	2.6	15
19	Age at cancer diagnosis may influence risk of heart disease death. <i>Cancer</i> , 2017, 123, 1484-1485.	2.0	0
20	Rheumatic immune-related adverse events of checkpoint therapy for cancer: case series of a new nosological entity. <i>RMD Open</i> , 2017, 3, e000412.	1.8	161
21	Immune checkpoint inhibitors in lung cancer: an update. <i>Future Oncology</i> , 2017, 13, 955-959.	1.1	6

#	ARTICLE	IF	CITATIONS
22	Immune-related fulminant myocarditis in a patient receiving ipilimumab therapy for relapsed chronic myelomonocytic leukaemia. <i>European Journal of Heart Failure</i> , 2017, 19, 682-685.	2.9	39
23	Second-line therapy of squamous non-small cell lung cancer: an evolving landscape. <i>Expert Review of Respiratory Medicine</i> , 2017, 11, 469-479.	1.0	11
24	Role of modern immunotherapy in gastrointestinal malignancies: a review of current clinical progress. <i>Journal of Hematology and Oncology</i> , 2017, 10, 86.	6.9	64
25	Is autoimmunity the Achilles' heel of cancer immunotherapy?. <i>Nature Medicine</i> , 2017, 23, 540-547.	15.2	367
26	Immune checkpoint-associated cardiotoxicity: case report with systematic review of literature. <i>Annals of Oncology</i> , 2017, 28, 2034-2038.	0.6	25
30	The Era of Checkpoint Blockade in Lung Cancer: Taking the Brakes Off the Immune System. <i>Annals of the American Thoracic Society</i> , 2017, 14, 1248-1260.	1.5	15
31	Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions. <i>Cancer Treatment Reviews</i> , 2017, 57, 36-49.	3.4	257
32	Myocarditis: A Clinical Overview. <i>Current Cardiology Reports</i> , 2017, 19, 63.	1.3	72
33	Severe Ocular Myositis After Ipilimumab Treatment for Melanoma: A Report of 2 Cases. <i>Journal of Immunotherapy</i> , 2017, 40, 282-285.	1.2	28
34	Immune checkpoint proteins: exploring their therapeutic potential to regulate atherosclerosis. <i>British Journal of Pharmacology</i> , 2017, 174, 3940-3955.	2.7	48
35	Cardiac Complications of Cancer Therapy: Pathophysiology, Identification, Prevention, Treatment, and Future Directions. <i>Current Cardiology Reports</i> , 2017, 19, 36.	1.3	72
36	Releasing the brake: safety profile of immune check-point inhibitors in non-small cell lung cancer. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 573-585.	1.0	21
37	Pharmacogenomics of off-target adverse drug reactions. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 1896-1911.	1.1	48
39	Novel agents in classical Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2017, 58, 2275-2286.	0.6	14
40	Radiation and Immune Checkpoint Blockade: From Bench to Clinic. <i>Seminars in Radiation Oncology</i> , 2017, 27, 289-298.	1.0	39
41	Autoimmune Cardiotoxicity of Cancer Immunotherapy. <i>Trends in Immunology</i> , 2017, 38, 77-78.	2.9	32
42	Atypical autoimmune adverse effects with checkpoint blockade therapies. <i>Annals of Oncology</i> , 2017, 28, 206-207.	0.6	11
43	Immune Interventions to Eliminate the HIV Reservoir. <i>Current Topics in Microbiology and Immunology</i> , 2017, 417, 181-210.	0.7	4

#	ARTICLE	IF	CITATIONS
44	Severe Delayed Drug Reactions. <i>Immunology and Allergy Clinics of North America</i> , 2017, 37, 785-815.	0.7	27
45	Pharmacovigilance Assessment of Immune-Mediated Reactions Reported for Checkpoint Inhibitor Cancer Immunotherapies. <i>Pharmacotherapy</i> , 2017, 37, 1383-1390.	1.2	33
47	Small-Molecule Targets in Immuno-Oncology. <i>Cell Chemical Biology</i> , 2017, 24, 1148-1160.	2.5	44
48	Acute Oncology Care: A narrative review of the acute management of neutropenic sepsis and immune-related toxicities of checkpoint inhibitors. <i>European Journal of Internal Medicine</i> , 2017, 45, 59-65.	1.0	20
49	Early diagnosis of acute coronary syndrome. <i>European Heart Journal</i> , 2017, 38, 3049-3055.	1.0	50
50	Inflammatory gastrointestinal diseases associated with PD-1 blockade antibodies. <i>Annals of Oncology</i> , 2017, 28, 2860-2865.	0.6	115
51	Local Immunotherapy of Cancer: Innovative Approaches to Harnessing Tumor-Specific Immune Responses. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	3.0	31
53	Inflammatory Cardiomyopathic Syndromes. <i>Circulation Research</i> , 2017, 121, 803-818.	2.0	213
54	PD-1 checkpoint inhibition: Toxicities and management. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 701-707.	0.8	57
55	High-dose interleukin-2 (IL-2) for the treatment of melanoma: safety considerations and future directions. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 1347-1357.	1.0	60
56	Unraveling Vascular Inflammation. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1403-1412.	1.2	59
57	Survival After Fulminant Myocarditis Induced by Immune-Checkpoint Inhibitors. <i>Annals of Internal Medicine</i> , 2017, 167, 683.	2.0	60
58	<sc>PD</sc>-1</sc> and <sc>CTLA</sc>-1 inhibitors in haematological malignancies: update 2017. <i>Immunology</i> , 2017, 152, 357-371.	2.0	108
59	Progressive and Reversible Conduction Disease With Checkpoint Inhibitors. <i>Canadian Journal of Cardiology</i> , 2017, 33, 1335.e13-1335.e15.	0.8	46
61	Is Disease-Specific Immunotherapy a Potential Reality for MDS?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S26-S30.	0.2	5
62	A Case of Heart Failure after Treatment with Anti-PD-1 Antibody Followed by Adoptive Transfer of Cytokine-Activated Killer Cells in a Recurrent Lung Cancer Patient. <i>Journal of Thoracic Oncology</i> , 2017, 12, e128-e130.	0.5	6
63	A review of serious adverse effects under treatment with checkpoint inhibitors. <i>Current Opinion in Oncology</i> , 2017, 29, 136-144.	1.1	56
64	Hepatitis B cure: From discovery to regulatory approval. <i>Journal of Hepatology</i> , 2017, 67, 847-861.	1.8	189

#	ARTICLE	IF	CITATIONS
65	Hepatitis B cure: From discovery to regulatory approval. <i>Hepatology</i> , 2017, 66, 1296-1313.	3.6	235
66	Lung cancer as a cardiotoxic state: a review. <i>Medical Oncology</i> , 2017, 34, 159.	1.2	12
67	Immunotherapy in Non-Small Cell Lung Cancer Treatment. <i>Journal of Thoracic Imaging</i> , 2017, 32, 300-312.	0.8	47
68	Successful use of equine anti-thymocyte globulin (ATGAM) for fulminant myocarditis secondary to nivolumab therapy. <i>British Journal of Cancer</i> , 2017, 117, 921-924.	2.9	81
69	Polymyositis induced by PD-1 blockade in a patient in hepatitis B remission. <i>Journal of the Neurological Sciences</i> , 2017, 381, 22-24.	0.3	4
70	Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. <i>Neurology</i> , 2017, 89, 1127-1134.	1.5	312
71	Cardiogenic shock in a patient being treated with atezolizumab for metastatic non-small cell lung cancer. <i>Lung Cancer</i> , 2017, 114, 106-107.	0.9	8
72	Comparative immunologic characterization of autoimmune giant cell myocarditis with ipilimumab. <i>Oncolimmunology</i> , 2017, 6, e1361097.	2.1	50
73	Regulatory T cells control toxicity in a humanized model of IL-2 therapy. <i>Nature Communications</i> , 2017, 8, 1762.	5.8	40
74	Liver immunotolerance and hepatocellular carcinoma: Patho-physiological mechanisms and therapeutic perspectives. <i>European Journal of Cancer</i> , 2017, 87, 101-112.	1.3	56
75	Cardiac Toxicity of Immune Checkpoint Inhibitors. <i>Circulation</i> , 2017, 136, 1989-1992.	1.6	83
76	Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor-Related Cardiotoxicity. <i>Circulation</i> , 2017, 136, 2085-2087.	1.6	364
77	Targeting Retired Antigens for Cancer Immunoprevention. <i>Cancer Prevention Research</i> , 2017, 10, 607-608.	0.7	3
78	Cardiotoxicity of immune checkpoint inhibitors. <i>ESMO Open</i> , 2017, 2, e000247.	2.0	186
79	A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy. <i>Nature</i> , 2017, 551, 517-520.	13.7	532
80	Complications of Emerging Oncology Therapies Requiring Treatment in the Pediatric Intensive Care Unit. <i>Current Pediatrics Reports</i> , 2017, 5, 220-227.	1.7	0
81	Chemotherapy-induced cardiotoxicity in children. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 817-832.	1.5	57
82	Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2017, 28, iv119-iv142.	0.6	1,744

#	ARTICLE	IF	CITATIONS
84	The safety of nivolumab for the treatment of metastatic melanoma. Expert Opinion on Drug Safety, 2017, 16, 955-961.	1.0	7
85	Acute coronary syndrome as a possible immune-related adverse event in a lung cancer patient achieving a complete response to anti-PD-1 immune checkpoint antibody. Annals of Oncology, 2017, 28, 2893-2895.	0.6	55
86	The second wave of immune checkpoint inhibitor tsunami: advance, challenges and perspectives. Immunotherapy, 2017, 9, 647-657.	1.0	19
87	The evolving role of targeted drugs in the treatment of Hodgkin lymphoma. Expert Review of Hematology, 2017, 10, 775-782.	1.0	6
88	Winning the battle, but losing the war: mechanisms and morphology of cancer-therapy-associated cardiovascular toxicity. Cardiovascular Pathology, 2017, 30, 55-63.	0.7	31
89	Les complications de l'immunothérapie. Revue Des Maladies Respiratoires Actualites, 2017, 9, 325-331.	0.0	1
91	Management and Supportive Care of Patients Undergoing Immunotherapy. , 2017, , .		0
92	Ipilimumab-nivolumab therapy causing STEMI in a melanoma patient: A case report. Case Reports in Internal Medicine, 2017, 4, 57.	0.0	0
93	The Multi-Purpose Tool of Tumor Immunotherapy: Gene-Engineered T Cells. Journal of Cancer, 2017, 8, 1690-1703.	1.2	17
94	Clinical features, predictive correlates, and pathophysiology of immune-related adverse events in immune checkpoint inhibitor treatments in cancer: a short review. ImmunoTargets and Therapy, 2017, Volume 6, 73-82.	2.7	121
95	Fulminant Myocarditis Managed by Extracorporeal Life Support (Impella® CP): A Rare Case. Case Reports in Cardiology, 2017, 2017, 1-4.	0.1	14
96	Smoldering myocarditis following immune checkpoint blockade. , 2017, 5, 91.		147
97	Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. , 2017, 5, 95.		1,460
98	Evaluation of rare but severe immune related adverse effects in PD-1 and PD-L1 inhibitors in non-small cell lung cancer: a meta-analysis. Translational Lung Cancer Research, 2017, 6, S8-S20.	1.3	97
99	Developing a comprehensive Cardio-Oncology Program at a Cancer Institute: the Moffitt Cancer Center experience. Oncology Reviews, 2017, 11, 340.	0.8	37
100	Spotlight on nivolumab in the treatment of renal cell carcinoma: design, development, and place in therapy. Drug Design, Development and Therapy, 2017, Volume11, 1175-1182.	2.0	14
101	Immune Checkpoint Inhibitors in the Cancer Patient with An Organ Transplant. Journal of Onco-Nephrology, 2017, 1, 42-48.	0.3	21
102	Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma. Journal of Clinical Oncology, 2017, 35, 3815-3822.	0.8	244

#	ARTICLE	IF	CITATIONS
103	Emerging treatment options for the management of Hodgkin's lymphoma: clinical utility of Nivolumab. <i>Journal of Blood Medicine</i> , 2017, Volume 8, 41-54.	0.7	5
104	In situ formed reactive oxygen species-responsive scaffold with gemcitabine and checkpoint inhibitor for combination therapy. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	439
105	Quantitative Analysis of Immune Infiltrates in Primary Melanoma. <i>Cancer Immunology Research</i> , 2018, 6, 481-493.	1.6	92
106	Histopathological and immunophenotypic features of ipilimumab-associated colitis compared to ulcerative colitis. <i>Journal of Internal Medicine</i> , 2018, 283, 568-577.	2.7	78
107	Immunotherapy in Lung Cancer and the Role of Imaging. <i>Seminars in Ultrasound, CT and MRI</i> , 2018, 39, 314-321.	0.7	4
108	Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial. <i>Lancet Oncology</i> , The, 2018, 19, 451-460.	5.1	228
109	Immune Checkpoint Inhibitors: Game Changing Cancer Therapy With a Cardiac Cost. What Are the Mechanisms and Unresolved Questions in Cardiotoxicity?. <i>Canadian Journal of Cardiology</i> , 2018, 34, 970-971.	0.8	1
110	Immunotherapy and the role of imaging. <i>Cancer</i> , 2018, 124, 2906-2922.	2.0	63
111	"No pain, No gain" still true with immunotherapy: When the finger shows the moon, look at the moon!. <i>Critical Reviews in Oncology/Hematology</i> , 2018, 127, 1-5.	2.0	4
112	Cardioprotection in the Modern Era of Cancer Chemotherapy. <i>Cardiology in Review</i> , 2018, 26, 113-121.	0.6	9
113	Targeted Therapy and Immunotherapy in the Treatment of Non-Small Cell Lung Cancer. <i>Radiologic Clinics of North America</i> , 2018, 56, 485-495.	0.9	61
114	Clinical assessment of immune-related adverse events. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591876462.	1.4	101
115	Science and biology drives the immune system to cure lung cancer patients: a revolution but not without challenges. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591876372.	1.4	3
116	Seronegative antibody-mediated neurology after immune checkpoint inhibitors. <i>Annals of Clinical and Translational Neurology</i> , 2018, 5, 640-645.	1.7	54
117	Cardiotoxicity of Immunotherapy: Incidence, Diagnosis, and Management. <i>Current Oncology Reports</i> , 2018, 20, 44.	1.8	53
118	Electrophysiologic Toxicity of Chemoradiation. <i>Current Oncology Reports</i> , 2018, 20, 45.	1.8	18
119	Anti-PD1 associated fulminant myocarditis after a single pembrolizumab dose: the role of occult pre-existing autoimmunity. <i>Haematologica</i> , 2018, 103, e318-e321.	1.7	50
120	Molecular signatures of circulating melanoma cells for monitoring early response to immune checkpoint therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 2467-2472.	3.3	131

#	ARTICLE	IF	CITATIONS
121	Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study. <i>Lancet Oncology</i> , The, 2018, 19, 347-355.	5.1	290
122	Nivolumab-induced myositis: A case report and a literature review. <i>Journal of the Neurological Sciences</i> , 2018, 387, 51-53.	0.3	31
123	Success of rechallenging dabrafenib and trametinib combination therapy after trametinib-induced rhabdomyolysis: a case report. <i>Melanoma Research</i> , 2018, 28, 151-154.	0.6	11
124	Common Cardiovascular Complications of Cancer Therapy: Epidemiology, Risk Prediction, and Prevention. <i>Annual Review of Medicine</i> , 2018, 69, 97-111.	5.0	31
125	Biomarkers for immune-related toxicities of checkpoint inhibitors: current progress and the road ahead. <i>Expert Review of Molecular Diagnostics</i> , 2018, 18, 297-305.	1.5	23
126	Toxicities Associated With PD-1/PD-L1 Blockade. <i>Cancer Journal (Sudbury, Mass)</i> , 2018, 24, 36-40.	1.0	72
127	Combination Strategies PD-1/PD-L1 Antagonists. <i>Cancer Journal (Sudbury, Mass)</i> , 2018, 24, 54-57.	1.0	1
128	Immune Checkpoint Inhibitor-Associated Myocarditis: A New Challenge for Cardiologists. <i>Canadian Journal of Cardiology</i> , 2018, 34, 92.e1-92.e3.	0.8	71
129	The Clinical Presentation, Survival Outcomes, and Management of Patients With Renal Cell Carcinoma and Cardiac Metastasis Without Inferior Vena Cava Involvement: Results From a Pooled Clinical Trial Database and Systematic Review of Reported Cases. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e327-e333.	0.9	12
130	Left Ventricular Dysfunction in Cancer Treatment. <i>JACC: Heart Failure</i> , 2018, 6, 87-95.	1.9	37
131	PD-1 Modulates Radiation-Induced Cardiac Toxicity through Cytotoxic T Lymphocytes. <i>Journal of Thoracic Oncology</i> , 2018, 13, 510-520.	0.5	77
132	Potential cardiac risk of immune checkpoint blockade as anticancer treatment: What we know, what we do not know, and what we can do to prevent adverse effects. <i>Medicinal Research Reviews</i> , 2018, 38, 1447-1468.	5.0	27
133	Exploring immune checkpoints as potential therapeutic targets in atherosclerosis. <i>Cardiovascular Research</i> , 2018, 114, 368-377.	1.8	64
134	Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. <i>New England Journal of Medicine</i> , 2018, 378, 158-168.	13.9	3,047
135	Fever reaction and haemophagocytic syndrome induced by immune checkpoint inhibitors. <i>Annals of Oncology</i> , 2018, 29, 518-520.	0.6	22
136	Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis. <i>BMJ: British Medical Journal</i> , 2018, 360, k793.	2.4	438
137	Incidence and outcomes of cancer treatment-related cardiomyopathy among referrals for advanced heart failure. <i>Cardio-Oncology</i> , 2018, 4, 3.	0.8	9
138	<i>In Silico</i> Pharmacoeconomic Evaluation of Drug-Induced Cardiovascular Complications Using Combined Classifiers. <i>Journal of Chemical Information and Modeling</i> , 2018, 58, 943-956.	2.5	37

#	ARTICLE	IF	CITATIONS
139	Cardiovascular Risk in Cancer Survivors. Current Treatment Options in Cardiovascular Medicine, 2018, 20, 47.	0.4	13
140	Anticancer drug-induced cardiac rhythm disorders: Current knowledge and basic underlying mechanisms. , 2018, 189, 89-103.		101
141	Cardiac Complications Associated With Checkpoint Inhibition: A Systematic Review of the Literature in an Important Emerging Area. Canadian Journal of Cardiology, 2018, 34, 1059-1068.	0.8	95
142	Immunotherapy for metastatic urothelial carcinoma: putting the brakes on releasing the brake. Immunotherapy, 2018, 10, 423-425.	1.0	1
143	Expression and Targeting of Tumor Markers in Gelfoam® Histoculture: Potential Individualized Assays for Immuno-Oncology. Methods in Molecular Biology, 2018, 1760, 29-37.	0.4	0
144	Myocarditis in Patients Treated With Immune Checkpoint Inhibitors. Journal of the American College of Cardiology, 2018, 71, 1755-1764.	1.2	997
145	Cardiac Toxicity in Patients Treated With Immune Checkpoint Inhibitors. Journal of the American College of Cardiology, 2018, 71, 1765-1767.	1.2	49
146	Serial Troponin for Early Detection of Nivolumab Cardiotoxicity in Advanced Non-Small Cell Lung Cancer Patients. Oncologist, 2018, 23, 936-942.	1.9	69
147	Late-Onset Fulminant Myocarditis With Immune Checkpoint Inhibitor Nivolumab. Canadian Journal of Cardiology, 2018, 34, 812.e1-812.e3.	0.8	57
148	Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 310-320.	2.3	476
149	Takotsubo-Like Syndrome in Cancer Patients Treated With Immune Checkpoint Inhibitors. JACC: Cardiovascular Imaging, 2018, 11, 1187-1190.	2.3	82
150	Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet, The, 2018, 391, 933.	6.3	618
151	Combination Strategies on the Basis of Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer: Where Do We Stand?. Clinical Lung Cancer, 2018, 19, 1-11.	1.1	48
152	Toxicity profiles of immunotherapy. , 2018, 181, 91-100.		55
153	Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma. Annals of Oncology, 2018, 29, 250-255.	0.6	304
154	Immune checkpoint inhibitor-related myocarditis. Japanese Journal of Clinical Oncology, 2018, 48, 7-12.	0.6	57
155	Life-threatening Autoimmune Cardiomyopathy Reproducibly Induced in a Patient by Checkpoint Inhibitor Therapy. Journal of Immunotherapy, 2018, 41, 35-38.	1.2	58
156	Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy. Annals of Oncology, 2018, 29, 71-83.	0.6	253

#	ARTICLE	IF	CITATIONS
157	The T cell repertoire in tumors overlaps with pulmonary inflammatory lesions in patients treated with checkpoint inhibitors. <i>Oncolmunology</i> , 2018, 7, e1386362.	2.1	62
158	ESC position paper on cardiovascular toxicity of cancer treatments: challenges and expectations. <i>Internal and Emergency Medicine</i> , 2018, 13, 1-9.	1.0	21
159	Myeloid-derived Suppressor Cells Are Necessary for Development of Pulmonary Hypertension. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2018, 58, 170-180.	1.4	35
160	Fatal Myocarditis Following Treatment with the <sc>PD</sc> Inhibitor Nivolumab. <i>Journal of Forensic Sciences</i> , 2018, 63, 954-957.	0.9	59
161	Emerging biomarkers for cancer immunotherapy in melanoma. <i>Seminars in Cancer Biology</i> , 2018, 52, 207-215.	4.3	42
162	The evolving role of the rheumatologist in the management of immune-related adverse events (irAEs) caused by cancer immunotherapy. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 162-164.	0.5	39
163	Implications of the tumor immune microenvironment for staging and therapeutics. <i>Modern Pathology</i> , 2018, 31, 214-234.	2.9	278
164	Hodgkin lymphoma: A review and update on recent progress. <i>Ca-A Cancer Journal for Clinicians</i> , 2018, 68, 116-132.	157.7	315
165	PD-L1 Prevents the Development of Autoimmune Heart Disease in Graft-versus-Host Disease. <i>Journal of Immunology</i> , 2018, 200, 834-846.	0.4	23
166	CTLA-4: a moving target in immunotherapy. <i>Blood</i> , 2018, 131, 58-67.	0.6	704
167	PD-1-PD-L1 immune-checkpoint blockade in malignant lymphomas. <i>Annals of Hematology</i> , 2018, 97, 229-237.	0.8	44
168	Fatal myocarditis and rhabdomyolysis induced by nivolumab during the treatment of type B3 thymoma. <i>Clinical Toxicology</i> , 2018, 56, 667-671.	0.8	49
169	Rheumatologic symptoms in oncologic patients on PD-1 inhibitors. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 47, 907-910.	1.6	45
170	Hepatitis is the new myositis: immune checkpoint inhibitor-induced myositis. <i>Melanoma Research</i> , 2018, 28, 484-485.	0.6	7
171	Challenging Cases: Management of Immune-Related Toxicity. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 179-183.	1.8	7
172	Checkpoint inhibitor-associated autoimmunity. <i>Best Practice and Research in Clinical Rheumatology</i> , 2018, 32, 781-802.	1.4	13
173	ClinicalTrials.gov for Facilitating Rapid Understanding of Potential Harms of New Drugs: The Case of Checkpoint Inhibitors. <i>Journal of Oncology Practice</i> , 2018, 14, 72-76.	2.5	8
174	Cardiac Toxicities in the Era of Precision Medicine: Underlying Risk Factors, Targeted Therapies, and Cardiac Biomarkers. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 764-774.	1.8	18

#	ARTICLE	IF	CITATIONS
175	Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2018, 36, 1714-1768.	0.8	2,691
176	Myocarditis With Radiotherapy and Immunotherapy in Multiple Myeloma. <i>Journal of Oncology Practice</i> , 2018, 14, 561-564.	2.5	8
177	Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma. <i>Journal of Clinical Oncology</i> , 2018, 36, 1658-1667.	0.8	483
178	Cardiovascular Disease in Survivors of Childhood Cancer: Insights Into Epidemiology, Pathophysiology, and Prevention. <i>Journal of Clinical Oncology</i> , 2018, 36, 2135-2144.	0.8	139
179	Cardio-toxicity of checkpoint inhibitors. <i>Journal of Thoracic Disease</i> , 2018, 10, S4400-S4404.	0.6	19
180	Immune checkpoint blockade for advanced non-small cell lung cancer: challenging clinical scenarios. <i>Journal of Thoracic Disease</i> , 2018, 10, S1494-S1502.	0.6	12
181	Heart failure in cancer: role of checkpoint inhibitors. <i>Journal of Thoracic Disease</i> , 2018, 10, S4323-S4334.	0.6	15
182	Autoimmune Myocarditis Caused by Immune Checkpoint Inhibitors Treated With Antithymocyte Globulin. <i>Journal of Immunotherapy</i> , 2018, 41, 332-335.	1.2	68
183	Identifying and managing the adverse effects of immune checkpoint blockade. <i>Journal of Thoracic Disease</i> , 2018, 10, S480-S489.	0.6	78
184	Biomarkers for the detection of apparent and subclinical cancer therapy-related cardiotoxicity. <i>Journal of Thoracic Disease</i> , 2018, 10, S4282-S4295.	0.6	69
185	Rare Case of Intracardiac Renal Cell Carcinoma Metastasis with Response to Nivolumab: Case Report and Literature Review. <i>Case Reports in Oncology</i> , 2018, 11, 861-870.	0.3	11
186	Prognostic significance of tumor immune microenvironment and immunotherapy: Novel insights and future perspectives in gastric cancer. <i>World Journal of Gastroenterology</i> , 2018, 24, 3583-3616.	1.4	118
187	Arterial events in cancer patients—the case of acute coronary thrombosis. <i>Journal of Thoracic Disease</i> , 2018, 10, S4367-S4385.	0.6	31
188	Immune checkpoint inhibitor-induced lymphocytic fasciitis. <i>Internal Medicine Journal</i> , 2018, 48, 1550-1552.	0.5	7
189	New drugs and new toxicities: pembrolizumab-induced myocarditis. <i>BMJ Case Reports</i> , 2018, 2018, bcr-2017-223252.	0.2	19
190	OBSOLETE: Stage A Heart Failure: Identification and Management of Heart Failure Risk Factors. , 2018, , .		0
191	Nivolumab-Induced Fatal Fulminant Myocarditis Presenting as Complete Heart Block in a Patient With Metastatic Renal Cell Carcinoma. <i>Heart Lung and Circulation</i> , 2018, 27, S114-S115.	0.2	0
192	Cardiovascular oncology: exploring the effects of targeted cancer therapies on atherosclerosis. <i>Current Opinion in Lipidology</i> , 2018, 29, 381-388.	1.2	8

#	ARTICLE	IF	CITATIONS
193	Neuromuscular complications of immune checkpoint inhibitors. <i>Presse Medicale</i> , 2018, 47, e253-e259.	0.8	28
194	Reinforce the antitumor activity of CD8 ⁺ T cells via glutamine restriction. <i>Cancer Science</i> , 2018, 109, 3737-3750.	1.7	109
195	Autoimmune Neuromuscular Diseases Induced by Immunomodulating Drugs. <i>Journal of Clinical Neuromuscular Disease</i> , 2018, 20, 28-34.	0.3	3
196	Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. <i>Lancet Oncology</i> , The, 2018, 19, 1579-1589.	5.1	742
197	Pharmacovigilating cardiotoxicity of immune checkpoint inhibitors. <i>Lancet Oncology</i> , The, 2018, 19, 1545-1546.	5.1	16
198	Incidence of Cancer Treatment-Induced Arrhythmia Associated With Novel Targeted Chemotherapeutic Agents. <i>Journal of the American Heart Association</i> , 2018, 7, e010101.	1.6	12
199	Fulminant myocarditis: Characteristics, treatment, and outcomes. <i>Anatolian Journal of Cardiology</i> , 2018, 19, 279-286.	0.5	55
200	Aptamers: novelty tools for cancer biology. <i>Oncotarget</i> , 2018, 9, 26934-26953.	0.8	34
201	Unmet Needs and Therapeutic Strategies in Cardio-Hemato-Oncology. <i>Acta Haematologica</i> , 2018, 140, 226-230.	0.7	4
202	Modern-day cardio-oncology: a report from the Heart Failure and World Congress on Acute Heart Failure 2018™. <i>ESC Heart Failure</i> , 2018, 5, 1083-1091.	1.4	23
204	Myocarditis in a patient treated with Nivolumab and PROSTVAC: a case report. , 2018, 6, 150.		27
205	Progresses and Perspectives of Anti-PD-1/PD-L1 Antibody Therapy in Head and Neck Cancers. <i>Frontiers in Oncology</i> , 2018, 8, 563.	1.3	35
206	Granulomatous myositis induced by anti-PD-1 monoclonal antibodies. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2018, 5, .	3.1	13
207	Cardio-oncology: A Focus on Cardiotoxicity. <i>European Cardiology Review</i> , 2018, 13, 64.	0.7	65
208	Cardio-Oncology: mechanisms of cardiovascular toxicity. <i>F1000Research</i> , 2018, 7, 113.	0.8	9
209	The Balancing Act between Cancer Immunity and Autoimmunity in Response to Immunotherapy. <i>Cancer Immunology Research</i> , 2018, 6, 1445-1452.	1.6	132
210	Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer. <i>Chest</i> , 2018, 154, 1416-1423.	0.4	230
211	Acute and Fulminant Myocarditis: a Pragmatic Clinical Approach to Diagnosis and Treatment. <i>Current Cardiology Reports</i> , 2018, 20, 114.	1.3	72

#	ARTICLE	IF	CITATIONS
212	Mechanism and Management of Cancer Chemotherapy-Induced Atherosclerosis. <i>Journal of Atherosclerosis and Thrombosis</i> , 2018, 25, 994-1002.	0.9	29
213	Stage A Heart Failure: Identification and Management of Heart Failure Risk Factors. , 2018, , 446-455.		0
215	Toxicity of radiation and immunotherapy combinations. <i>Advances in Radiation Oncology</i> , 2018, 3, 506-511.	0.6	42
216	Retrospective Side Effect Profiling of the Metastatic Melanoma Combination Therapy Ipilimumab-Nivolumab Using Adverse Event Data. <i>Diagnostics</i> , 2018, 8, 76.	1.3	23
217	The Macrophage in Cardiac Homeostasis and Disease. <i>Journal of the American College of Cardiology</i> , 2018, 72, 2213-2230.	1.2	149
218	A CHIP mutation to battle cancer: potential or hazard for cardiovascular disease?. <i>Cardiovascular Research</i> , 2018, 114, e96-e98.	1.8	0
221	T1 Mapping in Cardiomyopathy from Cancer Treatment. , 2018, , 27-43.		0
222	Survivorship, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 1216-1247.	2.3	113
223	Trastuzumab-mediated cardiotoxicity: current understanding, challenges, and frontiers. <i>Antibody Therapeutics</i> , 2018, 1, 13-17.	1.2	81
224	Fatal enteric plexus neuropathy after one dose of ipilimumab plus nivolumab: a case report. , 2018, 6, 82.		30
225	Cardioimmunology: the immune system in cardiac homeostasis and disease. <i>Nature Reviews Immunology</i> , 2018, 18, 733-744.	10.6	482
226	Toxic myopathies. <i>Current Opinion in Neurology</i> , 2018, 31, 575-582.	1.8	28
227	Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors. <i>JAMA Oncology</i> , 2018, 4, 1721.	3.4	1,625
228	Incidence, Risk Factors, and Effect on Survival of Immune-related Adverse Events in Patients With Nonâ€“Small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2018, 19, e893-e900.	1.1	98
229	Tattoo-associated complications of metastatic melanoma treated with dabrafenib and trametinib. <i>Melanoma Research</i> , 2018, 28, 485-487.	0.6	5
230	Immune checkpoint inhibitors and cardiovascular toxicity. <i>Lancet Oncology</i> , The, 2018, 19, e447-e458.	5.1	376
231	Rheumatic immune-related adverse events from cancer immunotherapy. <i>Nature Reviews Rheumatology</i> , 2018, 14, 569-579.	3.5	162
232	Clinical Presentation and Outcome in a Contemporary Cohort of Patients With Acute Myocarditis. <i>Circulation</i> , 2018, 138, 1088-1099.	1.6	253

#	ARTICLE	IF	CITATIONS
233	Immune Checkpoint Inhibitor Toxicity Review for the Palliative Care Clinician. <i>Journal of Pain and Symptom Management</i> , 2018, 56, 460-472.	0.6	14
234	Keeping Tumors in Check: A Mechanistic Review of Clinical Response and Resistance to Immune Checkpoint Blockade in Cancer. <i>Journal of Molecular Biology</i> , 2018, 430, 2014-2029.	2.0	42
235	<scp>BRAF</scp> and <scp>MEK</scp> inhibitor therapy eliminates Nestin-expressing melanoma cells in human tumors. <i>Pigment Cell and Melanoma Research</i> , 2018, 31, 708-719.	1.5	9
236	Immune Checkpoint Inhibitor-Associated Myocarditis. <i>Oncologist</i> , 2018, 23, 879-886.	1.9	207
237	Biomarker Discovery in Cardio-Oncology. <i>Current Cardiology Reports</i> , 2018, 20, 52.	1.3	9
238	Myocarditis Associated with Immune Checkpoint Inhibitors: An Expert Consensus on Data Gaps and a Call to Action. <i>Oncologist</i> , 2018, 23, 874-878.	1.9	89
239	Response by Thuny et al to Letter Regarding Article, "Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor-Related Cardiotoxicity". <i>Circulation</i> , 2018, 137, 2423-2424.	1.6	0
241	Neoplasia and the Heart. <i>Journal of the American College of Cardiology</i> , 2018, 72, 202-227.	1.2	107
242	The Integration of Radiotherapy with Immunotherapy for the Treatment of Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 5792-5806.	3.2	200
243	Immune Toxicity with Checkpoint Inhibition for Metastatic Melanoma: Case Series and Clinical Management. <i>Journal of Skin Cancer</i> , 2018, 2018, 1-13.	0.5	21
244	Nephrotoxicity of Cancer Immunotherapies: Past, Present and Future. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 2039-2052.	3.0	121
245	2016 Jeffrey M. Hoeg Award Lecture. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, 1678-1688.	1.1	12
246	Influenza vaccination of cancer patients during PD-1 blockade induces serological protection but may raise the risk for immune-related adverse events. , 2018, 6, 40.		110
247	Immune Checkpoint Inhibitor Toxicity. <i>Current Oncology Reports</i> , 2018, 20, 72.	1.8	91
248	An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0. , 2018, 6, 44.		59
249	Cardiovascular Magnetic Resonance in the Oncology Patient. <i>JACC: Cardiovascular Imaging</i> , 2018, 11, 1150-1172.	2.3	77
251	Antineoplastic Drug-Induced Cardiotoxicity: A Redox Perspective. <i>Frontiers in Physiology</i> , 2018, 9, 167.	1.3	118
252	Monoclonal antibody therapy in cancer: When two is better (and considerably more expensive) than one. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2018, 43, 925-930.	0.7	5

#	ARTICLE	IF	CITATIONS
253	Toward Biomaterials for Enhancing Immune Checkpoint Blockade Therapy. <i>Advanced Functional Materials</i> , 2018, 28, 1802540.	7.8	92
254	Neuromuscular Complications of Programmed Cell Death-1 (PD-1) Inhibitors. <i>Current Neurology and Neuroscience Reports</i> , 2018, 18, 63.	2.0	88
255	Reporting of immune checkpoint inhibitor-associated myocarditis – Authors' reply. <i>Lancet, The</i> , 2018, 392, 384-385.	6.3	7
256	Cardiotoxicity of Anticancer Therapeutics. <i>Frontiers in Cardiovascular Medicine</i> , 2018, 5, 9.	1.1	68
257	Nanoparticle-based photothermal and photodynamic immunotherapy for tumor treatment. <i>International Journal of Cancer</i> , 2018, 143, 3050-3060.	2.3	171
258	Fatal autoimmune myocarditis with anti-PD-L1 and tyrosine kinase inhibitor therapy for renal cell cancer. <i>European Journal of Cancer</i> , 2018, 101, 287-290.	1.3	12
259	Cardiorenal complications of immune checkpoint inhibitors. <i>Nature Reviews Nephrology</i> , 2018, 14, 571-588.	4.1	80
260	Toxicities and outcomes: Do steroids matter?. <i>Cancer</i> , 2018, 124, 3638-3640.	2.0	5
261	Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC. <i>Cancer Immunology Research</i> , 2018, 6, 1093-1099.	1.6	258
262	Cancer immune checkpoint blockade therapy and its associated autoimmune cardiotoxicity. <i>Acta Pharmacologica Sinica</i> , 2018, 39, 1693-1698.	2.8	39
263	Recent developments with immunotherapy for hepatocellular carcinoma. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 905-910.	1.4	89
264	Cardiotoxicities associated with immune checkpoint inhibitors. <i>Current Problems in Cancer</i> , 2018, 42, 422-432.	1.0	42
265	Sick sinus syndrome associated with anti-programmed cell death-1. , 2018, 6, 72.		16
266	Cardiac MRI for the evaluation of oncologic cardiotoxicity. <i>Journal of Nuclear Cardiology</i> , 2018, 25, 2148-2158.	1.4	38
268	Thoracic Imaging of Solid Tumor Patients Treated with Immune Checkpoint Inhibitors. <i>Current Radiology Reports</i> , 2018, 6, 1.	0.4	1
269	Programmed cell death-1 and programmed cell death ligand-1 antibodies-induced dysthyroidism. <i>Endocrine Connections</i> , 2018, 7, R196-R211.	0.8	10
270	Immune checkpoint blockade for the treatment of human hepatocellular carcinoma. <i>Hepatology Research</i> , 2018, 48, 622-634.	1.8	58
271	Autologous graft-versus-host disease with combined immune checkpoint blockade. <i>European Journal of Cancer</i> , 2018, 101, 275-277.	1.3	0

#	ARTICLE	IF	CITATIONS
272	Metastatic Melanoma: Recent Therapeutic Progress and Future Perspectives. <i>Drugs</i> , 2018, 78, 1197-1209.	4.9	34
273	Fundamental Mechanisms of Immune Checkpoint Blockade Therapy. <i>Cancer Discovery</i> , 2018, 8, 1069-1086.	7.7	2,128
274	Optimizing drug combinations against multiple myeloma using a quadratic phenotypic optimization platform (QPOP). <i>Science Translational Medicine</i> , 2018, 10, .	5.8	80
275	Checkpoint blockade-based immunotherapy in the context of tumor microenvironment: Opportunities and challenges. <i>Cancer Medicine</i> , 2018, 7, 4517-4529.	1.3	34
276	Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer. <i>Neurology</i> , 2018, 91, e985-e994.	1.5	247
277	Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain. <i>New England Journal of Medicine</i> , 2018, 379, 722-730.	13.9	983
278	Cardiovascular safety of oncologic agents: A double-edged sword even in the era of targeted therapies – part 1. <i>Expert Opinion on Drug Safety</i> , 2018, 17, 875-892.	1.0	14
279	Letter by Campochiaro et al Regarding Article, “Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor-Related Cardiotoxicity”. <i>Circulation</i> , 2018, 137, 2421-2422.	1.6	3
280	Immune-Related Adverse Toxicities and Clinical Management. , 2018, , 577-589.		0
281	Twenty years of adverse drug reactions: a look back – part 2. <i>Adverse Drug Reaction Bulletin</i> , 2018, 310, 1199-1202.	0.6	0
282	Complete Atrioventricular Block Associated with Pembrolizumab-induced Acute Myocarditis: The Need for Close Cardiac Monitoring. <i>Internal Medicine</i> , 2018, 57, 3157-3162.	0.3	31
283	Les cardiomyopathies toxiques liées aux chimiothérapies. <i>Archives Des Maladies Du Coeur Et Des Vaisseaux - Pratique</i> , 2018, 2018, 10-14.	0.0	0
284	Myocarditis with tremelimumab plus durvalumab combination therapy for endometrial cancer: A case report. <i>Gynecologic Oncology Reports</i> , 2018, 25, 74-77.	0.3	42
285	Cardiac Immune-Related Adverse Events in Immune Checkpoint Inhibition Therapy. <i>Cardiology in Review</i> , 2019, 27, 97-107.	0.6	19
286	Update on cardio-oncology: Novel cancer therapeutics and associated cardiotoxicities. <i>Trends in Cardiovascular Medicine</i> , 2019, 29, 29-39.	2.3	43
288	Myositis as an adverse event of immune checkpoint blockade for cancer therapy. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 736-740.	1.6	90
289	Editorial Commentary: Update on cardio-oncology: Novel cancer therapeutics and associated cardiotoxicities. <i>Trends in Cardiovascular Medicine</i> , 2019, 29, 40.	2.3	1
290	Applications of Immunopharmacogenomics: Predicting, Preventing, and Understanding Immune-Mediated Adverse Drug Reactions. <i>Annual Review of Pharmacology and Toxicology</i> , 2019, 59, 463-486.	4.2	42

#	ARTICLE	IF	CITATIONS
291	Immune tumor board: integral part in the multidisciplinary management of cancer patients treated with cancer immunotherapy. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 474, 485-495.	1.4	3
292	Pembrolizumab and epacadostat induced fatal myocarditis and myositis presenting as a case of ptosis and ophthalmoplegia. <i>Orbit</i> , 2019, 38, 244-247.	0.5	16
293	Decoding inflammation, its causes, genomic responses, and emerging countermeasures. <i>Scandinavian Journal of Immunology</i> , 2019, 90, e12812.	1.3	39
294	Evolving Role of the Oncology Nurse in the Care of Patients with Melanoma. , 2019, , 791-817.		0
295	Immune checkpoint inhibitorsâ€”induced neuromuscular toxicity: From pathogenesis to treatment. <i>Journal of the Peripheral Nervous System</i> , 2019, 24, S74-S85.	1.4	42
296	PD-L1 Distribution and Perspective for Cancer Immunotherapyâ€”Blockade, Knockdown, or Inhibition. <i>Frontiers in Immunology</i> , 2019, 10, 2022.	2.2	270
297	Factors Associated With Immune Checkpoint Inhibitorâ€”Related Myocarditis. <i>JAMA Oncology</i> , 2019, 5, 1635.	3.4	73
298	A Review of Immune-Mediated Adverse Events in Melanoma. <i>Oncology and Therapy</i> , 2019, 7, 101-120.	1.0	23
299	Fundamental Mechanisms of Regulated Cell Death and Implications for Heart Disease. <i>Physiological Reviews</i> , 2019, 99, 1765-1817.	13.1	550
300	Immune checkpoint inhibitors in non-small cell lung cancer: A bird's eye view. <i>Life Sciences</i> , 2019, 233, 116713.	2.0	42
301	Immune checkpoint inhibitorâ€”mediated myocarditis and ventricular tachycardia storm. <i>HeartRhythm Case Reports</i> , 2019, 5, 497-500.	0.2	12
302	Vaccinations for Colorectal Cancer: Progress, Strategies, and Novel Adjuvants. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3403.	1.8	20
303	Diagnosis of immune checkpoint inhibitor-associated myocarditis: A systematic review. <i>International Journal of Cardiology</i> , 2019, 296, 113-121.	0.8	34
304	Correlation between thyroid transcription factor-1 expression, immune-related thyroid dysfunction, and efficacy of anti-programmed cell death protein-1 treatment in non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2019, 11, 1919-1928.	0.6	13
305	Immune-Related Adverse Events: A Case-Based Approach. <i>Frontiers in Oncology</i> , 2019, 9, 530.	1.3	31
306	Fulminant Versus Acute Nonfulminant Myocarditis in Patients With Leftâ€”Ventricular Systolicâ€”Dysfunction. <i>Journal of the American College of Cardiology</i> , 2019, 74, 299-311.	1.2	148
307	Fulminant Myocarditis. <i>Journal of the American College of Cardiology</i> , 2019, 74, 312-314.	1.2	12
308	Anticytokine Immune Therapy and Atherothrombotic Cardiovascular Risk. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2019, 39, 1510-1519.	1.1	57

#	ARTICLE	IF	CITATIONS
309	Colitis after checkpoint blockade: A retrospective cohort study of melanoma patients requiring admission for symptom control. <i>Cancer Medicine</i> , 2019, 8, 4986-4999.	1.3	27
310	A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis. <i>Nature Medicine</i> , 2019, 25, 1243-1250.	15.2	133
311	Fatal Myocarditis and Rhabdomyositis in a Patient with Stage Iv Melanoma Treated with Combined Ipilimumab and Nivolumab. <i>Current Oncology</i> , 2019, 26, 418-421.	0.9	26
312	Myocarditis in the Setting of Cancer Therapeutics. <i>Circulation</i> , 2019, 140, 80-91.	1.6	278
313	Immunotherapy Toxicities. <i>Surgical Oncology Clinics of North America</i> , 2019, 28, 387-401.	0.6	10
314	Immune Checkpoint Inhibitor Toxicities. <i>Mayo Clinic Proceedings</i> , 2019, 94, 1321-1329.	1.4	105
315	Cardiogenic shock in cancer. <i>Heart Failure Reviews</i> , 2019, 24, 997-1004.	1.7	15
316	Pericardial effusion under nivolumab: case-reports and review of the literature. , 2019, 7, 266.		35
317	Susceptible loci associated with autoimmune disease as potential biomarkers for checkpoint inhibitor-induced immune-related adverse events. <i>ESMO Open</i> , 2019, 4, e000472.	2.0	26
318	The mechanisms of acute interstitial nephritis in the era of immune checkpoint inhibitors in melanoma. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591987554.	1.4	21
319	Adverse Effects of Immune Checkpoint Inhibitors (Programmed Death-1 Inhibitors and Cytotoxic) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 Medicine Research, 2019, 11, 225-236.	0.6	133
320	Single-Cell Sequencing of Mouse Heart Immune Infiltrate in Pressure Overload-Driven Heart Failure Reveals Extent of Immune Activation. <i>Circulation</i> , 2019, 140, 2089-2107.	1.6	212
321	Microbiota-derived peptide mimics drive lethal inflammatory cardiomyopathy. <i>Science</i> , 2019, 366, 881-886.	6.0	179
322	Microbes and genes in heart failure. <i>Science</i> , 2019, 366, 806-807.	6.0	0
324	Neurological Immune Related Adverse Events Associated with Nivolumab, Ipilimumab, and Pembrolizumab Therapy-Review of the Literature and Future Outlook. <i>Journal of Clinical Medicine</i> , 2019, 8, 1777.	1.0	87
325	Mismatches in the interpretation of fragment negative expressions in Mandarin Chinese. <i>Journal of Pragmatics</i> , 2019, 152, 28-45.	0.8	4
326	MRI in cardio-oncology: A review of cardiac complications in oncologic care. <i>Journal of Magnetic Resonance Imaging</i> , 2019, 50, 1349-1366.	1.9	18
328	Severe toxicity from checkpoint protein inhibitors: What intensive care physicians need to know?. <i>Annals of Intensive Care</i> , 2019, 9, 25.	2.2	46

#	ARTICLE	IF	CITATIONS
329	Cancer immunotherapy and its renal effects. <i>Journal of Onco-Nephrology</i> , 2019, 3, 151-159.	0.3	3
330	Myocarditis following the use of different immune checkpoint inhibitor regimens: A real-world analysis of post-marketing surveillance data. <i>International Immunopharmacology</i> , 2019, 76, 105866.	1.7	26
331	Tales of the Unexpected. <i>JACC: Case Reports</i> , 2019, 1, 337-338.	0.3	0
332	Non-canonical Expression of Cardiac Troponin-T in Neuroendocrine Ethmoid Sinus Carcinoma Following Immune Checkpoint Blockade. <i>Frontiers in Cardiovascular Medicine</i> , 2019, 6, 124.	1.1	5
333	Direct comparison of target-reactivity and cross-reactivity induced by CAR- and BiTE-redirected T cells for the development of antibody-based T-cell therapy. <i>Scientific Reports</i> , 2019, 9, 13293.	1.6	20
334	Immune checkpoint inhibition alters the inflammatory cell composition of human coronary artery atherosclerosis. <i>Cardiovascular Pathology</i> , 2019, 43, 107148.	0.7	39
335	Cardiotoxicity from immune checkpoint inhibitors. <i>IJC Heart and Vasculature</i> , 2019, 25, 100420.	0.6	79
336	Autoimmune rhabdomyolysis and a multiorgan display of PD-1 inhibitor induced immune related adverse events during treatment of metastatic melanoma. <i>Experimental Hematology and Oncology</i> , 2019, 8, 20.	2.0	4
337	The Diverse Function of PD-1/PD-L Pathway Beyond Cancer. <i>Frontiers in Immunology</i> , 2019, 10, 2298.	2.2	244
338	Efficacy of Neurohormonal Therapies in Preventing Cardiotoxicity in Patients With Cancer Undergoing Chemotherapy. <i>JACC: CardioOncology</i> , 2019, 1, 54-65.	1.7	74
339	Case 30-2019: A 65-Year-Old Woman with Lung Cancer and Chest Pain. <i>New England Journal of Medicine</i> , 2019, 381, 1268-1277.	13.9	10
340	Cardiovascular Toxicities of Immune Checkpoint Inhibitors. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1714-1727.	1.2	124
341	Acute and Long-term Adverse Events Associated With Checkpoint Blockade. <i>Seminars in Oncology Nursing</i> , 2019, 35, 150926.	0.7	7
342	Changing Hearts and Minds: Improving Outcomes in Cancer Treatment-Related Cardiotoxicity. <i>Current Oncology Reports</i> , 2019, 21, 9.	1.8	15
343	Immunotherapy Toxicity. <i>Hematology/Oncology Clinics of North America</i> , 2019, 33, 275-290.	0.9	23
344	Adverse Event Profiles of Anti-CTLA-4 and Anti-PD-1 Monoclonal Antibodies Alone or in Combination: Analysis of Spontaneous Reports Submitted to FAERS. <i>Clinical Drug Investigation</i> , 2019, 39, 319-330.	1.1	78
345	SEOM clinical guidelines on cardiovascular toxicity (2018). <i>Clinical and Translational Oncology</i> , 2019, 21, 94-105.	1.2	20
346	Cardiovascular toxicities associated with immune checkpoint inhibitors. <i>Cardiovascular Research</i> , 2019, 115, 854-868.	1.8	311

#	ARTICLE	IF	CITATIONS
347	<p>Cardiac toxicity of immune-checkpoint inhibitors: a clinical case of nivolumab-induced myocarditis and review of the evidence and new challenges</p>. Cancer Management and Research, 2019, Volume 11, 4541-4548.	0.9	23
348	Nivolumab-induced Myocarditis Successfully Treated with Corticosteroid Therapy: A Case Report and Review of the Literature. Internal Medicine, 2019, 58, 2367-2372.	0.3	16
349	Application value of hypersensitive C-reactive protein, lactic acid and myoglobin in the combined detection of myocarditis. Experimental and Therapeutic Medicine, 2019, 17, 4471-4476.	0.8	4
350	Incidence of and risk factors for cardiotoxicity after fluorouracil-based chemotherapy in locally advanced or metastatic gastric cancer patients. Cancer Chemotherapy and Pharmacology, 2019, 84, 599-607.	1.1	16
351	Cardiotoxicities of Modern Treatments in Breast Cancer. Current Treatment Options in Cardiovascular Medicine, 2019, 21, 34.	0.4	2
352	Assessing cardiac safety in oncology drug development. American Heart Journal, 2019, 214, 125-133.	1.2	10
354	Checkpoint Inhibitors. Deutsches Ärztblatt International, 2019, 116, 119-126.	0.6	83
355	Paraneoplastic dermatomyositis appearing after nivolumab therapy for gastric cancer: a case report. Journal of Medical Case Reports, 2019, 13, 168.	0.4	28
356	Cardiotoxicity of Immune Checkpoint Inhibitors. Current Treatment Options in Cardiovascular Medicine, 2019, 21, 32.	0.4	42
357	Cancer therapy-induced cardiovascular toxicity: old/new problems and old drugs. American Journal of Physiology - Heart and Circulatory Physiology, 2019, 317, H164-H167.	1.5	17
358	Heart Failure and Cancer: Mechanisms of Old and New Cardiotoxic Drugs in Cancer Patients. Cardiac Failure Review, 2019, 5, 112-118.	1.2	39
359	Cardio-oncology: Network-Based Prediction of Cancer Therapy-Induced Cardiotoxicity. Challenges and Advances in Computational Chemistry and Physics, 2019, , 75-97.	0.6	1
360	Pediatric Cardio-Oncology: Development of Cancer Treatment-Related Cardiotoxicity and the Therapeutic Approach to Affected Patients. Current Treatment Options in Oncology, 2019, 20, 56.	1.3	17
361	New oncologic emergencies: What is there to know about immunotherapy and its potential side effects?. European Journal of Internal Medicine, 2019, 66, 1-8.	1.0	19
362	Molecular targeted therapy-related life-threatening toxicity in patients with malignancies. A systematic review of published cases. Intensive Care Medicine, 2019, 45, 988-997.	3.9	18
363	Abatacept for Severe Immune Checkpoint Inhibitorâ€Associated Myocarditis. New England Journal of Medicine, 2019, 380, 2377-2379.	13.9	296
364	Immunotherapy for hepatocellular carcinoma: A review of potential new drugs based on ongoing clinical studies as of 2019. Digestive and Liver Disease, 2019, 51, 1067-1073.	0.4	25
365	Combination of CTLA-4 and PD-1 blockers for treatment of cancer. Journal of Experimental and Clinical Cancer Research, 2019, 38, 255.	3.5	577

#	ARTICLE	IF	CITATIONS
366	B cell depletion or absence does not impede anti-tumor activity of PD-1 inhibitors. , 2019, 7, 153.		58
367	T-cell recruitment to the heart: friendly guests or unwelcome visitors?. American Journal of Physiology - Heart and Circulatory Physiology, 2019, 317, H124-H140.	1.5	80
368	Inhibition of immune checkpoints PD-1, CTLA-4, and IDO1 coordinately induces immune-mediated liver injury in mice. PLoS ONE, 2019, 14, e0217276.	1.1	34
370	Cardio-Oncology Fellowship Training and Education. Current Treatment Options in Cardiovascular Medicine, 2019, 21, 27.	0.4	6
371	Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study. , 2019, 7, 134.		237
372	Myocarditis in Cynomolgus Monkeys Following Treatment with Immune Checkpoint Inhibitors. Clinical Cancer Research, 2019, 25, 4735-4748.	3.2	80
373	Myocarditis in Humans and in Experimental Animal Models. Frontiers in Cardiovascular Medicine, 2019, 6, 64.	1.1	99
374	The Role of Cardiac Magnetic Resonance Imaging to Detect Cardiac Toxicity From Cancer Therapeutics. Current Treatment Options in Cardiovascular Medicine, 2019, 21, 28.	0.4	12
375	Heart Inflammation. American Journal of Pathology, 2019, 189, 1482-1494.	1.9	70
376	Adaptive immune cells in calcific aortic valve disease. American Journal of Physiology - Heart and Circulatory Physiology, 2019, 317, H141-H155.	1.5	47
377	Identification and Management of Immune Checkpoint Inhibitor-Related Myocarditis: Use Troponin Wisely. Journal of Clinical Oncology, 2019, 37, 2201-2205.	0.8	39
378	Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nature Reviews Clinical Oncology, 2019, 16, 563-580.	12.5	1,235
379	Adaptation of Human iPSC-Derived Cardiomyocytes to Tyrosine Kinase Inhibitors Reduces Acute Cardiotoxicity via Metabolic Reprogramming. Cell Systems, 2019, 8, 412-426.e7.	2.9	49
380	Immune Checkpoint Inhibitor-Associated Pericarditis. Journal of Thoracic Oncology, 2019, 14, 1102-1108.	0.5	72
381	Cardiotoxicity with immune system targeting drugs: a meta-analysis of anti-PD/PD-L1 immunotherapy randomized clinical trials. Immunotherapy, 2019, 11, 725-735.	1.0	25
382	An essential role for GLUT5-mediated fructose utilization in exacerbating the malignancy of clear cell renal cell carcinoma. Cell Biology and Toxicology, 2019, 35, 471-483.	2.4	18
383	Managing cardiotoxicity associated with immune checkpoint inhibitors. Chronic Diseases and Translational Medicine, 2019, 5, 6-14.	0.9	52
384	Current knowledge of Ipilimumab and its use in treating non-small cell lung cancer. Expert Opinion on Biological Therapy, 2019, 19, 509-515.	1.4	16

#	ARTICLE	IF	CITATIONS
385	Re: Roger Li, Philippe E. Spiess, Scott M. Gilbert, Andrea Necchi. Towards Personalized Neoadjuvant Therapy for Muscle-invasive Bladder Cancer. <i>Eur Urol</i> 2019;76:4â€“6. <i>European Urology</i> , 2019, 76, e33.	0.9	0
386	Management of immune related adverse events induced by immune checkpoint inhibition. <i>Cancer Letters</i> , 2019, 456, 80-87.	3.2	36
387	Immune cell diversity contributes to the pathogenesis of myocarditis. <i>Heart Failure Reviews</i> , 2019, 24, 1019-1030.	1.7	18
388	Reply to Yubo Yang, Xin Wei, and Ping Han's Letter to the Editor re: Roger Li, Philippe E. Spiess, Scott M. Gilbert, Andrea Necchi. Towards Personalized Neoadjuvant Therapy for Muscle-invasive Bladder Cancer. <i>Eur Urol</i> 2019;76:4â€“6. <i>European Urology</i> , 2019, 76, e34.	0.9	0
389	Nivolumab-induced myocardial necrosis in a patient with lung cancer: A case report. <i>Respiratory Medicine Case Reports</i> , 2019, 27, 100839.	0.2	8
390	Emerging therapies for non-small cell lung cancer. <i>Journal of Hematology and Oncology</i> , 2019, 12, 45.	6.9	111
391	Sequential Blockade of PD-1 and PD-L1 Causes Fulminant Cardiotoxicityâ€”From Case Report to Mouse Model Validation. <i>Cancers</i> , 2019, 11, 580.	1.7	28
392	Immune checkpoint inhibitor therapy and myocarditis: a systematic review of reported cases. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 1527-1557.	1.2	65
393	Cardio-oncology: a novel platform for basic and translational cardiovascular investigation driven by clinical need. <i>Cardiovascular Research</i> , 2019, 115, 819-823.	1.8	17
394	Ubiquitin Ligases in Cancer Immunotherapy â€” Balancing Antitumor and Autoimmunity. <i>Trends in Molecular Medicine</i> , 2019, 25, 428-443.	3.5	35
395	Site-Specific Immuno-PET Tracer to Image PD-L1. <i>Molecular Pharmaceutics</i> , 2019, 16, 2028-2036.	2.3	41
398	Neuromuscular adverse events associated with anti-PD-1 monoclonal antibodies. <i>Neurology</i> , 2019, 92, 663-674.	1.5	115
399	A Pictorial Essay of Immunotherapy: Complications that Internists Will See, Whether They Like it or Not. <i>American Journal of Medicine</i> , 2019, 132, 808-815.	0.6	1
400	Myocarditis with checkpoint inhibitor immunotherapy: case report of late gadolinium enhancement on cardiac magnetic resonance with pathology correlate. <i>European Heart Journal - Case Reports</i> , 2019, 3, yty149.	0.3	25
401	Targeting Barriers of Systems of Care in a Growing Multi-disciplinary Field. <i>Current Oncology Reports</i> , 2019, 21, 36.	1.8	3
403	Inflammatory myopathy associated with PD-1 inhibitors. <i>Journal of Autoimmunity</i> , 2019, 100, 105-113.	3.0	73
404	Position Paper From the Association of Pathology Chairs: Assessing Autopsy Competency in Pathology Residency Training. <i>Academic Pathology</i> , 2019, 6, 237428951882405.	0.7	4
405	Exceptional response and multisystem autoimmune-like toxicities associated with the same T cell clone in a patient with uveal melanoma treated with immune checkpoint inhibitors. , 2019, 7, 61.		40

#	ARTICLE	IF	CITATIONS
406	Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: Case Series and Review of the Literature. <i>Case Reports in Oncology</i> , 2019, 12, 260-276.	0.3	63
407	Multi-organ failure induced by Nivolumab in the context of allo-stem cell transplantation. <i>Experimental Hematology and Oncology</i> , 2019, 8, 8.	2.0	16
408	Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System. <i>Targeted Oncology</i> , 2019, 14, 205-221.	1.7	72
409	Immune Checkpoint Inhibitor-Induced Myositis: a Case Report and Literature Review. <i>Current Rheumatology Reports</i> , 2019, 21, 10.	2.1	49
410	Inflammation-induced hypoparathyroidism triggered by combination immune checkpoint blockade for melanoma. , 2019, 7, 52.		43
411	Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors. , 2019, 7, 53.		59
412	Myocardial Dysfunction Associated with Cancer Therapy. <i>Cardiovascular Medicine</i> , 2019, , 71-79.	0.0	0
413	T cell checkpoint regulators in the heart. <i>Cardiovascular Research</i> , 2019, 115, 869-877.	1.8	70
414	Cardiac Complications in Immune Checkpoint Inhibition Therapy. <i>Frontiers in Cardiovascular Medicine</i> , 2019, 6, 3.	1.1	65
415	Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors. <i>American Journal of Hematology</i> , 2019, 94, 563-574.	2.0	51
416	Cardio-Oncology: Vascular and Metabolic Perspectives: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2019, 139, e579-e602.	1.6	142
417	T cell co-stimulation and co-inhibition in cardiovascular disease: a double-edged sword. <i>Nature Reviews Cardiology</i> , 2019, 16, 325-343.	6.1	65
418	Personalized medicine in cardio-oncology: the role of induced pluripotent stem cell. <i>Cardiovascular Research</i> , 2019, 115, 949-959.	1.8	38
419	Nivolumab-induced myocarditis complicated by complete atrioventricular block in a patient with metastatic non-small cell lung cancer. <i>BMJ Case Reports</i> , 2019, 12, e229963.	0.2	9
420	Nivolumab-Induced Concomitant Severe Upper and Lower Gastrointestinal Immune-Related Adverse Effects. <i>ACG Case Reports Journal</i> , 2019, 6, e00249.	0.2	17
421	Sicca Syndrome Associated with Immune Checkpoint Inhibitor Therapy. <i>Oncologist</i> , 2019, 24, 1259-1269.	1.9	127
422	Toxicity of tumor immune checkpoint inhibitorsâ€”more attention should be paid. <i>Translational Lung Cancer Research</i> , 2019, 8, 1125-1133.	1.3	7
423	A case report: metastasis of melanoma to the heart in an era of immunotherapy. <i>European Heart Journal - Case Reports</i> , 2019, 3, 1-7.	0.3	1

#	ARTICLE	IF	CITATIONS
424	Severe Epididymo-Orchitis and Encephalitis Complicating Anti-PD-1 Therapy. <i>Oncologist</i> , 2019, 24, 872-876.	1.9	38
425	Cardiotoxicity of Immune Therapy. <i>Cardiology Clinics</i> , 2019, 37, 385-397.	0.9	54
426	Mechanisms and clinical course of cardiovascular toxicity of cancer treatment I. <i>Oncology. Seminars in Oncology</i> , 2019, 46, 397-402.	0.8	16
427	Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. , 2019, 7, 306.		642
428	Combination Nivolumab/Ipilimumab Immunotherapy For Melanoma With Subsequent Unexpected Cardiac Arrest: A Case Report and Review of Literature. <i>Journal of Immunotherapy</i> , 2019, 42, 313-317.	1.2	11
429	Immune Checkpoint Inhibitor-Related Adverse Cardiovascular Events in Patients With Lung Cancer. <i>JACC: CardioOncology</i> , 2019, 1, 182-192.	1.7	47
430	Immune Checkpoint Inhibitor-Related Cardiovascular Toxicity in Lung Cancer. <i>JACC: CardioOncology</i> , 2019, 1, 193-195.	1.7	1
431	Radiothérapie et immunothérapie : nouveau standard, nouvelles options. <i>Revue Des Maladies Respiratoires Actualites</i> , 2019, 11, S484-S490.	0.0	0
432	Fatal myositis and spontaneous haematoma induced by combined immune checkpoint inhibitor treatment in a patient with pancreatic adenocarcinoma. <i>BMC Cancer</i> , 2019, 19, 1193.	1.1	6
433	Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T). <i>Journal of the American College of Cardiology</i> , 2019, 74, 3099-3108.	1.2	225
435	Cardiovascular Toxicities in Pediatric Cancer Survivors. <i>Cardiology Clinics</i> , 2019, 37, 533-544.	0.9	17
436	Cancer Treatment-Associated Pericardial Disease: Epidemiology, Clinical Presentation, Diagnosis, and Management. <i>Current Cardiology Reports</i> , 2019, 21, 156.	1.3	36
437	Neurologic Immune-Related Adverse Events Associated with Immune Checkpoint Inhibition. <i>Current Oncology Reports</i> , 2019, 21, 108.	1.8	46
438	Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO+IPI: a systematic review and meta-analysis. , 2019, 7, 341.		126
439	Immune Checkpoint Inhibitor Associated Rheumatic Adverse Events: a Review of Their Presentations and Treatments. <i>Current Treatment Options in Rheumatology</i> , 2019, 5, 272-289.	0.6	2
440	Immune-related adverse events in cancer patients treated with immune checkpoint inhibitors. <i>Medicine (United States)</i> , 2019, 98, e17348.	0.4	28
441	Checkpoint Inhibitor-Associated Autoimmunity. <i>Journal of Clinical Rheumatology</i> , 2019, Publish Ahead of Print, .	0.5	0
442	Immune Checkpoint Inhibitor-Associated Cardiotoxicity: Current Understanding on Its Mechanism, Diagnosis and Management. <i>Frontiers in Pharmacology</i> , 2019, 10, 1350.	1.6	75

#	ARTICLE	IF	CITATIONS
443	The Prognostic Value of Late Gadolinium Enhancement in Nonischemic Heart Disease. <i>Magnetic Resonance Imaging Clinics of North America</i> , 2019, 27, 545-561.	0.6	3
444	Hypophysitis induced by immune checkpoint inhibitors: a 10-year assessment. <i>Expert Review of Endocrinology and Metabolism</i> , 2019, 14, 381-398.	1.2	54
445	Cardiac toxicities of anticancer treatments. <i>Current Opinion in Cardiology</i> , 2019, 34, 441-450.	0.8	16
446	Abscopal effect in lung cancer: three case reports and a concise review. <i>Immunotherapy</i> , 2019, 11, 1445-1461.	1.0	37
448	Cardio-oncological management of patients. <i>Seminars in Oncology</i> , 2019, 46, 408-413.	0.8	10
449	Pathology of immune-mediated tissue lesions following treatment with immune checkpoint inhibitors. <i>Rheumatology</i> , 2019, 58, vii17-vii28.	0.9	39
450	Immune checkpoint inhibitor myocarditis. <i>Current Opinion in Cardiology</i> , 2019, 34, 303-306.	0.8	13
451	Toxicities associated with checkpoint inhibitorsâ€”an overview. <i>Rheumatology</i> , 2019, 58, vii7-vii16.	0.9	80
452	Management of rheumatic complications of immune checkpoint inhibitor therapy â€” an oncological perspective. <i>Rheumatology</i> , 2019, 58, vii29-vii39.	0.9	22
453	Arrhythmogenic Anticancer Drugs in Cardio-Oncology. <i>Cardiology Clinics</i> , 2019, 37, 459-468.	0.9	11
455	Monitoring the heart during cancer therapy. <i>European Heart Journal Supplements</i> , 2019, 21, M44-M49.	0.0	14
456	Safe Transition to Pembrolizumab following Ipilimumab-Induced Guillain-BarrÃ© Syndrome: A Case Report and Review of the Literature. <i>Case Reports in Oncological Medicine</i> , 2019, 2019, 1-5.	0.2	6
457	Acute progressive neuropathyâ€”myositisâ€”myasthenia-like syndrome associated with immune-checkpoint inhibitor therapy in patients with metastatic melanoma. <i>Melanoma Research</i> , 2019, 29, 435-440.	0.6	23
458	Toxicities in Immune Checkpoint Inhibitors. , 2019, , 205-226.		2
459	High-dimensional single-cell proteomics analysis identifies immune checkpoint signatures and therapeutic targets in ulcerative colitis. <i>European Journal of Immunology</i> , 2019, 49, 462-475.	1.6	18
460	Fatal Airway Inflammation Induced by Pembrolizumab in a Patient With NSCLC. <i>Journal of Thoracic Oncology</i> , 2019, 14, e9-e10.	0.5	9
461	Reply to â€”Cardioimmunology of arrhythmias: the role of autoimmune and inflammatory cardiac channelopathiesâ€”™. <i>Nature Reviews Immunology</i> , 2019, 19, 65-65.	10.6	0
462	Inflammatory myopathy with myasthenia gravis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019, 6, e535.	3.1	33

#	ARTICLE	IF	CITATIONS
463	Managing immune dysregulation resulting from immune checkpoint inhibitors: impact of the ASCO guidelines and key take-homes for immunologists. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 211-213.	1.3	5
464	Myocardial Inflammation, Measured Using 18â€Fluorodeoxyglucose Positron Emission Tomography With Computed Tomography, Is Associated With Disease Activity in Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2019, 71, 496-506.	2.9	33
465	Novel Cancer Therapeutics in Geriatrics: What is Unique to the Aging Patient?. <i>Drugs and Aging</i> , 2019, 36, 1-11.	1.3	10
466	Product review: avelumab, an anti-PD-L1 antibody. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 891-908.	1.4	50
467	Autopsy in the 21st Century. , 2019, , .		1
468	Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors. <i>European Journal of Cancer</i> , 2019, 106, 12-23.	1.3	171
469	Imaging of Cancer Immunotherapy: Current Approaches and Future Directions. <i>Radiology</i> , 2019, 290, 9-22.	3.6	147
470	Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer. <i>Drug Safety</i> , 2019, 42, 281-294.	1.4	69
471	Management of immune-related adverse events resulting from immune checkpoint blockade. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 209-222.	1.1	20
472	Presence of antibodies to striated muscle and acetylcholine receptor in association with occurrence of myasthenia gravis with myositis and myocarditis in a patient with melanoma treated with an antiâ€programmed death 1 antibody. <i>European Journal of Cancer</i> , 2019, 106, 193-195.	1.3	18
473	Cardio-oncology - strategies for management of cancer-therapy related cardiovascular disease. <i>International Journal of Cardiology</i> , 2019, 280, 163-175.	0.8	138
474	Autoimmune hemolytic anemia associated with the use of immune checkpoint inhibitors for cancer: 68 cases from the Food and Drug Administration database and review. <i>European Journal of Haematology</i> , 2019, 102, 157-162.	1.1	73
475	Clinical characterization of colitis arising from anti-PD-1 based therapy. <i>Oncolmmunology</i> , 2019, 8, e1524695.	2.1	44
476	Fulminant Myocarditis Caused by an Immune Checkpoint Inhibitor: A Case Report With Pathologic Findings. <i>Journal of Thoracic Oncology</i> , 2019, 14, e36-e38.	0.5	22
477	Italian expert panel consensus statement on the optimal use of PD-1 blockade therapy in classical Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2019, 60, 1204-1213.	0.6	4
478	Chinese society of cardiology expert consensus statement on the diagnosis and treatment of adult fulminant myocarditis. <i>Science China Life Sciences</i> , 2019, 62, 187-202.	2.3	82
479	Clinical spectrum of neuromuscular complications after immune checkpoint inhibition. <i>Neuromuscular Disorders</i> , 2019, 29, 127-133.	0.3	42
480	Cardiotoxicity of cancer chemotherapy in clinical practice. <i>Hospital Practice (1995)</i> , 2019, 47, 6-15.	0.5	36

#	ARTICLE	IF	CITATIONS
481	Rheumatic diseases associated with immune checkpoint inhibitors in cancer immunotherapy. <i>Modern Rheumatology</i> , 2019, 29, 721-732.	0.9	10
482	Cancer therapy-induced cardiomyopathy: can human induced pluripotent stem cell modelling help prevent it?. <i>European Heart Journal</i> , 2019, 40, 1764-1770.	1.0	21
483	Acute autoimmune myocarditis and hepatitis due to ipilimumab monotherapy for malignant melanoma. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 966-968.	0.5	21
484	Checkpoints and beyond – Immunotherapy in colorectal cancer. <i>Seminars in Cancer Biology</i> , 2019, 55, 78-89.	4.3	38
486	Cardiovascular toxicities of therapy for genitourinary malignancies. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 121-128.	0.8	1
487	Cardiovascular Effects of Cancer Therapy. , 2020, , 649-664.e4.		1
488	Nuclear cardiology in the context of multimodality imaging to detect cardiac toxicity from cancer therapeutics: Established and emerging methods. <i>Journal of Nuclear Cardiology</i> , 2020, 27, 1210-1224.	1.4	18
489	Immune checkpoint inhibitor associated myocarditis occurs in both high-grade and low-grade forms. <i>Modern Pathology</i> , 2020, 33, 99-108.	2.9	64
490	Cardiotoxicity associated with immune checkpoint inhibitors in cutaneous oncology. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 986-994.	0.6	2
491	Adverse Events of Novel Therapies for Hematologic Malignancies: What Emergency Physicians Should Know. <i>Annals of Emergency Medicine</i> , 2020, 75, 264-286.	0.3	3
492	Acute coronary syndrome and recurrent colitis as immune-related adverse events in a lung cancer patient. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 252-255.	0.5	6
493	Autoimmune Effects of Lung Cancer Immunotherapy Revealed by Data-Driven Analysis on a Nationwide Cohort. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 388-396.	2.3	12
494	Cardio-Oncology and Heart Failure. , 2020, , 665-673.e3.		0
495	Cardiovascular toxicity of immune checkpoint inhibitors in cancer patients: A review when cardiology meets immuno-oncology. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 1461-1475.	0.8	57
496	Clinical Presentation and Laboratory Findings in Men Versus Women with Myocarditis. <i>Journal of Women's Health</i> , 2020, 29, 193-199.	1.5	16
497	Fatal Simultaneous Multi-organ Failure Following Pembrolizumab Treatment for Refractory Thymoma. <i>Clinical Lung Cancer</i> , 2020, 21, e74-e77.	1.1	16
498	Epidemiology Characteristics and Outcome of Patients With Clinically Diagnosed Acute Myocarditis. <i>American Journal of Medicine</i> , 2020, 133, 492-499.	0.6	39
499	Health care utilization and steroid-refractory toxicities from immune checkpoint inhibitors. <i>Cancer</i> , 2020, 126, 322-328.	2.0	13

#	ARTICLE	IF	CITATIONS
500	Cardiovascular Magnetic Resonance Imaging. <i>Journal of Thoracic Imaging</i> , 2020, 35, 12-25.	0.8	8
501	Recognition and Initial Management of Fulminant Myocarditis. <i>Circulation</i> , 2020, 141, e69-e92.	1.6	368
502	Risk factors for cancer-associated thrombosis in patients undergoing treatment with immune checkpoint inhibitors. <i>Investigational New Drugs</i> , 2020, 38, 1200-1206.	1.2	52
503	Acute Coronary Syndrome With Immune Checkpoint Inhibitors: A Proof-of-Concept Case and Pharmacovigilance Analysis of a Life-Threatening Adverse Event. <i>Canadian Journal of Cardiology</i> , 2020, 36, 476-481.	0.8	40
504	Emerging PD-1 and PD-1L inhibitors-associated myopathy with a characteristic histopathological pattern. <i>Autoimmunity Reviews</i> , 2020, 19, 102455.	2.5	51
505	A closer look at immune-mediated myocarditis in the era of combined checkpoint blockade and targeted therapies. <i>European Journal of Cancer</i> , 2020, 124, 15-24.	1.3	31
506	Immune Checkpoint Inhibitorsâ€“Related Cardiotoxicity. <i>American Journal of Therapeutics</i> , 2020, 27, e591-e598.	0.5	14
507	Checkpoint inhibitors in AML: are we there yet?. <i>British Journal of Haematology</i> , 2020, 188, 159-167.	1.2	31
508	Muscle Toxicity of Drugs: When Drugs Turn Physiology into Pathophysiology. <i>Physiological Reviews</i> , 2020, 100, 633-672.	13.1	39
509	Current status and development of anti-PD-1/PD-L1 immunotherapy for lung cancer. <i>International Immunopharmacology</i> , 2020, 79, 106088.	1.7	39
510	Treatment-related adverse events as surrogate to response rate to immune checkpoint blockade. <i>Medicine (United States)</i> , 2020, 99, e22153.	0.4	7
511	Association Between Immune Checkpoint Inhibitors With Cardiovascular Events and Atherosclerotic Plaque. <i>Circulation</i> , 2020, 142, 2299-2311.	1.6	282
512	Immune Checkpoint Inhibitors and Cardiac Toxicity in Patients Treated for Non-Small Lung Cancer: A Review. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7195.	1.8	55
513	Understanding and Overcoming the Inflammatory Toxicities of Immunotherapy. <i>Cancer Immunology Research</i> , 2020, 8, 1230-1235.	1.6	10
514	Severe combined cardiac and neuromuscular toxicity from immune checkpoint blockade: an institutional case series. <i>Cardio-Oncology</i> , 2020, 6, 21.	0.8	14
515	Targeted Delivery of CXCL9 and OX40L by Mesenchymal Stem Cells Elicits Potent Antitumor Immunity. <i>Molecular Therapy</i> , 2020, 28, 2553-2563.	3.7	22
516	Comparative efficacy and safety of PD-1/PD-L1 Inhibitors versus platinum-based chemotherapy for the first-line treatment of advanced non-small cell lung cancer: a meta analysis of randomized controlled trials. <i>Pharmacological Research</i> , 2020, 160, 105194.	3.1	13
517	Tumor invasion in the central airway is a risk factor for earlyâ€“onset checkpoint inhibitor pneumonitis in patients with nonâ€“small cell lung cancer. <i>Thoracic Cancer</i> , 2020, 11, 3576-3584.	0.8	13

#	ARTICLE	IF	CITATIONS
518	Anti-Extraintestinal antibodies: Expanding their clinical significance. <i>Clinical and Experimental Neuroimmunology</i> , 2020, 11, 218-224.	0.5	5
519	<p><p>Management of Immune Checkpoint Inhibitor Toxicities</p></p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 9139-9158.	0.9	18
520	Uncoupling Therapeutic Efficacy from Immune-Related Adverse Events in Immune Checkpoint Blockade. <i>IScience</i> , 2020, 23, 101580.	1.9	22
521	Immunotherapy with Checkpoint Inhibitors for Hepatocellular Carcinoma: Where Are We Now?. <i>Vaccines</i> , 2020, 8, 578.	2.1	16
522	Management of Patients with Acute Coronary Syndrome and Cancer. <i>Current Cardiology Reports</i> , 2020, 22, 159.	1.3	10
523	Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the <scp>CardioÖncology Study Group</scp> of the <scp>Heart Failure Association</scp> and the <scp>CardioÖncology Council of the European Society of Cardiology</scp>. <i>European Journal of Heart Failure</i> , 2020, 22, 1966-1983.	2.9	184
524	Î±-Galactosylceramide and its analog OCH differentially affect the pathogenesis of ISO-induced cardiac injury in mice. <i>Acta Pharmacologica Sinica</i> , 2020, 41, 1416-1426.	2.8	2
525	Multi-omics prediction of immune-related adverse events during checkpoint immunotherapy. <i>Nature Communications</i> , 2020, 11, 4946.	5.8	120
526	Emergency management of immune-related toxicity. <i>Current Opinion in Oncology</i> , 2020, 32, 274-281.	1.1	5
527	Preservation of microvascular barrier function requires CD31 receptor-induced metabolic reprogramming. <i>Nature Communications</i> , 2020, 11, 3595.	5.8	22
528	The Role of Biomarkers in Cardio-Oncology. <i>Journal of Cardiovascular Translational Research</i> , 2020, 13, 431-450.	1.1	92
529	Cardiomyopathies and Arrhythmias Induced by Cancer Therapies. <i>Biomedicines</i> , 2020, 8, 496.	1.4	10
530	Characterization of Immune Checkpoint Inhibitor-Related Cardiotoxicity in Lung Cancer Patients From a Rural Setting. <i>JACC: CardioOncology</i> , 2020, 2, 491-502.	1.7	20
531	Management of Acute Myocarditis and Chronic Inflammatory Cardiomyopathy. <i>Circulation: Heart Failure</i> , 2020, 13, e007405.	1.6	353
532	Pre-Existing Cardiovascular Conditions as Clinical Predictors of Myocarditis Reporting with Immune Checkpoint Inhibitors: A VigiBase Study. <i>Cancers</i> , 2020, 12, 3480.	1.7	12
533	<p><p>Nanomaterial-Based Tumor Photothermal Immunotherapy</p></p>. <i>International Journal of Nanomedicine</i> , 2020, Volume 15, 9159-9180.	3.3	104
534	Immune checkpoint inhibitor myocarditis mimicking Takotsubo cardiomyopathy on MPI. <i>Journal of Nuclear Cardiology</i> , 2022, 29, 2694-2698.	1.4	4
535	Immunobiology of Thymic Epithelial Tumors: Implications for Immunotherapy with Immune Checkpoint Inhibitors. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9056.	1.8	19

#	ARTICLE	IF	CITATIONS
536	Cardiotoxicity of Contemporary Anticancer Immunotherapy. Current Treatment Options in Cardiovascular Medicine, 2020, 22, 62.	0.4	34
537	Breaking β^2 Cell Tolerance After 100 Years of Life: Intratumoral Immunotherapyâ€“Induced Diabetes Mellitus. Journal of the Endocrine Society, 2020, 4, bvaa114.	0.1	3
538	SARS-CoV-2 Infection and Cardioncology: From Cardiometabolic Risk Factors to Outcomes in Cancer Patients. Cancers, 2020, 12, 3316.	1.7	23
539	Primer on Biomarker Discovery in Cardio-Oncology. JACC: CardioOncology, 2020, 2, 379-384.	1.7	14
540	Late-Onset Giant Cell Myocarditis Due to Enterovirus During Treatment With Immune Checkpoint Inhibitors. JACC: CardioOncology, 2020, 2, 511-514.	1.7	8
541	The Role of Biomarkers to Evaluate Cardiotoxicity. Current Treatment Options in Oncology, 2020, 21, 79.	1.3	6
542	Immune checkpoint inhibitor-induced inflammatory arthritis: identification and management. Expert Review of Clinical Immunology, 2020, 16, 771-785.	1.3	10
543	Elucidation of disease mechanisms underlying rheumatic immune-related adverse events may lead to novel therapeutic strategies for autoimmune diseases. Annals of the Rheumatic Diseases, 2022, 81, e262-e262.	0.5	3
544	The use of cardiovascular magnetic resonance as an early non-invasive biomarker for cardiotoxicity in cardio-oncology. Cardiovascular Diagnosis and Therapy, 2020, 10, 610-624.	0.7	15
545	Immune checkpoint inhibitor induces cardiac injury through polarizing macrophages via modulating microRNA-34a/Kruppel-like factor 4 signaling. Cell Death and Disease, 2020, 11, 575.	2.7	41
547	Mechanisms of Immune-Related Complications in Cancer Patients Treated with Immune Checkpoint Inhibitors. Pharmacology, 2021, 106, 123-136.	0.9	24
548	Targeting Viral cccDNA for Cure of Chronic Hepatitis B. Current Hepatology Reports, 2020, 19, 235-244.	0.4	12
549	Immune checkpoint inhibitor toxicities: systems-based approaches to improve patient care and research. Lancet Oncology, The, 2020, 21, e398-e404.	5.1	74
550	Novel Targeted Therapies for Metastatic Thyroid Cancerâ€”A Comprehensive Review. Cancers, 2020, 12, 2104.	1.7	50
551	Modulation of Determinant Factors to Improve Therapeutic Combinations with Immune Checkpoint Inhibitors. Cells, 2020, 9, 1727.	1.8	8
552	Adverse cardiac events in the treatment of non-small cell lung cancer with programmed death-1and programmed death-ligand 1 inhibitors. Medicine (United States), 2020, 99, e21613.	0.4	0
553	<p>Conjunctival Melanoma: Update on Genetics, Epigenetics and Targeted Molecular and Immune-Based Therapies</p>. Clinical Ophthalmology, 2020, Volume 14, 3137-3152.	0.9	12
554	Effective combinations of radiotherapy and immunotherapy in the treatment of esophageal squamous cell carcinoma. Future Oncology, 2020, 16, 2537-2549.	1.1	9

#	ARTICLE	IF	CITATIONS
555	COVID-19 and Cardiovascular Health Among Patients with Cancer. <i>Current Cardiology Reports</i> , 2020, 22, 171.	1.3	8
556	NLRP3 as Putative Marker of Ipilimumab-Induced Cardiotoxicity in the Presence of Hyperglycemia in Estrogen-Responsive and Triple-Negative Breast Cancer Cells. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7802.	1.8	42
557	Case of anti-Zic4 antibody-mediated cerebellar toxicity induced by dual checkpoint inhibition in head and neck squamous cell carcinoma. <i>BMJ Case Reports</i> , 2020, 13, e235607.	0.2	9
558	Clinical Outcomes for PD-1 Inhibitor Plus Chemotherapy as Second-Line or Later Therapy Compared to PD-1/PD-L1 Inhibitor Alone in Advanced Non-small-cell Lung Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 556275.	1.3	6
559	PD-1 inhibitor inducing exosomal miR-34a-5p expression mediates the cross talk between cardiomyocyte and macrophage in immune checkpoint inhibitor-related cardiac dysfunction. , 2020, 8, e001293.		37
560	Evidences of CTLA-4 and PD-1 Blocking Agents-Induced Cardiotoxicity in Cellular and Preclinical Models. <i>Journal of Personalized Medicine</i> , 2020, 10, 179.	1.1	41
561	Predictive Biomarkers of Immune Checkpoint Inhibitors-Related Toxicities. <i>Frontiers in Immunology</i> , 2020, 11, 2023.	2.2	50
562	The cancer patient and cardiology. <i>European Journal of Heart Failure</i> , 2020, 22, 2290-2309.	2.9	62
563	Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-mediated cardiovascular, rheumatic, and renal toxicities from checkpoint inhibitors. <i>Supportive Care in Cancer</i> , 2020, 28, 6159-6173.	1.0	11
564	Analysis of immune-related adverse events caused by immune checkpoint inhibitors using the Japanese Adverse Drug Event Report database. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 1279-1294.	0.9	28
565	Pembrolizumab in a Patient With Heavily Pre-Treated Squamous Cell Thymic Carcinoma and Cardiac Impairment: A Case Report and Literature Review. <i>Frontiers in Oncology</i> , 2020, 10, 1478.	1.3	7
566	Editorial Comment to Resumption of anti-programmed cell death 1 monotherapy for severe immune-related adverse events experienced patient with renal cell carcinoma. <i>IJU Case Reports</i> , 2020, 3, 179-180.	0.1	0
567	MASCC 2020 recommendations for the management of immune-related adverse events of patients undergoing treatment with immune checkpoint inhibitors. <i>Supportive Care in Cancer</i> , 2020, 28, 6107-6110.	1.0	16
568	Cardiothoracic Complications of Immune Checkpoint Inhibitor Therapy: An Imaging Review. <i>Journal of Computer Assisted Tomography</i> , 2020, 44, 652-655.	0.5	2
569	Pembrolizumab on pre-existing inclusion body myositis: a case report. <i>BMC Rheumatology</i> , 2020, 4, 48.	0.6	4
570	Immune Related Adverse Events. <i>Cancer Journal (Sudbury, Mass)</i> , 2020, 26, 432-440.	1.0	4
571	Resumption of anti-programmed cell death 1 monotherapy for severe immune-related adverse events experienced patient with renal cell carcinoma. <i>IJU Case Reports</i> , 2020, 3, 176-179.	0.1	1
572	Concomitant myopericarditis and takotsubo syndrome following immune checkpoint inhibitor therapy. <i>BMJ Case Reports</i> , 2020, 13, e235265.	0.2	18

#	ARTICLE	IF	CITATIONS
573	Cardiovascular Toxicity Related to Cancer Treatment: A Pragmatic Approach to the American and European Cardio-Oncology Guidelines. <i>Journal of the American Heart Association</i> , 2020, 9, e018403.	1.6	149
574	Concomitant development of neurologic and cardiac immune-related adverse effects in patients treated with immune checkpoint inhibitors for melanoma. <i>Melanoma Research</i> , 2020, 30, 484-491.	0.6	10
575	Diagnosis and management of immune-related adverse effects of immune checkpoint therapy in the emergency department. <i>Journal of the American College of Emergency Physicians Open</i> , 2020, 1, 1637-1659.	0.4	17
576	Immune-related myositis resulting from combination therapy of ipilimumab and nivolumab in patient with metastatic renal cell carcinoma. <i>BMJ Case Reports</i> , 2020, 13, e235199.	0.2	3
577	Immune-Driven Pathogenesis of Neurotoxicity after Exposure of Cancer Patients to Immune Checkpoint Inhibitors. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5774.	1.8	23
578	Intensified immunosuppressive therapy in patients with immune checkpoint inhibitor-induced myocarditis. , 2020, 8, e001887.		45
579	Diagnosis and Differential Diagnosis of Neurological Adverse Events during Immune Checkpoint Inhibitor Therapy. <i>Journal of Oncology</i> , 2020, 2020, 1-9.	0.6	6
582	Complete heart block and subsequent sudden cardiac death from immune checkpoint inhibitor-associated myocarditis. <i>HeartRhythm Case Reports</i> , 2020, 6, 761-764.	0.2	11
583	Inflammatory Biomarkers to Detect Immune Checkpoint Inhibitor-Associated Cardiotoxicity in Lung Cancer Patients. <i>JACC: CardioOncology</i> , 2020, 2, 503-505.	1.7	2
584	Blind Spot. <i>JACC: CardioOncology</i> , 2020, 2, 611-613.	1.7	1
585	Cancer and Cardiovascular Disease. <i>JACC: CardioOncology</i> , 2020, 2, 578-580.	1.7	1
586	Cardiotoxicity of immune checkpoint inhibitors: An updated review. <i>Biotechnology and Applied Biochemistry</i> , 2022, 69, 61-69.	1.4	6
587	Fulminant myocarditis: a comprehensive review from etiology to treatments and outcomes. <i>Signal Transduction and Targeted Therapy</i> , 2020, 5, 287.	7.1	72
588	The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand?. <i>Frontiers in Immunology</i> , 2020, 11, 574271.	2.2	112
589	Cardiotoxicity danger in immunotherapy. <i>IUBMB Life</i> , 2020, 72, 1160-1167.	1.5	4
590	Early detection and management of immune-related myocarditis: Experience from a case with advanced squamous cell lung carcinoma. <i>European Journal of Cancer</i> , 2020, 131, 5-8.	1.3	5
591	Supramolecular prodrug hydrogelator as an immune booster for checkpoint blocker-based immunotherapy. <i>Science Advances</i> , 2020, 6, eaaz8985.	4.7	93
592	Demographic Factors Associated with Toxicity in Patients Treated with Anti-Programmed Cell Death-1 Therapy. <i>Cancer Immunology Research</i> , 2020, 8, 851-855.	1.6	37

#	ARTICLE	IF	CITATIONS
593	Immune Checkpoint Inhibitor-Related Myositis: From Biology to Bedside. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3054.	1.8	41
594	Investigational Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Event Prediction and Diagnosis. <i>Clinical Chemistry</i> , 2020, 66, 779-793.	1.5	74
595	The top 100 most cited articles on rhabdomyolysis: A bibliometric analysis. <i>American Journal of Emergency Medicine</i> , 2020, 38, 1754-1759.	0.7	9
596	Exacerbation of autoimmune myocarditis by an immune checkpoint inhibitor is dependent on its time of administration in mice. <i>International Journal of Cardiology</i> , 2020, 313, 67-75.	0.8	19
597	Immune-related adverse events of checkpoint inhibitors. <i>Nature Reviews Disease Primers</i> , 2020, 6, 38.	18.1	684
598	Blocking interaction between SHP2 and PD-1 denotes a novel opportunity for developing PD-1 inhibitors. <i>EMBO Molecular Medicine</i> , 2020, 12, e11571.	3.3	40
599	Rheumatic Manifestations in Patients Treated with Immune Checkpoint Inhibitors. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3389.	1.8	19
600	Factors affecting tumor responders and predictive biomarkers of toxicities in cancer patients treated with immune checkpoint inhibitors. <i>International Immunopharmacology</i> , 2020, 85, 106628.	1.7	14
601	T-cell lymphoma secondary to checkpoint inhibitor therapy. , 2020, 8, e000104.		25
602	Immune checkpoint inhibitor-mediated myasthenia gravis with focal subclinical myocarditis progressing to symptomatic cardiac disease. <i>BMJ Case Reports</i> , 2020, 13, e232920.	0.2	9
604	EAPCI Position Statement on Invasive Management of Acute Coronary Syndromes during the COVID-19 pandemic. <i>European Heart Journal</i> , 2020, 41, 1839-1851.	1.0	106
605	Onco-Cardiology: Consensus Paper of the German Cardiac Society, the German Society for Pediatric Cardiology and Congenital Heart Defects and the German Society for Hematology and Medical Oncology. <i>Clinical Research in Cardiology</i> , 2020, 109, 1197-1222.	1.5	71
606	Childhood cancer survivors: The integral role of the cardiologist and cardiovascular imaging. <i>American Heart Journal</i> , 2020, 226, 127-139.	1.2	3
607	Therapeutic strategies for virus-negative myocarditis: a comprehensive review. <i>European Journal of Internal Medicine</i> , 2020, 77, 9-17.	1.0	30
608	Recent Advances in T1 and T2 Mapping in the Assessment of Fulminant Myocarditis by Cardiac Magnetic Resonance. <i>Current Cardiology Reports</i> , 2020, 22, 47.	1.3	14
609	Cardiac injuries in coronavirus disease 2019 (COVID-19). <i>Journal of Molecular and Cellular Cardiology</i> , 2020, 145, 25-29.	0.9	26
610	Emerging role of immune checkpoint inhibitors and their relevance for the cardiovascular system. <i>Herz</i> , 2020, 45, 645-651.	0.4	16
611	Tissue Is the Issue, Even During a Pandemic. <i>Circulation</i> , 2020, 142, 423-425.	1.6	1

#	ARTICLE	IF	CITATIONS
612	Cardioprotective Strategies to Prevent Cancer Treatment-Related Cardiovascular Toxicity: a Review. <i>Current Oncology Reports</i> , 2020, 22, 72.	1.8	5
613	Development of Severe Heart Failure in a Patient with Squamous Non-small-cell Lung Cancer During Nivolumab Treatment. <i>Internal Medicine</i> , 2020, 59, 2003-2008.	0.3	10
614	Pulmonary Complications of Immunotherapy. <i>Clinics in Chest Medicine</i> , 2020, 41, 295-305.	0.8	1
615	Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy. , 2020, 8, e000604.		98
616	Evolving insights into the mechanisms of toxicity associated with immune checkpoint inhibitor therapy. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1778-1789.	1.1	34
617	Glycyrrhizin improved autophagy flux via HMGB1-dependent Akt/mTOR signaling pathway to prevent Doxorubicin-induced cardiotoxicity. <i>Toxicology</i> , 2020, 441, 152508.	2.0	29
618	New Insights into Mechanisms of Immune Checkpoint Inhibitor-Induced Cardiovascular Toxicity. <i>Current Oncology Reports</i> , 2020, 22, 65.	1.8	44
619	Mapping endocrine toxicity spectrum of immune checkpoint inhibitors: a disproportionality analysis using the WHO adverse drug reaction database, Vigibase. <i>Endocrine</i> , 2020, 69, 670-681.	1.1	32
620	Immune Checkpoint Inhibitors and Immune-Related Adverse Drug Reactions: Data From Italian Pharmacovigilance Database. <i>Frontiers in Pharmacology</i> , 2020, 11, 830.	1.6	21
621	Immune checkpoint inhibitor cardiotoxicity: what can we learn from real life data on CMR as a diagnostic tool?. <i>European Heart Journal</i> , 2020, 41, 1744-1746.	1.0	6
622	Natural Compounds with Potential to Modulate Cancer Therapies and Self-Reactive Immune Cells. <i>Cancers</i> , 2020, 12, 673.	1.7	24
623	Obstacles and opportunities in the prevention and treatment of HBV-related hepatocellular carcinoma. <i>Genes and Diseases</i> , 2020, 7, 291-298.	1.5	4
624	Histopathologic Characterization of Myocarditis Associated With Immune Checkpoint Inhibitor Therapy. <i>Archives of Pathology and Laboratory Medicine</i> , 2020, 144, 1392-1396.	1.2	31
625	Neurologic complications of immune checkpoint inhibitors. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 479-488.	1.0	82
626	Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1177-1187.	2.0	66
627	Management of immune-related adverse events associated with immune checkpoint inhibitors in cancer patients: a patient-centred approach. <i>Internal and Emergency Medicine</i> , 2020, 15, 587-598.	1.0	16
628	Immune-related adverse events of checkpoint inhibitors: Insights into immunological dysregulation. <i>Clinical Immunology</i> , 2020, 213, 108377.	1.4	44
629	Immune checkpoint inhibitor associated neurotoxicity: Much more than meets the eye. <i>Immunology Letters</i> , 2020, 221, 72-74.	1.1	0

#	ARTICLE	IF	CITATIONS
630	Checkpoint Inhibitors and Therapeutic Vaccines for the Treatment of Chronic HBV Infection. <i>Frontiers in Immunology</i> , 2020, 11, 401.	2.2	39
631	Autoimmunity in Acute Myocarditis: How Immunopathogenesis Steers New Directions for Diagnosis and Treatment. <i>Current Cardiology Reports</i> , 2020, 22, 28.	1.3	18
632	State-of-the-art Review: Interventional Onco-Cardiology. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2020, 22, 1.	0.4	3
633	Hemophagocytic Lymphohistiocytosis in a Patient with Rheumatoid Arthritis on Pembrolizumab for Lung Adenocarcinoma. <i>Internal Medicine</i> , 2020, 59, 1075-1080.	0.3	16
634	Immune-Related Adverse Events (irAEs): Diagnosis, Management, and Clinical Pearls. <i>Current Oncology Reports</i> , 2020, 22, 39.	1.8	199
635	Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia. <i>Nature Reviews Cardiology</i> , 2020, 17, 474-502.	6.1	332
636	Moving towards personalized treatments of immune-related adverse events. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 504-515.	12.5	189
637	Clinical Characteristics and Treatment of Immune-Related Adverse Events of Immune Checkpoint Inhibitors. <i>Immune Network</i> , 2020, 20, e9.	1.6	143
638	The Role of Cardiac MRI in Animal Models of Cardiotoxicity: Hopes and Challenges. <i>Journal of Cardiovascular Translational Research</i> , 2020, 13, 367-376.	1.1	7
639	Heart-Specific Immune Responses in an Animal Model of Autoimmune-Related Myocarditis Mitigated by an Immunoproteasome Inhibitor and Genetic Ablation. <i>Circulation</i> , 2020, 141, 1885-1902.	1.6	53
640	Personalized Approach to Cancer Treatment-Related Cardiomyopathy. <i>Current Heart Failure Reports</i> , 2020, 17, 43-55.	1.3	3
641	Myocarditis associated with immune checkpoint inhibitor therapy: a case report of three patients. <i>Emergency Radiology</i> , 2020, 27, 455-460.	1.0	10
642	Immune Checkpoint Inhibitors in the Treatment of Renal Cell Carcinoma. <i>Seminars in Nephrology</i> , 2020, 40, 76-85.	0.6	18
643	Cardiovascular immune-related adverse events: Evaluation, diagnosis and management. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2020, 16, 232-240.	0.7	16
644	Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy. <i>Cell</i> , 2020, 182, 655-671.e22.	13.5	259
645	Evaluation of the usefulness of protocol-based pharmacist-facilitated laboratory monitoring to ensure the safety of immune checkpoint inhibitors in patients with lung cancer. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2020, 45, 1288-1294.	0.7	7
646	<p>Multiple Immune-Related Adverse Events and Anti-Tumor Efficacy: Real-World Data on Various Solid Tumors</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 4585-4593.	0.9	37
647	Pharmacogenomics for immunotherapy and immune-related cardiotoxicity. <i>Human Molecular Genetics</i> , 2020, 29, R186-R196.	1.4	7

#	ARTICLE	IF	CITATIONS
648	Tumor-targeted CD28 bispecific antibodies enhance the antitumor efficacy of PD-1 immunotherapy. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	49
649	Calcium-sensing receptor autoantibody-mediated hypoparathyroidism associated with immune checkpoint inhibitor therapy: diagnosis and long-term follow-up. , 2020, 8, e000687.		21
650	Balancing Cancer Immunotherapy Efficacy and Toxicity. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 2898-2906.	2.0	28
651	How to Monitor Cardiac Complications of Immune Checkpoint Inhibitor Therapy. <i>Frontiers in Pharmacology</i> , 2020, 11, 972.	1.6	26
652	Cardiac Mast Cells: Underappreciated Immune Cells in Cardiovascular Homeostasis and Disease. <i>Trends in Immunology</i> , 2020, 41, 734-746.	2.9	49
653	Axitinib plus immune checkpoint inhibitor: evidence- and expert-based consensus recommendation for treatment optimisation and management of related adverse events. <i>British Journal of Cancer</i> , 2020, 123, 898-904.	2.9	36
654	Virome Sequencing in Patients With Myocarditis. <i>Circulation: Heart Failure</i> , 2020, 13, e007103.	1.6	16
655	The quest for diagnostic approaches of cardiac involvement in polymyositis and dermatomyositis. <i>Annals of Palliative Medicine</i> , 2020, 9, 2256-2270.	0.5	15
656	Immune checkpoint inhibitor diabetes mellitus: a novel form of autoimmune diabetes. <i>Clinical and Experimental Immunology</i> , 2020, 200, 131-140.	1.1	104
657	Immune-Related Adverse Events and Immune Checkpoint Inhibitor Efficacy in Patients with Gastrointestinal Cancer with Food and Drug Administration-Approved Indications for Immunotherapy. <i>Oncologist</i> , 2020, 25, 669-679.	1.9	30
658	Immune-mediated adverse effects of immune-checkpoint inhibitors and their management in cancer. <i>Immunology Letters</i> , 2020, 221, 61-71.	1.1	12
659	Case of pembrolizumab-induced myocarditis presenting as torsades de pointes with safe re-challenge. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 1544-1548.	0.5	16
660	Cardiac Adverse Events Related to Immune Checkpoint Inhibitors. <i>JACC: Case Reports</i> , 2020, 2, 200-202.	0.3	2
661	Immune-related adverse events are clustered into distinct subtypes by T-cell profiling before and early after anti-PD-1 treatment. <i>OncImmunity</i> , 2020, 9, 1722023.	2.1	37
662	Drug-induced myocardial dysfunction â€œ recommendations for assessment in clinical and pre-clinical studies. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 281-294.	1.0	1
663	Fatal Adverse Events Associated With Programmed Cell Death Ligand 1 Inhibitors: A Systematic Review and Meta-Analysis. <i>Frontiers in Pharmacology</i> , 2020, 11, 5.	1.6	12
665	Immunomodulatory treatment of immune checkpoint inhibitor-induced myocarditis: Pathway toward precision-based therapy. <i>Cardiovascular Pathology</i> , 2020, 47, 107211.	0.7	31
666	Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis. <i>European Heart Journal</i> , 2020, 41, 1733-1743.	1.0	212

#	ARTICLE	IF	CITATIONS
667	Imaging manifestations of immune-related adverse effects in checkpoint inhibitor therapies: A primer for the radiologist. <i>Clinical Imaging</i> , 2020, 63, 35-49.	0.8	3
668	Myocardial and Pericardial Toxicity Associated With Immune Checkpoint Inhibitors in Cancer Patients. <i>JACC: Case Reports</i> , 2020, 2, 191-199.	0.3	15
669	Resistance to Checkpoint Inhibition in Cancer Immunotherapy. <i>Translational Oncology</i> , 2020, 13, 100738.	1.7	173
670	Eosinophilic Fasciitis Following Checkpoint Inhibitor Therapy: Four Cases and a Review of Literature. <i>Oncologist</i> , 2020, 25, 140-149.	1.9	38
671	Targeting GPCRs Against Cardiotoxicity Induced by Anticancer Treatments. <i>Frontiers in Cardiovascular Medicine</i> , 2019, 6, 194.	1.1	11
672	Pembrolizumab-Induced Mobitz Type 2 Second-Degree Atrioventricular Block. <i>Case Reports in Cardiology</i> , 2020, 2020, 1-5.	0.1	6
673	A review of cancer immunotherapy toxicity. <i>Ca-A Cancer Journal for Clinicians</i> , 2020, 70, 86-104.	157.7	753
674	Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. <i>Annals of Oncology</i> , 2020, 31, 171-190.	0.6	582
675	Toxicity of Immune Checkpoint Inhibitors: Considerations for the Surgeon. <i>Annals of Surgical Oncology</i> , 2020, 27, 1533-1545.	0.7	6
677	Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2020, 72, 320-341.	1.8	165
678	Acute fatal myocarditis after a single dose of anti-PD-1 immunotherapy, autopsy findings: a case report. <i>Cardiovascular Pathology</i> , 2020, 46, 107202.	0.7	25
679	Immune checkpoint inhibitor-induced myocarditis not visible with cardiac magnetic resonance imaging but detected with PET-CT: a case report. <i>Acta Oncologica</i> , 2020, 59, 490-492.	0.8	11
680	Codelivery of Anti-PD-1 Antibody and Paclitaxel with Matrix Metalloproteinase and pH Sensitive Micelles for Enhanced Tumor Chemoimmunotherapy. <i>Small</i> , 2020, 16, e1906832.	5.2	80
681	Mechanisms of checkpoint inhibition-induced adverse events. <i>Clinical and Experimental Immunology</i> , 2020, 200, 141-154.	1.1	33
682	Myositis as a neuromuscular complication of immune checkpoint inhibitors. <i>Acta Neurologica Belgica</i> , 2020, 120, 355-364.	0.5	17
683	Immune Checkpoint Inhibitor Myocarditis: Pathophysiological Characteristics, Diagnosis, and Treatment. <i>Journal of the American Heart Association</i> , 2020, 9, e013757.	1.6	240
684	Multimodality Cardiac Imaging in the Era of Emerging Cancer Therapies. <i>Journal of the American Heart Association</i> , 2020, 9, e013755.	1.6	37
685	Management of Patients With Immune Checkpoint Inhibitor-Induced Enterocolitis: A Systematic Review. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1393-1403.e1.	2.4	47

#	ARTICLE	IF	CITATIONS
686	Immune Checkpoint Inhibitor-induced Fatal Myositis in a Patient With Squamous Cell Carcinoma and a History of Thymoma. <i>Clinical Lung Cancer</i> , 2020, 21, e246-e249.	1.1	2
687	Global Longitudinal Strain and Cardiac Events in Patients With Immune Checkpoint Inhibitor-Related Myocarditis. <i>Journal of the American College of Cardiology</i> , 2020, 75, 467-478.	1.2	179
688	The immunopathogenesis of rheumatic immune adverse events from checkpoint inhibitors: prospects for targeted therapy. <i>Current Opinion in Rheumatology</i> , 2020, 32, 175-183.	2.0	1
689	An autoimmune-based, paraneoplastic neurologic syndrome following checkpoint inhibition and concurrent radiotherapy for merkel cell carcinoma: case report. <i>Strahlentherapie Und Onkologie</i> , 2020, 196, 664-670.	1.0	4
690	Fatal association of fulminant myocarditis and rhabdomyolysis after immune checkpoint blockade. <i>European Journal of Cancer</i> , 2020, 132, 224-227.	1.3	7
691	Strategies to Prevent Cardiotoxicity. <i>Current Treatment Options in Oncology</i> , 2020, 21, 32.	1.3	12
692	Precision Cardio-Oncology: a Systems-Based Perspective on Cardiotoxicity of Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors. <i>Journal of Cardiovascular Translational Research</i> , 2020, 13, 402-416.	1.1	16
693	Immune-checkpoint profiles for T cells in bronchoalveolar lavage fluid of patients with immune-checkpoint inhibitor-related interstitial lung disease. <i>International Immunology</i> , 2020, 32, 547-557.	1.8	18
694	Autoimmune complications of immunotherapy: pathophysiology and management. <i>BMJ, The</i> , 2020, 369, m736.	3.0	79
695	Regulatory T Cells Beyond Autoimmunity: From Pregnancy to Cancer and Cardiovascular Disease. <i>Frontiers in Immunology</i> , 2020, 11, 509.	2.2	7
696	Late cardiac adverse events in patients with cancer treated with immune checkpoint inhibitors. , 2020, 8, e000261.		53
697	Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer. <i>Nature Medicine</i> , 2020, 26, 732-740.	15.2	322
698	An update on the safety of nivolumab for the treatment of advanced melanoma. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 409-421.	1.0	5
700	Immunologic adverse events from immune checkpoint therapy. <i>Best Practice and Research in Clinical Rheumatology</i> , 2020, 34, 101511.	1.4	3
701	Programmed cell death-1 (PD-1) and programmed death-ligand 1 (PD-L1) expression in PD-1 inhibitor-associated colitis and its mimics. <i>Histopathology</i> , 2020, 77, 240-249.	1.6	13
702	Immunotherapy to treat malignancy in patients with pre-existing autoimmunity. , 2020, 8, e000356.		34
703	Myositis-myasthenia gravis overlap syndrome complicated with myasthenia crisis and myocarditis associated with anti-programmed cell death-1 (sintilimab) therapy for lung adenocarcinoma. <i>Annals of Translational Medicine</i> , 2020, 8, 250-250.	0.7	42
704	A retrospective study of immune checkpoint inhibitor-associated myocarditis in a single center in China. <i>Chinese Clinical Oncology</i> , 2020, 9, 16-16.	0.4	23

#	ARTICLE	IF	CITATIONS
705	Programmed Cell Death-1: Programmed Cell Death-Ligand 1 Interaction Protects Human Cardiomyocytes Against T-Cell Mediated Inflammation and Apoptosis Response In Vitro. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2399.	1.8	29
706	Update on myocarditis “ what we know so far and where we may be heading. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 455-467.	0.4	26
707	Re-introducing immunotherapy in patients surviving immune checkpoint inhibitors-mediated myocarditis. <i>Clinical Research in Cardiology</i> , 2021, 110, 50-60.	1.5	20
708	The PD-1/PD-L pathway in rheumatic diseases. <i>Journal of the Formosan Medical Association</i> , 2021, 120, 48-59.	0.8	26
709	EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 36-48.	0.5	153
710	Retrospective analysis of hospital admissions due to immune checkpoint inhibitor-induced immune-related adverse events (irAE). <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021, 17, e109-e116.	0.7	6
711	Tofacitinib for treatment in immune-mediated myocarditis: The first reported cases. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 739-746.	0.5	18
712	Bilateral Sensorineural Hearing Loss Associated With Nivolumab Therapy for Stage IV Malignant Melanoma. <i>Ear, Nose and Throat Journal</i> , 2021, 100, 286S-291S.	0.4	9
713	Immune Checkpoint Inhibitor Cardiotoxicity: Understanding Basic Mechanisms and Clinical Characteristics and Finding a Cure. <i>Annual Review of Pharmacology and Toxicology</i> , 2021, 61, 113-134.	4.2	40
714	MHC class I loss in endometrial carcinoma: a potential resistance mechanism to immune checkpoint inhibition. <i>Modern Pathology</i> , 2021, 34, 627-636.	2.9	13
715	Coronary and aortic calcification are associated with cardiovascular events on immune checkpoint inhibitor therapy. <i>International Journal of Cardiology</i> , 2021, 322, 177-182.	0.8	18
716	PD-1/PDL-1 Inhibitors and Cardiotoxicity; Molecular, Etiological and Management Outlines. <i>Journal of Advanced Research</i> , 2021, 29, 45-54.	4.4	31
717	Novel human immunomodulatory T cell receptors and their double-edged potential in autoimmunity, cardiovascular disease and cancer. <i>Cellular and Molecular Immunology</i> , 2021, 18, 919-935.	4.8	11
718	A Genetic Mouse Model Recapitulates Immune Checkpoint Inhibitor-Associated Myocarditis and Supports a Mechanism-Based Therapeutic Intervention. <i>Cancer Discovery</i> , 2021, 11, 614-625.	7.7	145
719	Myocardial damage assessed by late gadolinium enhancement on cardiovascular magnetic resonance imaging in cancer patients treated with anthracyclines and/or trastuzumab. <i>European Heart Journal Cardiovascular Imaging</i> , 2021, 22, 427-434.	0.5	14
720	Inflammatory Myositis in Cancer Patients Receiving Immune Checkpoint Inhibitors. <i>Arthritis and Rheumatology</i> , 2021, 73, 866-874.	2.9	56
721	Toxicities Associated with Immunotherapy and Approach to Cardiotoxicity with Novel Cancer Therapies. <i>Critical Care Clinics</i> , 2021, 37, 47-67.	1.0	5
722	Frontiers in cancer immunotherapy—a symposium report. <i>Annals of the New York Academy of Sciences</i> , 2021, 1489, 30-47.	1.8	39

#	ARTICLE	IF	CITATIONS
723	Improving cardiotoxicity prediction in cancer treatment: integration of conventional circulating biomarkers and novel exploratory tools. <i>Archives of Toxicology</i> , 2021, 95, 791-805.	1.9	4
724	Practical guidance for echocardiography for cancer therapeutics-related cardiac dysfunction. <i>Journal of Echocardiography</i> , 2021, 19, 1-20.	0.4	14
725	Are we underestimating the potential for cardiotoxicity related to immune checkpoint inhibitors?. <i>European Heart Journal</i> , 2021, 42, 1632-1635.	1.0	18
726	The risk of cardiac events in patients receiving immune checkpoint inhibitors: a nationwide Danish study. <i>European Heart Journal</i> , 2021, 42, 1621-1631.	1.0	102
727	Cardiotoxicity Related to Immune Checkpoint Inhibitors. Current Treatment Options in <i>Cardiovascular Medicine</i> , 2021, 23, 1.	0.4	1
728	Immortal time bias in the association between toxicity and response for immune checkpoint inhibitors: a meta-analysis. <i>Immunotherapy</i> , 2021, 13, 257-270.	1.0	28
729	Considerations when treating high-grade pediatric glioma patients with immunotherapy. <i>Expert Review of Neurotherapeutics</i> , 2021, 21, 205-219.	1.4	5
730	The Role of Cardiovascular MRI in Cardio-Oncology. <i>Heart Failure Clinics</i> , 2021, 17, 121-133.	1.0	5
731	Management perspectives from the 2019 Wuhan international workshop on fulminant myocarditis. <i>International Journal of Cardiology</i> , 2021, 324, 131-138.	0.8	24
732	Emerging Immunotherapies in the Treatment of Brain Metastases. <i>Oncologist</i> , 2021, 26, 231-241.	1.9	29
733	Clinical Pharmacology and Interplay of Immune Checkpoint Agents: A Yin-Yang Balance. <i>Annual Review of Pharmacology and Toxicology</i> , 2021, 61, 85-112.	4.2	50
734	Emerging cancer therapies and cardiovascular risk. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 51, 837-845.	1.0	0
735	Autoimmune Endocrinopathies: An Emerging Complication of Immune Checkpoint Inhibitors. <i>Annual Review of Medicine</i> , 2021, 72, 313-330.	5.0	24
736	Current status and future perspectives of immunotherapy in bladder cancer treatment. <i>Science China Life Sciences</i> , 2021, 64, 512-533.	2.3	21
737	Pre-treatment high-sensitivity troponin T for the short-term prediction of cardiac outcomes in patients on immune checkpoint inhibitors. <i>European Journal of Clinical Investigation</i> , 2021, 51, e13400.	1.7	17
738	Persistent anti-tumor response in cancer patients experiencing pneumonitis related to immune checkpoint blockade. <i>Acta Clinica Belgica</i> , 2021, 76, 144-148.	0.5	2
739	Emergency myelopoiesis contributes to immune cell exhaustion and pulmonary vascular remodelling. <i>British Journal of Pharmacology</i> , 2021, 178, 187-202.	2.7	14
740	Clinical types of checkpoint inhibitor-related pneumonitis in lung cancer patients: a multicenter experience. <i>Translational Lung Cancer Research</i> , 2021, 10, 415-429.	1.3	13

#	ARTICLE	IF	CITATIONS
741	Efficacy and side effects of immune checkpoint inhibitors in the treatment of colorectal cancer. Therapeutic Advances in Gastroenterology, 2021, 14, 175628482110020.	1.4	11
742	Toxicities of Novel Antineoplastic Therapies. , 2021, , 711-738.		1
743	Management of Immunotherapy Adverse Events in Oncological Patients: Anti-CTLA-4, Anti-PD-1/PD-L1. Reviews on Recent Clinical Trials, 2021, 15, 339-346.	0.4	5
744	Non-depleting reformation of immunosuppressive myeloid cells to broaden the application of anti-PD therapy. Nanoscale, 2021, 13, 4420-4431.	2.8	13
745	Immunopathogenesis of Immune-Related Adverse Events from Cancer Immunotherapy. , 2021, , 49-68.		0
746	Myositis. , 2021, , 99-107.		0
747	Cardiotoxic effects of angiogenesis inhibitors. Clinical Science, 2021, 135, 71-100.	1.8	46
748	Cardiovascular Oncologic Emergencies. , 2021, , 269-290.		0
749	Immunotherapy-associated complete heart block in a patient with NSCLC: A case report and literature review. Respiratory Medicine Case Reports, 2021, 33, 101390.	0.2	3
750	Cardiac Toxicities Associated with Immune Checkpoints Inhibitors: Mechanisms, Manifestations and Management. Korean Circulation Journal, 2021, 51, 579.	0.7	3
751	Immunotherapy-Associated Cardiotoxicity of Immune Checkpoint Inhibitors and Chimeric Antigen Receptor T Cell Therapy: Diagnostic and Management Challenges and Strategies. Current Cardiology Reports, 2021, 23, 11.	1.3	35
752	Cardiovascular Side Effects of Medications for Skin Diseases. , 2021, , 391-418.		0
753	Echocardiographic evaluation of patients undergoing cancer therapy. European Heart Journal Cardiovascular Imaging, 2021, 22, 375-382.	0.5	11
754	Immune checkpoint inhibitor-induced myocarditis in lung cancer patients: a case report of sintilimab-induced myocarditis and a review of the literature. Annals of Palliative Medicine, 2021, 10, 793-802.	0.5	12
755	Immune checkpoint inhibitors-related myocarditis in patients with cancer: an analysis of international spontaneous reporting systems. BMC Cancer, 2021, 21, 38.	1.1	17
756	Myocarditis and Pericarditis. , 2021, , .		1
757	Immune System Efficiency in Cancer and the Microbiota Influence. Pathobiology, 2021, 88, 170-186.	1.9	14
759	Case Report: Fatal Multiorgan Failure and Heterochronous Pneumonitis Following Pembrolizumab Treatment in a Patient With Large-Cell Neuroendocrine Carcinoma of Lung. Frontiers in Pharmacology, 2020, 11, 569466.	1.6	9

#	ARTICLE	IF	CITATIONS
760	Chemoradiotherapy in Cancer Treatment: Rationale and Clinical Applications. <i>Anticancer Research</i> , 2021, 41, 1-7.	0.5	43
761	Acute motor axonal neuropathy after ipilimumab and nivolumab treatment in melanoma brain metastases: A case report and review of the literature. <i>SAGE Open Medical Case Reports</i> , 2021, 9, 2050313X2110422.	0.2	3
762	Mechanisms and Management of Immune Checkpoint Inhibitor-Related Cardiac Adverse Events. <i>JMA Journal</i> , 2021, 4, 91-98.	0.6	13
763	Cardiovascular Toxicity of Immune Checkpoint Inhibitors: Clinical Risk Factors. <i>Current Oncology Reports</i> , 2021, 23, 13.	1.8	38
764	Hydrogels for Engineering the Immune System. <i>Advanced NanoBiomed Research</i> , 2021, 1, 2000073.	1.7	18
765	Onco-hypertension: Overview of hypertension with anti-cancer agents. <i>Journal of Onco-Nephrology</i> , 2021, 5, 57-69.	0.3	8
766	Paraneoplastic neurological syndrome: an evolving story. <i>Neuro-Oncology Practice</i> , 2021, 8, 362-374.	1.0	5
767	Immune Checkpoint Inhibitors: Cardiotoxicity in Pre-clinical Models and Clinical Studies. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 619650.	1.1	17
768	Cardiotoxicity Induced by Immune Checkpoint Inhibitors: A Pharmacovigilance Study From 2014 to 2019 Based on FAERS. <i>Frontiers in Pharmacology</i> , 2021, 12, 616505.	1.6	23
769	Mitigated viral myocarditis in A/J mice by the immunoproteasome inhibitor ONX 0914 depends on inhibition of systemic inflammatory responses in CoxsackievirusB3 infection. <i>Basic Research in Cardiology</i> , 2021, 116, 7.	2.5	8
770	Clinical Characterisation and Management of the Main Treatment-Induced Toxicities in Patients with Hepatocellular Carcinoma and Cirrhosis. <i>Cancers</i> , 2021, 13, 584.	1.7	6
771	Case Report: Simultaneous Hyperprogression and Fulminant Myocarditis in a Patient With Advanced Melanoma Following Treatment With Immune Checkpoint Inhibitor Therapy. <i>Frontiers in Immunology</i> , 2020, 11, 561083.	2.2	12
772	The Cytokine Expression in Patients with Cardiac Complication after Immune Checkpoint Inhibitor Therapy. <i>Internal Medicine</i> , 2021, 60, 423-429.	0.3	18
773	Subclinical Myocarditis After Combination Immune Checkpoint Inhibitor Therapy. <i>Circulation: Heart Failure</i> , 2021, 14, e007524.	1.6	6
774	Pharmacological and Genetic Inhibition of PD-1 Demonstrate an Important Role of PD-1 in Ischemia-Induced Skeletal Muscle Inflammation, Oxidative Stress, and Angiogenesis. <i>Frontiers in Immunology</i> , 2021, 12, 586429.	2.2	6
775	At the Heart of Immune Checkpoint Inhibitor-Induced Immune Toxicity. <i>Cancer Discovery</i> , 2021, 11, 537-539.	7.7	2
776	Newly diagnosed cardiovascular disease in patients treated with immune checkpoint inhibitors: a retrospective analysis of patients at an academic tertiary care center. <i>Cardio-Oncology</i> , 2021, 7, 10.	0.8	12
777	Understanding and treating the inflammatory adverse events of cancer immunotherapy. <i>Cell</i> , 2021, 184, 1575-1588.	13.5	111

#	ARTICLE	IF	CITATIONS
778	Toward a broader view of mechanisms of drug cardiotoxicity. <i>Cell Reports Medicine</i> , 2021, 2, 100216.	3.3	44
779	Management of Immune Checkpoint Inhibitor-Induced Myocarditis. <i>JACC: CardioOncology</i> , 2021, 3, 157-161.	1.7	22
780	Checkpoint blockade toxicities: Insights into autoimmunity and treatment. <i>Seminars in Immunology</i> , 2021, 52, 101473.	2.7	11
783	The Evolving Immunotherapy Landscape and the Epidemiology, Diagnosis, and Management of Cardiotoxicity. <i>JACC: CardioOncology</i> , 2021, 3, 35-47.	1.7	80
784	Thyroid Dysfunction in Lung Cancer Patients Treated with Immune Checkpoint Inhibitors (ICIs): Outcomes in a Multiethnic Urban Cohort. <i>Cancers</i> , 2021, 13, 1464.	1.7	7
785	Neoadjuvant Pembrolizumab and High-Dose IFN-2b in Resectable Regionally Advanced Melanoma. <i>Clinical Cancer Research</i> , 2021, 27, 4195-4204.	3.2	18
786	Immune-Related Adverse Events and Their Association With the Effectiveness of PD-1/PD-L1 Inhibitors in Non-Small Cell Lung Cancer: A Real-World Study From China. <i>Frontiers in Oncology</i> , 2021, 11, 607531.	1.3	18
787	Association Between Sex and Immune-Related Adverse Events During Immune Checkpoint Inhibitor Therapy. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1396-1404.	3.0	56
788	Immune checkpoint inhibitor-associated myocarditis: manifestations and mechanisms. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	84
789	Rheumatic Complications of Immune Checkpoint Inhibitors. <i>Medical Clinics of North America</i> , 2021, 105, 227-245.	1.1	3
790	Electrocardiographic features of immune checkpoint inhibitor associated myocarditis. , 2021, 9, e002007.		36
791	Prognostic Value of Deep Learning-Mediated Treatment Monitoring in Lung Cancer Patients Receiving Immunotherapy. <i>Frontiers in Oncology</i> , 2021, 11, 609054.	1.3	23
792	Recurrent Myocarditis Induced by Immune-Checkpoint Inhibitor Treatment Is Accompanied by Persistent Inflammatory Markers Despite Immunosuppressive Treatment. <i>JCO Precision Oncology</i> , 2021, 5, 485-491.	1.5	5
793	Treatment of corticosteroid refractory immune checkpoint inhibitor myocarditis with Infliximab: a case series. <i>Cardio-Oncology</i> , 2021, 7, 13.	0.8	16
794	Combination of echocardiography and emergency endomyocardial biopsy for suspected myocarditis in the cardiovascular emergency medical care. <i>Journal of Echocardiography</i> , 2021, 19, 86-94.	0.4	4
795	Cardiotoxicities of novel cancer immunotherapies. <i>Heart</i> , 2021, 107, 1694-1703.	1.2	42
796	Mechanisms and clinical manifestations of cardiovascular toxicities associated with immune checkpoint inhibitors. <i>Clinical Science</i> , 2021, 135, 703-724.	1.8	18
797	Clinical Trial in a Dish. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, 1019-1031.	1.1	21

#	ARTICLE	IF	CITATIONS
798	Bispecific c-Met/PD-L1 CAR-T Cells Have Enhanced Therapeutic Effects on Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 546586.	1.3	30
799	Cardiac adverse events associated with anti-PD-1 therapy in patients treated for advanced melanoma: relevance of dosing troponin T levels. <i>European Journal of Dermatology</i> , 2021, 31, 205-212.	0.3	3
800	Checkpoint Inhibitor-Induced Colitis—A Clinical Overview of Incidence, Prognostic Implications and Extension of Current Treatment Options. <i>Pharmaceuticals</i> , 2021, 14, 367.	1.7	13
801	Anti-cancer Therapy Leads to Increased Cardiovascular Susceptibility to COVID-19. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 634291.	1.1	6
802	How can we manage the cardiac toxicity of immune checkpoint inhibitors?. <i>Expert Opinion on Drug Safety</i> , 2021, 20, 1-10.	1.0	8
804	Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204). <i>Neuro-Oncology</i> , 2021, 23, 1961-1973.	0.6	66
805	Cancer Therapy-Related Cardiovascular Complications in Clinical Practice: Current Perspectives. <i>Journal of Clinical Medicine</i> , 2021, 10, 1647.	1.0	13
806	Higher CD4/CD8 ratio of pleural effusion predicts better survival for lung cancer patients receiving immune checkpoint inhibitors. <i>Scientific Reports</i> , 2021, 11, 9381.	1.6	9
807	Pericardial Involvement in Cancer. <i>American Journal of Cardiology</i> , 2021, 145, 151-159.	0.7	22
808	Hematological immune related adverse events after treatment with immune checkpoint inhibitors. <i>European Journal of Cancer</i> , 2021, 147, 170-181.	1.3	40
809	Evolving Roles of Muscle-Resident Fibro-Adipogenic Progenitors in Health, Regeneration, Neuromuscular Disorders, and Aging. <i>Frontiers in Physiology</i> , 2021, 12, 673404.	1.3	55
810	Endocrine toxicities of immune checkpoint inhibitors. <i>Nature Reviews Endocrinology</i> , 2021, 17, 389-399.	4.3	162
811	Adverse events induced by immune checkpoint inhibitors. <i>Current Opinion in Immunology</i> , 2021, 69, 29-38.	2.4	25
812	Absolute Lymphocyte Count Predicts Immune-Related Adverse Events in Patients With Non-Small-Cell Lung Cancer Treated With Nivolumab Monotherapy: A Multicenter Retrospective Study. <i>Frontiers in Oncology</i> , 2021, 11, 618570.	1.3	12
813	Acute Myocarditis by Immune Checkpoint Inhibitor Identified by Quantitative Pixel-Wise Analysis of Native T1 Mapping. <i>Circulation: Cardiovascular Imaging</i> , 2021, 14, e012177.	1.3	1
814	Cardiotoxicity of Immune Checkpoint Inhibitors. <i>Current Oncology Reports</i> , 2021, 23, 79.	1.8	85
816	Role of cardiovascular magnetic resonance in early detection and treatment of cardiac dysfunction in oncology patients. <i>International Journal of Cardiovascular Imaging</i> , 2021, 37, 3003-3017.	0.7	4
817	Advances in drug development for hepatocellular carcinoma: clinical trials and potential therapeutic targets. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 172.	3.5	104

#	ARTICLE	IF	CITATIONS
818	Coping with sterile inflammation: between risk and necessity. <i>Cardiovascular Research</i> , 2021, 117, e84-e87.	1.8	5
819	Toxicities of Immunotherapy for Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 603658.	1.3	6
820	Cancer Therapeuticsâ€related Cardiac Dysfunction in Patients Treated With Immune Checkpoint Inhibitors: An Understudied Manifestation. <i>Journal of Immunotherapy</i> , 2021, 44, 179-184.	1.2	5
821	An Emergent Form of Cardiotoxicity: Acute Myocarditis Induced by Immune Checkpoint Inhibitors. <i>Biomolecules</i> , 2021, 11, 785.	1.8	9
822	Comparative Transcriptomics of Immune Checkpoint Inhibitor Myocarditis Identifies Guanylate Binding Protein 5 and 6 Dysregulation. <i>Cancers</i> , 2021, 13, 2498.	1.7	23
823	What the Cardiologist Needs to Know About Cancer Immunotherapies and Complications. <i>Current Treatment Options in Oncology</i> , 2021, 22, 53.	1.3	2
824	Heart Failure With Targeted Cancer Therapies. <i>Circulation Research</i> , 2021, 128, 1576-1593.	2.0	33
825	Preclinical Models of Cancer Therapyâ€Associated Cardiovascular Toxicity: A Scientific Statement From the American Heart Association. <i>Circulation Research</i> , 2021, 129, e21-e34.	2.0	37
826	Immune Checkpoint Inhibitors and Atherosclerotic Vascular Events in Cancer Patients. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 652186.	1.1	22
827	Mechanisms of Cardiovascular Toxicities Associated With Immunotherapies. <i>Circulation Research</i> , 2021, 128, 1780-1801.	2.0	48
828	Sipuleucelâ€associated inflammatory cardiomyopathy: a case report and observations from a large pharmacovigilance database. <i>ESC Heart Failure</i> , 2021, 8, 3360-3368.	1.4	3
829	Immune Checkpoint Inhibitor-Associated Pneumonitis in Non-Small Cell Lung Cancer: Current Understanding in Characteristics, Diagnosis, and Management. <i>Frontiers in Immunology</i> , 2021, 12, 663986.	2.2	50
830	A case of immune checkpoint inhibitor-associated myocarditis after initiation of atezolizumab plus bevacizumab therapy for advanced hepatocellular carcinoma. <i>Clinical Journal of Gastroenterology</i> , 2021, 14, 1233-1239.	0.4	8
831	Cytokine release syndrome in a patient with colorectal cancer after vaccination with BNT162b2. <i>Nature Medicine</i> , 2021, 27, 1362-1366.	15.2	70
832	Cardiotoxicity of immune checkpoint inhibitors: A systematic review and meta-analysis of randomised clinical trials. <i>European Journal of Cancer</i> , 2021, 148, 76-91.	1.3	33
833	Combining anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4) and -programmed cell death protein 1 (PD-1) agents for cancer immunotherapy. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 1623-1634.	1.4	10
834	Role of Cardiac Imaging in the Diagnosis of Immune Checkpoints Inhibitors Related Myocarditis. <i>Frontiers in Oncology</i> , 2021, 11, 640985.	1.3	9
835	Risk of Cardiac Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-Analysis. <i>Frontiers in Oncology</i> , 2021, 11, 645245.	1.3	9

#	ARTICLE	IF	CITATIONS
836	A retrospective analysis of cardiovascular adverse events associated with immune checkpoint inhibitors. <i>Cardio-Oncology</i> , 2021, 7, 19.	0.8	14
837	Nuclear Imaging for the Assessment of Cardiotoxicity from Chemotherapeutic Agents in Oncologic Disease. <i>Current Cardiology Reports</i> , 2021, 23, 65.	1.3	6
838	Neurological Immunotoxicity from Cancer Treatment. <i>International Journal of Molecular Sciences</i> , 2021, 22, 6716.	1.8	9
839	Cardiac Magnetic Resonance in Cardio-Oncology. <i>JACC: CardioOncology</i> , 2021, 3, 191-200.	1.7	6
840	Takotsubo Cardiomyopathy Associated With Checkpoint Inhibitor Therapy. <i>JACC: CardioOncology</i> , 2021, 3, 330-334.	1.7	19
842	Managing side effects of immune checkpoint inhibitors in breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 162, 103354.	2.0	15
843	Diffuse Alveolar Hemorrhage With Avelumab Maintenance Therapy. <i>Cureus</i> , 2021, 13, e15805.	0.2	1
844	Cardiovascular Complications Associated with Contemporary Lung Cancer Treatments. <i>Current Treatment Options in Oncology</i> , 2021, 22, 71.	1.3	3
845	Clinical characteristics, time course, treatment and outcomes of patients with immune checkpoint inhibitor-associated myocarditis. , 2021, 9, e002553.		24
846	Resistance mechanisms to programmed cell death protein 1 and programmed death ligand 1 inhibitors. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 1575-1590.	1.4	7
847	Not-so-opposite ends of the spectrum: CD8+ T cell dysfunction across chronic infection, cancer and autoimmunity. <i>Nature Immunology</i> , 2021, 22, 809-819.	7.0	113
848	The knowns & unknowns of pulmonary toxicity following immune checkpoint inhibitor therapies: a narrative review. <i>Translational Lung Cancer Research</i> , 2021, 10, 2752-2765.	1.3	5
849	Renal Complications Related to Checkpoint Inhibitors: Diagnostic and Therapeutic Strategies. <i>Diagnostics</i> , 2021, 11, 1187.	1.3	10
850	Immune Checkpoint Inhibitors and Cardiotoxicity: An Analysis of Spontaneous Reports in Eudravigilance. <i>Drug Safety</i> , 2021, 44, 957-971.	1.4	38
851	Advancing to the era of cancer immunotherapy. <i>Cancer Communications</i> , 2021, 41, 803-829.	3.7	90
852	A Tumor Progression Related 7-Gene Signature Indicates Prognosis and Tumor Immune Characteristics of Gastric Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 690129.	1.3	6
853	Impact of the development of immune related adverse events in metastatic melanoma treated with PD -1 inhibitors. <i>Melanoma Research</i> , 2021, 31, 258-263.	0.6	9
854	Immune checkpoint inhibitor myocarditis: elucidating the spectrum of disease through endomyocardial biopsy. <i>European Journal of Heart Failure</i> , 2021, 23, 1725-1735.	2.9	51

#	ARTICLE	IF	CITATIONS
855	Genetic variation associated with thyroid autoimmunity shapes the systemic immune response to PD-1 checkpoint blockade. <i>Nature Communications</i> , 2021, 12, 3355.	5.8	40
856	The possibilities of combination immunotherapy with radiation therapy for the treatment of patients with inoperable locally advanced non-small cell lung cancer. <i>IssledovaniĀ I Praktika V Medicine</i> , 2021, 8, 109-123.	0.1	0
857	Linagliptin, A Xanthine-Based Dipeptidyl Peptidase-4 Inhibitor, Ameliorates Experimental Autoimmune Myocarditis. <i>JACC Basic To Translational Science</i> , 2021, 6, 527-542.	1.9	6
858	Evaluating T-cell cross-reactivity between tumors and immune-related adverse events with TCR sequencing: pitfalls in interpretations of functional relevance. , 2021, 9, e002642.		7
859	Prognostic impact of immune-related adverse events on patients with and without cardiovascular disease: a retrospective review. <i>Cardio-Oncology</i> , 2021, 7, 26.	0.8	3
860	Cardiovascular toxicity of angiogenesis inhibitors and immune checkpoint inhibitors: synergistic anti-tumour effects at the cost of increased cardiovascular risk?. <i>Clinical Science</i> , 2021, 135, 1649-1668.	1.8	10
861	Refractory Nivolumab-Induced Myasthenia Gravis Treated With Abatacept. <i>American Journal of Therapeutics</i> , 2021, Publish Ahead of Print, .	0.5	3
862	Cardiotoxicity associated with immune checkpoint inhibitor therapy: a meta-analysis. <i>European Journal of Heart Failure</i> , 2021, 23, 1739-1747.	2.9	76
863	Pericardial Toxicities Associated With Immune Checkpoint Inhibitors: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS) Database. <i>Frontiers in Pharmacology</i> , 2021, 12, 663088.	1.6	19
864	Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies. <i>Nature Reviews Drug Discovery</i> , 2022, 21, 495-508.	21.5	120
865	Clinical Strategy for the Diagnosis and Treatment of Immune Checkpoint Inhibitor-Associated Myocarditis. <i>JAMA Cardiology</i> , 2021, 6, 1329.	3.0	64
867	Myocarditis Induced by Immune Checkpoint Inhibitors: Mechanisms and Therapeutic Prospects. <i>Journal of Inflammation Research</i> , 2021, Volume 14, 3077-3088.	1.6	5
868	Immune Myocarditis Overlapping With Myasthenia Gravis Due to Anti-PD-1 Treatment for a Chordoma Patient: A Case Report and Literature Review. <i>Frontiers in Immunology</i> , 2021, 12, 682262.	2.2	13
869	Analysis of risk factors for immune-related adverse events in various solid tumors using real-world data. <i>Future Oncology</i> , 2021, 17, 2593-2603.	1.1	14
870	Mechanisms Driving Immune-Related Adverse Events in Cancer Patients Treated with Immune Checkpoint Inhibitors. <i>Current Cardiology Reports</i> , 2021, 23, 98.	1.3	34
871	Fulminant myocarditis induced by immune checkpoint inhibitor nivolumab: a case report and review of the literature. <i>Journal of Medical Case Reports</i> , 2021, 15, 336.	0.4	7
872	The Growing Impact of Cardiovascular Oncology: Epidemiology and Pathophysiology. <i>Seminars in Thrombosis and Hemostasis</i> , 2021, 47, 899-906.	1.5	6
873	Serum Troponin T Concentrations Are Frequently Elevated in Advanced Skin Cancer Patients Prior to Immune Checkpoint Inhibitor Therapy: Experience From a Single Tertiary Referral Center. <i>Frontiers in Medicine</i> , 2021, 8, 691618.	1.2	4

#	ARTICLE	IF	CITATIONS
874	Immune-related myocarditis in two patients receiving camrelizumab therapy and document analysis. <i>Journal of Oncology Pharmacy Practice</i> , 2022, 28, 1350-1356.	0.5	8
875	Targeting early stages of cardiotoxicity from anti-PD1 immune checkpoint inhibitor therapy. <i>European Heart Journal</i> , 2022, 43, 316-329.	1.0	84
876	Hyperacute toxicity with combination ipilimumab and anti-PD1 immunotherapy. <i>European Journal of Cancer</i> , 2021, 153, 168-178.	1.3	14
877	Clinical implications of isolated troponinemia following immune checkpoint inhibitor therapy. <i>ESMO Open</i> , 2021, 6, 100216.	2.0	17
878	Cancer treatment-related cardiovascular disease: Current status and future research priorities. <i>Biochemical Pharmacology</i> , 2021, 190, 114599.	2.0	14
879	Immune Checkpoint Inhibitor-Induced Myocarditis with Myositis/Myasthenia Gravis Overlap Syndrome: A Systematic Review of Cases. <i>Oncologist</i> , 2021, 26, 1052-1061.	1.9	50
880	Novel actors on the stage of cardiac dysfunction induced by anti-PD1 oncological treatments. <i>European Heart Journal</i> , 2022, 43, 330-332.	1.0	6
881	Cardiac risk stratification in cancer patients: A longitudinal patient network analysis. <i>PLoS Medicine</i> , 2021, 18, e1003736.	3.9	19
882	Myocarditis occurrence with cancer immunotherapy across indications in clinical trial and post-marketing data. <i>Scientific Reports</i> , 2021, 11, 17324.	1.6	24
883	Lung Cancer Surgery after Neoadjuvant Immunotherapy. <i>Cancers</i> , 2021, 13, 4033.	1.7	12
884	Current status and future perspectives of onco-cardiology: Importance of early detection and intervention for cardiotoxicity, and cardiovascular complication of novel cancer treatment. <i>Global Health & Medicine</i> , 2021, 3, 214-225.	0.6	9
885	Acute cardiac manifestations under immune checkpoint inhibitors—beware of the obvious: a case report. <i>European Heart Journal - Case Reports</i> , 2021, 5, ytab262.	0.3	6
886	Immune checkpoint inhibitor-mediated colitis in gastrointestinal malignancies and inflammatory bowel disease. <i>World Journal of Gastrointestinal Oncology</i> , 2021, 13, 772-798.	0.8	11
887	Pembrolizumab-induced autoimmune Stevens-Johnson syndrome/toxic epidermal necrolysis with myositis and myocarditis in a patient with esophagogastric junction carcinoma: a case report. <i>Translational Cancer Research</i> , 2021, 10, 3870-3876.	0.4	13
888	Diagnosis and Management of Myocarditis in Children. <i>Circulation</i> , 2021, 144, e123-e135.	1.6	146
889	Immune checkpoint inhibitor-induced myocarditis in cancer patients: a case report and review of reported cases. <i>Cardio-Oncology</i> , 2021, 7, 27.	0.8	17
890	Immune checkpoint inhibitor myocarditis: a call for standardized histopathologic criteria. <i>European Journal of Heart Failure</i> , 2021, 23, 1736-1738.	2.9	3
891	Immune Checkpoint Inhibitors and Neurotoxicity. <i>Current Neuropharmacology</i> , 2021, 19, 1246-1263.	1.4	10

#	ARTICLE	IF	CITATIONS
893	Immune Checkpoint Inhibitors Mediated Lymphocytic and Giant Cell Myocarditis: Uncovering Etiological Mechanisms. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 721333.	1.1	14
895	JCS/JHFS 2018 Guideline on the Diagnosis and Treatment of Cardiomyopathies. <i>Circulation Journal</i> , 2021, 85, 1590-1689.	0.7	45
896	Immune-mediated adverse events in immune checkpoint inhibitors therapy: literature review. <i>Journal of Modern Oncology</i> , 2021, 23, 319-326.	0.1	4
897	Case Report: The Neuromuscular Triad of Immune Checkpoint Inhibitors: A Case Report of Myositis, Myocarditis, and Myasthenia Gravis Overlap Following Toripalimab Treatment. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 714460.	1.1	12
898	Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial. , 2021, 9, e002804.		5
900	Immune checkpoint inhibitors and cardiotoxicity: possible mechanisms, manifestations, diagnosis and management. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 1211-1228.	1.1	1
901	Cardiotoxicity of Cancer Treatments: Focus on Anthracycline Cardiomyopathy. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, 2648-2660.	1.1	20
902	Adverse Events as a Potential Clinical Marker of Antitumor Efficacy in Ovarian Cancer Patients Treated With Poly ADP-Ribose Polymerase Inhibitor. <i>Frontiers in Oncology</i> , 2021, 11, 724620.	1.3	3
903	Immune Checkpoint Inhibitors and the Heart. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 726426.	1.1	8
904	Imaging evaluation of lung cancer treated with PD-1/PD-L1 inhibitors. <i>British Journal of Radiology</i> , 2021, 94, 20210228.	1.0	2
905	Cardiovascular immunotoxicities associated with immune checkpoint inhibitors: a safety meta-analysis. <i>European Heart Journal</i> , 2021, 42, 4964-4977.	1.0	70
906	Interventional Strategies in Cancer-induced Cardiovascular Disease. <i>Current Oncology Reports</i> , 2021, 23, 133.	1.8	2
907	Cardiotoxicity in cancer immune-checkpoint therapy: Mechanisms, clinical evidence, and management strategies. <i>International Journal of Cardiology</i> , 2021, 344, 170-178.	0.8	13
908	Management of Immune-Related Adverse Events in Patients With Non-Small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 720759.	1.3	3
909	Inflammatory Myositis in a Patient With Melanoma. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 865.	3.8	1
910	Cardiac Toxicity Associated with Cancer Immunotherapy and Biological Drugs. <i>Cancers</i> , 2021, 13, 4797.	1.7	12
911	Cardiac MRI Depicts Immune Checkpoint Inhibitor-induced Myocarditis: A Prospective Study. <i>Radiology</i> , 2021, 301, 602-609.	3.6	22
912	PD-1 and PD-L1 expression in cardiac transplantation. <i>Cardiovascular Pathology</i> , 2021, 54, 107331.	0.7	9

#	ARTICLE	IF	CITATIONS
913	Immune-Related Multiple-Organ Injuries Following ICI Treatment With Tislelizumab in an Advanced Non-Small Cell Lung Cancer Patient: A Case Report. <i>Frontiers in Oncology</i> , 2021, 11, 664809.	1.3	10
914	Neurological disorders associated with immune checkpoint inhibitors: an association with autoantibodies. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 769-775.	2.0	22
915	Risk factors for immune-related adverse events from anti-PD-1 or anti-PD-L1 treatment in an Asian cohort of nonsmall cell lung cancer patients. <i>International Journal of Cancer</i> , 2022, 150, 636-644.	2.3	20
916	Re: Cardiotoxicity of immune checkpoint inhibitors: A systematic review and meta-analysis of randomised clinical trials. <i>European Journal of Cancer</i> , 2021, 155, 299-302.	1.3	3
917	PD-L1 (Programmed Death Ligand 1) as a Marker of Acute Cellular Rejection After Heart Transplantation. <i>Circulation: Heart Failure</i> , 2021, 14, e008563.	1.6	6
918	Endothelial Stromal PD-L1 (Programmed Death Ligand 1) Modulates CD8 ⁺ T-Cell Infiltration After Heart Transplantation. <i>Circulation: Heart Failure</i> , 2021, 14, e007982.	1.6	17
919	Cardiovascular adverse events are associated with usage of immune checkpoint inhibitors in real-world clinical data across the United States. <i>ESMO Open</i> , 2021, 6, 100252.	2.0	26
920	An Analysis of Global Research Trends and Top-Cited Research Articles in Cardio-Oncology. <i>Cardiology Research</i> , 2021, 12, 309-317.	0.5	4
921	Dynamic Changes of Serum Heart Type-Fatty Acid Binding Protein in Cancer Patients Treated With Immune Checkpoint Inhibitors. <i>Frontiers in Pharmacology</i> , 2021, 12, 748677.	1.6	8
922	Pharmacology-based ranking of anti-cancer drugs to guide clinical development of cancer immunotherapy combinations. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 311.	3.5	26
923	Clinical Characteristics and Outcomes in Immune Checkpoint Inhibitor Therapy-Associated Myocarditis. <i>Cardiology Research</i> , 2021, 12, 270-278.	0.5	6
924	Recent advances in immune checkpoint therapy in non-small cell lung cancer and opportunities for nanoparticle-based therapy. <i>European Journal of Pharmacology</i> , 2021, 909, 174404.	1.7	18
925	Successful Treatment of Steroid-Refractory Checkpoint Inhibitor Myocarditis with Globulin Derived-Therapy: A Case Report and Literature Review. <i>American Journal of the Medical Sciences</i> , 2021, 362, 424-432.	0.4	5
926	Treatment strategy for myocarditis in patients using immune checkpoint inhibitors or combined anti-vascular endothelial growth factor therapy by clinical severity. <i>European Journal of Cancer</i> , 2021, 157, 10-20.	1.3	4
927	Pathophysiology, diagnosis and management of cardiac toxicity induced by immune checkpoint inhibitors and BRAF and MEK inhibitors. <i>Cancer Treatment Reviews</i> , 2021, 100, 102282.	3.4	25
928	Immune checkpoint inhibitor cardiotoxicity: Breaking barriers in the cardiovascular immune landscape. <i>Journal of Molecular and Cellular Cardiology</i> , 2021, 160, 121-127.	0.9	6
929	Interleukin-6 blockade for prophylaxis and management of immune-related adverse events in cancer immunotherapy. <i>European Journal of Cancer</i> , 2021, 157, 214-224.	1.3	62
930	Prolactin enhances T regulatory cell promotion of breast cancer through the long form prolactin receptor. <i>Translational Oncology</i> , 2021, 14, 101195.	1.7	5

#	ARTICLE	IF	CITATIONS
931	Acute development of fatal myocarditis after pembrolizumab in non-small-cell lung cancer with thymoma. <i>Current Problems in Cancer Case Reports</i> , 2021, 4, 100105.	0.1	0
932	Cardiotoxicity associated with immune checkpoint inhibitors and CAR T-cell therapy. <i>American Journal of Emergency Medicine</i> , 2021, 50, 51-58.	0.7	6
933	Atezolizumab-induced bilateral anterior uveitis: A case report. <i>American Journal of Ophthalmology Case Reports</i> , 2021, 24, 101205.	0.4	2
934	Immune Checkpoint Inhibitor (ICI)-Associated Myocarditis. , 2021, , 27-37.		0
935	Spectrum and Management of Immune Related Adverse Events Due to Immune Checkpoint Inhibitors. <i>Current Cancer Research</i> , 2021, , 139-173.	0.2	0
936	Reciprocal organ interactions during heart failure: a position paper from the ESC Working Group on Myocardial Function. <i>Cardiovascular Research</i> , 2021, 117, 2416-2433.	1.8	27
938	Infliximab for the treatment of patients with checkpoint inhibitor associated acute tubular interstitial nephritis. <i>OncImmunology</i> , 2021, 10, 1877415.	2.1	32
939	A multicenter characterization of hepatitis associated with immune checkpoint inhibitors. <i>OncImmunology</i> , 2021, 10, 1875639.	2.1	30
940	Towards the use of localised delivery strategies to counteract cancer therapy-induced cardiotoxicities. <i>Drug Delivery and Translational Research</i> , 2021, 11, 1924-1942.	3.0	7
941	Noninvasive Imaging of Cancer Immunotherapy. <i>Nanotheranostics</i> , 2021, 5, 90-112.	2.7	22
942	Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. <i>European Heart Journal</i> , 2022, 43, 280-299.	1.0	213
943	Managing Checkpoint Inhibitor Symptoms and Toxicity for Metastatic Melanoma. , 2020, , 1187-1214.		2
944	Immune Checkpoint Inhibitors (ICIs)-Related Cardiotoxicity. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1244, 277-285.	0.8	9
945	Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort. , 2020, 69, 1177.		1
946	Cardiotoxicity of Novel Targeted Chemotherapeutic Agents. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2018, 20, 53.	0.4	17
947	Incidence of Pericardial Effusion in Patients with Advanced Non-Small Cell Lung Cancer Receiving Immunotherapy. <i>Advances in Therapy</i> , 2020, 37, 3178-3184.	1.3	27
948	Immune checkpoint inhibitors: a narrative review of considerations for the anaesthesiologist. <i>British Journal of Anaesthesia</i> , 2020, 124, 251-260.	1.5	35
949	Sinus Arrest and Cardiogenic Shock Precipitated by Immune Checkpoint Inhibitors. <i>JACC: CardioOncology</i> , 2020, 2, 810-814.	1.7	1

#	ARTICLE	IF	CITATIONS
950	Complete pathologic response of metastatic cutaneous squamous cell carcinoma and allograft rejection after treatment with combination immune checkpoint blockade. <i>JAAD Case Reports</i> , 2017, 3, 412-415.	0.4	40
951	Treatment- and immune-related adverse events of immune checkpoint inhibitors in advanced lung cancer. <i>Bioscience Reports</i> , 2020, 40, .	1.1	29
952	A different type of acute myocarditis: a case report of acute autoimmune myocarditis mediated by anti-PD-1 T lymphocyte receptor (pembrolizumab). <i>European Heart Journal - Case Reports</i> , 2020, 4, 1-6.	0.3	9
953	Inflammatory Cardiomyopathy: Case-based Review on Clinical Presentation, Diagnosis, and Management. <i>Cardiology in Review</i> , 2021, 29, 230-237.	0.6	2
954	Nivolumab-Induced Myocarditis Concomitant with Myasthenia Gravis. <i>Case Reports in Oncology</i> , 2018, 10, 809-812.	0.3	47
955	An adapted anti-CTLA4 therapeutic aimed at mitigating the toxicities of checkpoint inhibition. <i>Journal of Clinical Investigation</i> , 2018, 129, 75-77.	3.9	1
956	Immune-related adverse events: a retrospective look into the future of oncology in the intensive care unit. <i>Annals of Intensive Care</i> , 2020, 10, 143.	2.2	24
957	Imaging of tumour response to immunotherapy. <i>European Radiology Experimental</i> , 2020, 4, 2.	1.7	65
958	Toxic Myopathies. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2019, 25, 1712-1731.	0.4	22
959	Bringing a genomic perspective to the safety of drug treatment in oncology. <i>F1000Research</i> , 2017, 6, 385.	0.8	3
960	Cardio-oncology: management of cardiovascular toxicity. <i>F1000Research</i> , 2019, 8, 120.	0.8	1
961	Blockade of programmed cell death protein-1 pathway for the treatment of melanoma. <i>Journal of Antioxidant Activity</i> , 2017, 1, 1-11.	1.0	12
962	A Case of Acute Heart Failure due to Immune Checkpoint Blocker Nivolumab. <i>Cardiology Research</i> , 2019, 10, 120-123.	0.5	11
963	Myocarditis associated with immune check-point inhibitors: Practical considerations in diagnosis and management. <i>Anatolian Journal of Cardiology</i> , 2020, 24, 68-75.	0.5	12
964	Electrophysiologic Complications in Cancer Patients. <i>Methodist DeBakey Cardiovascular Journal</i> , 2021, 15, 282.	0.5	6
965	A Fatal Case of Myocarditis Following Myositis Induced by Pembrolizumab Treatment for Metastatic Upper Urinary Tract Urothelial Carcinoma. <i>International Heart Journal</i> , 2020, 61, 1070-1074.	0.5	21
966	Cancer and Heart Failure: Understanding the Intersection. <i>Cardiac Failure Review</i> , 2017, 03, 66-70.	1.2	10
967	Subclinical Left Ventricular Dysfunction During Chemotherapy. <i>Cardiac Failure Review</i> , 2019, 5, 31-36.	1.2	25

#	ARTICLE	IF	CITATIONS
968	Checkpoint inhibitor induced cardiotoxicity: managing the drawbacks of our newest agents against cancer. <i>Oncotarget</i> , 2017, 8, 106165-106166.	0.8	10
969	Detection of identical T cell clones in peritumoral pleural effusion and pneumonitis lesions in a cancer patient during immune-checkpoint blockade. <i>Oncotarget</i> , 2018, 9, 30587-30593.	0.8	18
970	Cardiotoxicity of cancer chemotherapy: identification, prevention and treatment. <i>Annals of Translational Medicine</i> , 2017, 5, 348-348.	0.7	31
971	Successful therapy for autoimmune myocarditis with pembrolizumab treatment for nasopharyngeal carcinoma. <i>Annals of Translational Medicine</i> , 2019, 7, 247-247.	0.7	15
972	A consensus on immunotherapy from the 2017 Chinese Lung Cancer Summit expert panel. <i>Translational Lung Cancer Research</i> , 2018, 7, 428-436.	1.3	7
973	Nivolumab resulting in persistently elevated troponin levels despite clinical remission of myocarditis and myositis in a patient with malignant pleural mesothelioma: case report. <i>Translational Lung Cancer Research</i> , 2020, 9, 360-365.	1.3	13
974	Fulminant Myocarditis After Initial Pembrolizumab Treatment for Squamous Cell Carcinoma of the Lung: an Autopsy Case Report. <i>Japanese Journal of Lung Cancer</i> , 2020, 60, 335-340.	0.0	3
975	Monoclonal Antibody-Based Immunotherapy and Its Role in the Development of Cardiac Toxicity. <i>Cancers</i> , 2021, 13, 86.	1.7	14
976	Rheumatic complications in cancer patients treated with immune checkpoint inhibitors. <i>Korean Journal of Internal Medicine</i> , 2019, 34, 1197-1209.	0.7	11
977	Requirement for CD40/CD40L Interactions for Development of Autoimmunity Differs Depending on Specific Checkpoint and Costimulatory Pathways. <i>ImmunoHorizons</i> , 2018, 2, 54-66.	0.8	14
978	Cardiovascular Complications of Novel Anti-Cancer Immunotherapy: Old Problems from New Agents?. <i>Korean Circulation Journal</i> , 2020, 50, 743.	0.7	6
979	Nivolumab-induced new-onset seronegative rheumatoid arthritis in a patient with advanced metastatic melanoma: A case report and literature review. <i>Avicenna Journal of Medicine</i> , 2018, 8, 34-36.	0.3	18
980	Cardiotoxicity of FDA-approved immune checkpoint inhibitors: A rare but serious adverse event. <i>Journal of Immunotherapy and Precision Oncology</i> , 2018, 1, 68-77.	0.6	8
981	Immunotherapy-induced acute pulmonary thromboembolism: A case report. <i>South Asian Journal of Cancer</i> , 2019, 08, 172-182.	0.2	6
982	Peripheral blood immune cell-based biomarkers in anti-PD-1/PD-L1 therapy. <i>Immune Network</i> , 2020, 20, e8.	1.6	19
983	EAPCI Position Statement on Invasive Management of Acute Coronary Syndromes during the COVID-19 pandemic. <i>EuroIntervention</i> , 2020, 16, 233-246.	1.4	19
984	Cardiac adverse events of immune checkpoint inhibitors in oncology patients: A systematic review and meta-analysis. <i>World Journal of Cardiology</i> , 2020, 12, 584-598.	0.5	24
985	Surviving Cancer without a Broken Heart. <i>Rambam Maimonides Medical Journal</i> , 2019, 10, e0012.	0.4	5

#	ARTICLE	IF	CITATIONS
986	Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 255-289.	2.3	393
987	Preexisting Autoimmune Disease: Implications for Immune Checkpoint Inhibitor Therapy in Solid Tumors. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 750-757.	2.3	86
988	NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 230-241.	2.3	284
989	Possible Precipitation of Acute Coronary Syndrome with Immune Checkpoint Blockade: A Case Report. , 2020, 24, 1.		5
990	The Advancement in Diagnosis and Therapy of Liver Injury Induced by Immune Checkpoint Inhibitors. Advances in Clinical Medicine, 2021, 11, 4628-4634.	0.0	0
991	Treatment Toxicity. UNIPA Springer Series, 2021, , 291-308.	0.1	0
992	Kardiale Toxizität antineoplastischer Substanzen. Springer Reference Medizin, 2021, , 1-7.	0.0	0
993	Adverse cardiovascular events in patients treated with mogamulizumab. American Heart Journal Plus, 2021, 9, 100049.	0.3	1
994	Severe Cardiac Toxicity Induced by Cancer Therapies Requiring Intensive Care Unit Admission. Frontiers in Cardiovascular Medicine, 2021, 8, 713694.	1.1	10
995	Potential Novel Therapeutic Target to Improve Graft Survival: New Insights Into the Role of Checkpoint Molecules in Heart Transplant Rejection. Circulation: Heart Failure, 2021, 14, e008859.	1.6	1
996	Consensus statement of Russian experts on the prevention, diagnosis and treatment of cardiotoxicity of anticancer therapy. Russian Journal of Cardiology, 2021, 26, 4703.	0.4	36
997	Checkpoint blocker induced autoimmunity as an indicator for tumour efficacy in melanoma. British Journal of Cancer, 2021, , .	2.9	1
998	Activation of Cascade-Like Antitumor Immune Responses through In Situ Doxorubicin Stimulation and Blockade of Checkpoint Coinhibitory Receptor TIGIT. Advanced Healthcare Materials, 2022, 11, e2102080.	3.9	5
999	Cardiotoxicity of Antineoplastic Therapies and Applications of Induced Pluripotent Stem Cell-Derived Cardiomyocytes. Cells, 2021, 10, 2823.	1.8	7
1000	Metabolic regulation by PD-1 signaling promotes long-lived quiescent CD8 T cell memory in mice. Science Translational Medicine, 2021, 13, eaba6006.	5.8	33
1001	Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: A Systematic Review. Cancers, 2021, 13, 5218.	1.7	53
1003	Bradyarrhythmias in Cardio-Oncology. South Asian Journal of Cancer, 2021, 10, 195-210.	0.2	0
1004	⁶⁸ Ga-DOTATOC PET/CT to detect immune checkpoint inhibitor-related myocarditis. , 2021, 9, e003594.		30

#	ARTICLE	IF	CITATIONS
1005	Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. <i>Cell</i> , 2021, 184, 5309-5337.	13.5	588
1006	Myocarditis as an immune-related adverse event following treatment with ipilimumab and nivolumab combination therapy for metastatic renal cell carcinoma: a case report. <i>Journal of Medical Case Reports</i> , 2021, 15, 508.	0.4	10
1007	Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Progresses and Challenges. <i>Frontiers in Oncology</i> , 2021, 11, 737497.	1.3	22
1008	The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry. <i>European Journal of Cancer</i> , 2021, 158, 217-224.	1.3	35
1009	Cancer Treatment-Related Cardiotoxicity: Role of Cardiovascular Magnetic Resonance Imaging. , 2018, , 9-31.		0
1010	Pericardial Effusion with Tamponade, an Immune-Related Adverse Event Associated with Nivolumab Therapy: A Case Report and Review of the Literature. <i>Journal of Cancer Therapy</i> , 2018, 09, 1039-1047.	0.1	2
1013	Toxicité des soins intensifs des immunothérapies du cancer. <i>Medecine Intensive Reanimation</i> , 2018, 27, 522-536.	0.1	0
1014	Evolving Role of the Oncology Nurse in the Care of Patients with Melanoma. , 2019, , 1-27.		1
1015	Complications and Toxicities Associated with Cancer Therapies in the Intensive Care Unit. , 2019, , 1-27.		0
1016	Managing Checkpoint Inhibitor Symptoms and Toxicity. , 2019, , 1-28.		0
1017	â...ç-«ãfã,šãffã,ãfã,ãfãf^é»â³è--ã*ã;fè±“æœ%ã³ã²<è±j. <i>Journal of JCS Cardiologists</i> , 2019, 28, 3-9.	0.1	2
1018	Management of Adverse Events Induced by Immune Checkpoint Inhibitors in Lung Cancer Treatment. <i>Japanese Journal of Lung Cancer</i> , 2019, 59, 231-237.	0.0	0
1019	Nivolumab-induced Third Degree Atrioventricular Block in a Patient with Stage IV Squamous Cell Lung Carcinoma. <i>Cureus</i> , 2019, 11, e4869.	0.2	7
1020	Prevention and Treatment of Chemotherapy-Induced Cardiotoxicity. <i>Methodist DeBakey Cardiovascular Journal</i> , 2021, 15, 267.	0.5	27
1021	Complications and Toxicities Associated with Cancer Therapies in the Intensive Care Unit. , 2020, , 201-227.		0
1022	Chemotherapy-Related Cardiovascular Complications. , 2020, , 815-836.		0
1024	Immune-related adverse events associated with cancer immunotherapy. <i>Practical Oncology</i> , 2019, 2, 24-44.	0.1	0
1027	Cardiovascular Toxicities of Immunotherapy. , 2020, , 259-276.		0

#	ARTICLE	IF	CITATIONS
1029	A Case of Acute Heart Failure Following Immunotherapy for Metastatic Lung Cancer. <i>Cureus</i> , 2020, 12, e8093.	0.2	7
1030	Cardiovascular effects of innovative therapies in lung cancer. , 2020, , 154-166.		0
1032	A REVIEW OF MODERN IMMUNOTHERAPY IN GASTROINTESTINAL MALIGNANT TUMORS. <i>EurasianUnionofScientists</i> , 2020, 6, 9-21.	0.0	0
1033	Cardiovascular Health and Risk Management in Cancer Survivors. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 1004-1006.	2.3	0
1034	Immune checkpoint inhibition for the treatment of cancers: An update and critical review of ongoing clinical trials. <i>Clinical Immunology</i> , 2021, 232, 108873.	1.4	19
1035	Biological Bases of Immune-Related Adverse Events and Potential Crosslinks With Immunogenic Effects of Radiation. <i>Frontiers in Pharmacology</i> , 2021, 12, 746853.	1.6	14
1036	Electrocardiographic Manifestations of Immune Checkpoint Inhibitor Myocarditis. <i>Circulation</i> , 2021, 144, 1521-1523.	1.6	44
1037	Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2021, 39, 4073-4126.	0.8	580
1039	Recurrent Fulminant Myocarditis Accompanied by Lymphoid Follicle Formation in Myocardium. <i>Internal Medicine</i> , 2020, 59, 3045-3049.	0.3	0
1040	Immune checkpoint inhibitor myocarditis: a systematic case study. <i>Russian Journal of Cardiology</i> , 2020, 25, 3910.	0.4	6
1042	Heart Failure in Relation to Tumor-Targeted Therapies and Immunotherapies. <i>Methodist DeBakey Cardiovascular Journal</i> , 2021, 15, 250.	0.5	7
1043	Mechanisms of Immune-Related Adverse Events. , 2020, , 179-186.		1
1044	Axitinib plus Immuncheckpoint-Inhibitor: evidenz- und expertenbasierte Konsensusempfehlungen für die Behandlungsoptimierung und das Management von therapieassoziierten Nebenwirkungen. <i>Karger Kompass Onkologie</i> , 2020, 7, 180-189.	0.0	0
1047	The Current Status and Future Perspective of Cardio-Oncology. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2020, 109, 819-826.	0.0	0
1048	Rheumatic Manifestations and Diseases From Immune Checkpoint Inhibitors in Cancer Immunotherapy. <i>Frontiers in Medicine</i> , 2021, 8, 762247.	1.2	11
1050	Risk factors for immune-related adverse events: what have we learned and what lies ahead?. <i>Biomarker Research</i> , 2021, 9, 79.	2.8	36
1051	Heart Failure in Breast Cancer Survivors: Focus on Early Detection and Novel Biomarkers. <i>Current Heart Failure Reports</i> , 2021, 18, 362-377.	1.3	4
1052	Clinical characteristics of gastrointestinal immune-related adverse events of immune checkpoint inhibitors and their association with survival. <i>World Journal of Gastroenterology</i> , 2021, 27, 7190-7206.	1.4	8

#	ARTICLE	IF	CITATIONS
1053	Defining the correlation between immune-checkpoint inhibitors-related adverse events and clinical outcomes: a narrative review. <i>Ecancermedalscience</i> , 2021, 15, 1314.	0.6	1
1054	The double-edged sword: Harnessing PD-1 blockade in tumor and autoimmunity. <i>Science Immunology</i> , 2021, 6, eabf4034.	5.6	22
1055	<sc>MLLT</sc>6 maintains <i><sc>PD</sc>â€1</i> expression and mediates tumor immune resistance. <i>EMBO Reports</i> , 2020, 21, e50155.	2.0	13
1056	Myocarditis and Inflammatory Cardiomyopathy. , 2021, , 551-563.		0
1057	Cardiotoxicity After Childhood Cancer Treatment. , 2021, , 3-15.		0
1058	Reply to Cortellini A. <i>JTO Clinical and Research Reports</i> , 2020, 1, 100095.	0.6	1
1060	Identifying Cancer Patients at Risk for Heart Failure Using Machine Learning Methods. <i>AMIA ... Annual Symposium proceedings</i> , 2019, 2019, 933-941.	0.2	2
1062	Fulminant myocarditis with myositis of ocular and respiratory muscles. <i>Nagoya Journal of Medical Science</i> , 2020, 82, 585-593.	0.6	0
1064	Mycophenolate as Primary Treatment for Immune Checkpoint Inhibitor Induced Acute Kidney Injury in a Patient with Concurrent Immunotherapy-Associated Diabetes: A Case Report. , 2021, 4, .		1
1065	An Overview of Cardio-Oncology, a New Frontier to Be Explored. <i>Acta Cardiologica Sinica</i> , 2021, 37, 457-463.	0.1	1
1067	Incidence of Cancer Treatment Induced Arrhythmia Associated with Immune Checkpoint Inhibitors. <i>Journal of Atrial Fibrillation</i> , 2021, 13, 2461.	0.5	9
1068	Bioadhesive injectable hydrogel with phenolic carbon quantum dot supported Pd single atom nanozymes as a localized immunomodulation niche for cancer catalytic immunotherapy. <i>Biomaterials</i> , 2022, 280, 121272.	5.7	68
1069	Immunopharmaco-genomics: future of clinical medicine. , 2022, , 347-384.		0
1070	Targeted Mass Spectrometry Enables Multiplexed Quantification of Immunomodulatory Proteins in Clinical Biospecimens. <i>Frontiers in Immunology</i> , 2021, 12, 765898.	2.2	13
1071	Current Strategies for Tumor Photodynamic Therapy Combined With Immunotherapy. <i>Frontiers in Oncology</i> , 2021, 11, 738323.	1.3	24
1072	Response criteria for immunotherapy and the radiologic patterns of immune-related adverse events. <i>European Journal of Radiology</i> , 2022, 146, 110062.	1.2	4
1073	Sudden and severe cardiotoxicity induced with pembrolizumab, its clinical course, therapeutic intervention, and outcome. <i>International Cancer Conference Journal</i> , 2022, 11, 81-86.	0.2	2
1074	Epsteinâ€Barr Virus+ B Cells in Breast Cancer Immune Response: A Case Report. <i>Frontiers in Immunology</i> , 2021, 12, 761798.	2.2	2

#	ARTICLE	IF	CITATIONS
1075	Ipilimumab and Nivolumab induced ventricular tachycardia in a patient with metastatic renal cell carcinoma. <i>Journal of Community Hospital Internal Medicine Perspectives</i> , 2021, 11, 874-876.	0.4	3
1076	From cardio-oncology to cardio-onco-pharmacology: Towards a multidisciplinary approach in the understanding and management of cardiotoxicity. <i>Therapie</i> , 2022, 77, 197-206.	0.6	1
1077	An ongoing evolution of cardio-oncology with the rapid development of modern immunotherapy. <i>International Journal of Cardiology</i> , 2021, 347, 60-61.	0.8	1
1078	Development of a Flow Cytometry Assay to Predict Immune Checkpoint Blockade-Related Complications. <i>Frontiers in Immunology</i> , 2021, 12, 765644.	2.2	5
1079	Pan-Cancer Analysis Reveals Alternative Splicing Characteristics Associated With Immune-Related Adverse Events Elicited by Checkpoint Immunotherapy. <i>Frontiers in Pharmacology</i> , 2021, 12, 797852.	1.6	8
1080	Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study. <i>Lancet Oncology</i> , The, 2021, 22, 1692-1704.	5.1	129
1081	Crossed Pathways for Radiation-Induced and Immunotherapy-Related Lung Injury. <i>Frontiers in Immunology</i> , 2021, 12, 774807.	2.2	22
1082	Immune Checkpoint Inhibitor (ICI)-Related Cardiotoxicity. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1342, 377-387.	0.8	2
1083	Mathematical modelling of autoimmune myocarditis and the effects of immune checkpoint inhibitors. <i>Journal of Theoretical Biology</i> , 2022, 537, 111002.	0.8	6
1084	Bridging the Gap: Connecting the Mechanisms of Immune-Related Adverse Events and Autoimmunity Through PD-1. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 790386.	1.8	8
1085	Camrelizumab-Related Myocarditis and Myositis With Myasthenia Gravis: A Case Report and Literature Review. <i>Frontiers in Oncology</i> , 2021, 11, 778185.	1.3	10
1086	Evaluation of cardiovascular comorbidity in cancer patients and analysis of potential risk factors for cardiovascular complications of checkpoint inhibitor therapy. <i>Russian Journal of Cardiology</i> , 2022, 26, 4697.	0.4	0
1087	Case Series of Steroid-Resistant Immune Checkpoint Inhibitor Associated Myocarditis: A Comparative Analysis of Corticosteroid and Tofacitinib Treatment. <i>Frontiers in Pharmacology</i> , 2021, 12, 770631.	1.6	23
1088	Cancer Chemotherapy-Induced Sinus Bradycardia: A Narrative Review of a Forgotten Adverse Effect of Cardiotoxicity. <i>Drug Safety</i> , 2022, 45, 101-126.	1.4	6
1089	Potential therapies for immune-related adverse events associated with immune checkpoint inhibition: from monoclonal antibodies to kinase inhibition. , 2022, 10, e003551.		19
1090	Harnessing big data to characterize immune-related adverse events. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 269-280.	12.5	41
1091	T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma. <i>Nature Medicine</i> , 2022, 28, 353-362.	15.2	132
1092	Association of antibiotic treatment with immune-related adverse events in patients with cancer receiving immunotherapy. , 2022, 10, e003779.		34

#	ARTICLE	IF	CITATIONS
1093	Methods of screening, monitoring and management of cardiac toxicity induced by chemotherapeutics. Chinese Chemical Letters, 2022, , .	4.8	3
1095	Systematic analysis of drug-associated myocarditis reported in the World Health Organization pharmacovigilance database. Nature Communications, 2022, 13, 25.	5.8	44
1096	Injectable Hydrogel as a Unique Platform for Antitumor Therapy Targeting Immunosuppressive Tumor Microenvironment. Frontiers in Immunology, 2021, 12, 832942.	2.2	18
1097	Myocardial PD-L1 Expression in Patients With Ischemic and Non-ischemic Heart Failure. Frontiers in Cardiovascular Medicine, 2021, 8, 759972.	1.1	13
1098	Asymptomatic Myocarditis with Mild Cardiac Marker Elevation Following Nivolumab-Induced Myositis. International Heart Journal, 2022, 63, 180-183.	0.5	9
1099	Immune-related adverse events in various organs caused by immune checkpoint inhibitors. Allergy International, 2022, 71, 169-178.	1.4	34
1100	Immune-checkpoint inhibitors: long-term implications of toxicity. Nature Reviews Clinical Oncology, 2022, 19, 254-267.	12.5	360
1101	Consider Myocarditis When Patients Treated with Immune Checkpoint Inhibitors Present with Ocular Symptoms. Oncologist, 2022, 27, e402-e405.	1.9	7
1102	Single-Cell RNA Sequencing Reveals the Altered Landscape of Immune Cells in Immune Checkpoint Inhibitor Related Myocarditis. SSRN Electronic Journal, 0, , .	0.4	0
1103	The current landscape of immunotherapy for pediatric brain tumors. Nature Cancer, 2022, 3, 11-24.	5.7	21
1104	Immune checkpoint inhibitor-associated myocarditis. Netherlands Heart Journal, 2022, 30, 295-301.	0.3	8
1105	The Role of miRNA in Tumor Immune Escape and miRNA-Based Therapeutic Strategies. Frontiers in Immunology, 2021, 12, 807895.	2.2	20
1106	Fatal Allograft Rejection and Cardiac Allograft Vasculopathy After Treatment With Pembrolizumab for Metastatic Melanoma in a Heart Transplant Recipient: A Case Report. Transplantation Proceedings, 2022, 54, 193-196.	0.3	4
1107	Pro-BNP in the differential diagnosis of dyspnea in patients treated with immune-checkpoint inhibitors: Case Report. Journal of Oncology Pharmacy Practice, 2022, 28, 1239-1243.	0.5	1
1108	Cardiotoxicity of Chemotherapeutic Drugs. Journal of Cardiovascular Pharmacology, 2022, Publish Ahead of Print, .	0.8	3
1109	Traditional Chinese Medicine Pien-Tze-Huang Inhibits Colorectal Cancer Growth and Immune Evasion by Reducing β -catenin Transcriptional Activity and PD-L1 Expression. Frontiers in Pharmacology, 2022, 13, 828440.	1.6	13
1110	Biomarkers and risk factors for the early prediction of immune-related adverse events: a review. Human Vaccines and Immunotherapeutics, 2022, 18, 1-12.	1.4	11
1111	Management of adverse events associated with cabozantinib plus nivolumab in renal cell carcinoma: A review. Cancer Treatment Reviews, 2022, 103, 102333.	3.4	21

#	ARTICLE	IF	CITATIONS
1112	18F-fluorodeoxyglucose positron emission tomography/computed tomography imaging for the diagnosis of immune checkpoint inhibitor-associated myocarditis. <i>Archives of Cardiovascular Diseases</i> , 2022, 115, 114-116.	0.7	13
1113	PD-1 inhibitor causes pathological injury to multiple organs in a Lewis lung cancer mouse model. <i>International Immunopharmacology</i> , 2022, 105, 108551.	1.7	4
1114	The Potential Cardiotoxicity of Immune Checkpoint Inhibitors. <i>Journal of Clinical Medicine</i> , 2022, 11, 865.	1.0	8
1115	Cardiotoxicity and Chemotherapy—The Role of Precision Medicine. <i>Diseases (Basel, Switzerland)</i> , 2021, 9, 90.	1.0	3
1116	An Autopsy Case of Late-onset Fulminant Myocarditis Induced by Nivolumab in Gastric Cancer. <i>Internal Medicine</i> , 2022, 61, 2867-2871.	0.3	6
1117	Sinus Node Dysfunction Co-occurring with Immune Checkpoint Inhibitor-associated Myocarditis. <i>Internal Medicine</i> , 2022, 61, 2161-2165.	0.3	8
1118	Cardiac Myosin-Specific Autoimmune T Cells Contribute to Immune Checkpoint Inhibitor-Associated Myocarditis. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
1119	Sick Sinus Syndrome: More Than a Needle-in-a-haystack Manifestation of Immune Checkpoint Inhibitor-associated Myocarditis. <i>Internal Medicine</i> , 2022, , .	0.3	1
1120	Rheumatic side effects of cancer immunotherapy with immune checkpoint inhibitors. <i>Klinicka Farmakologie A Farmacie</i> , 2022, 35, 106-111.	0.1	0
1121	Nivolumab-induced systemic lymphadenopathy occurring during treatment of malignant melanoma: a case report. <i>International Journal of Hematology</i> , 2022, 116, 302-306.	0.7	1
1122	A Rare Case of Hepatic Vanishing Bile Duct Syndrome Occurring after Combination Therapy with Nivolumab and Cabozantinib in a Patient with Renal Carcinoma. <i>Diagnostics</i> , 2022, 12, 539.	1.3	2
1123	The Diagnosis and Management of Immune Checkpoint Inhibitor Cardiovascular Toxicity: Myocarditis and Beyond. <i>Vaccines</i> , 2022, 10, 304.	2.1	2
1124	Cardiotoxicity of Non-Anthracycline Cancer Chemotherapy Agents. <i>Journal of Cardiovascular Development and Disease</i> , 2022, 9, 66.	0.8	10
1125	Immune Checkpoint Inhibitors—Associated Cardiotoxicity. <i>Cancers</i> , 2022, 14, 1145.	1.7	25
1126	Cardiotoxicity of Systemic Melanoma Treatments. <i>Current Treatment Options in Oncology</i> , 2022, 23, 240-253.	1.3	2
1127	Sex-Specific Cardiovascular Risks of Cancer and Its Therapies. <i>Circulation Research</i> , 2022, 130, 632-651.	2.0	29
1128	Immune checkpoint inhibitor-induced myocarditis, myositis, myasthenia gravis and transaminitis: a case series and review. <i>Immunotherapy</i> , 2022, , .	1.0	4
1129	Hypersensitivity Reactions and Immune-Related Adverse Events to Immune Checkpoint Inhibitors: Approaches, Mechanisms, and Models. <i>Immunology and Allergy Clinics of North America</i> , 2022, 42, 285-305.	0.7	4

#	ARTICLE	IF	CITATIONS
1130	Immune-related Adverse Event of Colitis due to Pembrolizumab Treatment. <i>International Journal of Oral-Medical Sciences</i> , 2022, 20, 184-188.	0.2	1
1131	Polyamine Immunometabolism: Central Regulators of Inflammation, Cancer and Autoimmunity. <i>Cells</i> , 2022, 11, 896.	1.8	23
1132	Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events. <i>Frontiers in Immunology</i> , 2022, 13, 804597.	2.2	27
1133	A Case of Lung Cancer with Very-Late-Onset Immune Checkpoint Inhibitor-Related Myocarditis. <i>CJC Open</i> , 2022, 4, 651-655.	0.7	2
1134	Applications of Circulating Tumor DNA in Immune Checkpoint Inhibition: Emerging Roles and Future Perspectives. <i>Frontiers in Oncology</i> , 2022, 12, 836891.	1.3	5
1135	A Systematic Review of the Mechanisms Involved in Immune Checkpoint Inhibitors Cardiotoxicity and Challenges to Improve Clinical Safety. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 851032.	1.8	14
1136	Concurrent myopathy and inflammatory cardiac disease in COVID-19 patients: a case series and literature review. <i>Rheumatology International</i> , 2022, 42, 905-912.	1.5	11
1138	Cardiotoxicity risk factors with immune checkpoint inhibitors. <i>Cardio-Oncology</i> , 2022, 8, 3.	0.8	12
1139	Cardiac MRI Features and Prognostic Value in Immune Checkpoint Inhibitor-induced Myocarditis. <i>Radiology</i> , 2022, 303, 512-521.	3.6	21
1140	Adverse Cardiovascular Complications following prescription of programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors: a propensity-score matched Cohort Study with competing risk analysis. <i>Cardio-Oncology</i> , 2022, 8, 5.	0.8	8
1141	Protective Effect of Crocin on Immune Checkpoint Inhibitors-Related Myocarditis Through Inhibiting NLRP3 Mediated Pyroptosis in Cardiomyocytes via NF- κ B Pathway. <i>Journal of Inflammation Research</i> , 2022, Volume 15, 1653-1666.	1.6	15
1142	The NOpioid Project: a prospective observational feasibility study examining the implementation of a non-narcotic post-operative pain control regimen. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2022, , 1.	1.3	1
1143	Cardiovascular disease and malignant melanoma. <i>Melanoma Research</i> , 2022, Publish Ahead of Print, .	0.6	3
1144	Incidence, Clinical Characteristics, and Predictors of Cardiovascular Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors. <i>Oncologist</i> , 2022, 27, e410-e419.	1.9	9
1145	Immunomodulating Therapies in Acute Myocarditis and Recurrent/Acute Pericarditis. <i>Frontiers in Medicine</i> , 2022, 9, 838564.	1.2	24
1146	Potential Role of Neutrophil Extracellular Traps in Cardio-Oncology. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3573.	1.8	2
1147	Cardio-Oncology Drug Interactions: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2022, 145, CIR0000000000001056.	1.6	40
1148	Urinary detection of early responses to checkpoint blockade and of resistance to it via protease-cleaved antibody-conjugated sensors. <i>Nature Biomedical Engineering</i> , 2022, 6, 310-324.	11.6	16

#	ARTICLE	IF	CITATIONS
1149	Exploring the Mechanisms Underlying the Cardiotoxic Effects of Immune Checkpoint Inhibitor Therapies. <i>Vaccines</i> , 2022, 10, 540.	2.1	8
1150	Immune checkpoint inhibitors-associated cardiotoxicity in immunotherapy trials on gastrointestinal cancer patients. <i>Chinese Medical Journal</i> , 2022, Publish Ahead of Print, .	0.9	1
1151	Dual PD-1 and CTLA-4 Checkpoint Blockade Using Balstilimab and Zalifrelimab Combination as Second-Line Treatment for Advanced Cervical Cancer: An Open-Label Phase II Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 762-771.	0.8	71
1152	Cardio-oncology imaging tools at the translational interface. <i>Journal of Molecular and Cellular Cardiology</i> , 2022, 168, 24-32.	0.9	1
1153	Cardiac Magnetic Resonance Imaging in Immune Check-Point Inhibitor Myocarditis: A Systematic Review. <i>Journal of Imaging</i> , 2022, 8, 99.	1.7	4
1154	PD-1/L1 inhibitors may increase the risk of pericardial disease in non-small-cell lung cancer patients: a meta-analysis and systematic review. <i>Immunotherapy</i> , 2022, , .	1.0	2
1155	Comorbidities and clinical complications associated with SARS-CoV-2 infection: an overview. <i>Clinical and Experimental Medicine</i> , 2023, 23, 313-331.	1.9	21
1156	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. <i>Circulation</i> , 2022, 145, 101161CIR0000000000001063.	1.6	756
1157	Balancing the good and the bad: controlling immune-related adverse events versus anti-tumor responses in cancer patients treated with immune checkpoint inhibitors. <i>Immunotherapy Advances</i> , 2022, 2, .	1.2	5
1158	Checkpoint Inhibitor Immune-Related Adverse Events: A Multimodality Pictorial Review. <i>Academic Radiology</i> , 2022, 29, 1869-1884.	1.3	3
1159	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. <i>Journal of the American College of Cardiology</i> , 2022, 79, e263-e421.	1.2	774
1160	Rheumatic Complications of Immune Checkpoint Inhibitors. <i>Rheumatic Disease Clinics of North America</i> , 2022, 48, 411-428.	0.8	3
1161	Genetics of cancer therapy-associated cardiotoxicity. <i>Journal of Molecular and Cellular Cardiology</i> , 2022, 167, 85-91.	0.9	10
1162	Case Report: Cardiac Toxicity Associated With Immune Checkpoint Inhibitors. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 727445.	1.1	7
1163	Improvement of PD-1 Blockade Efficacy and Elimination of Immune-Related Gastrointestinal Adverse Effect by mTOR Inhibitor. <i>Frontiers in Immunology</i> , 2021, 12, 793831.	2.2	16
1164	Advances in targeting programmed cell death 1/programmed cell death-ligand 1 therapy for hematological malignancies. <i>Aging Pathobiology and Therapeutics</i> , 2021, 3, 84-94.	0.3	0
1165	Case Report: Glucocorticoid Effect Observation in a Ureteral Urothelial Cancer Patient With ICI-Associated Myocarditis and Multiple Organ Injuries. <i>Frontiers in Immunology</i> , 2021, 12, 799077.	2.2	7
1166	The foundations of immune checkpoint blockade and the ipilimumab approval decennial. <i>Nature Reviews Drug Discovery</i> , 2022, 21, 509-528.	21.5	201

#	ARTICLE	IF	CITATIONS
1167	Cardiovascular Safety Assessment in Cancer Drug Development. <i>Journal of the American Heart Association</i> , 2021, 10, e024033.	1.6	5
1168	Association between Body Mass Index and Immune-Related Adverse Events (irAEs) among Advanced-Stage Cancer Patients Receiving Immune Checkpoint Inhibitors: A Pan-Cancer Analysis. <i>Cancers</i> , 2021, 13, 6109.	1.7	9
1169	Cardiac Computed Tomography in Cardio-Oncology. <i>JACC: CardioOncology</i> , 2021, 3, 635-649.	1.7	17
1170	Cardiac complications of cancer therapies. <i>Advances in Cancer Research</i> , 2022, , 167-214.	1.9	5
1171	PD-1/PD-L1 Inhibitor-Associated Myocarditis: Epidemiology, Characteristics, Diagnosis, Treatment, and Potential Mechanism. <i>Frontiers in Pharmacology</i> , 2022, 13, 835510.	1.6	10
1172	Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy. <i>Nature Communications</i> , 2022, 13, 1970.	5.8	34
1177	Fulminant myocarditis in adults: a narrative review.. <i>Journal of Geriatric Cardiology</i> , 2022, 19, 137-151.	0.2	4
1184	Real-world cardiovascular toxicity of immune checkpoint inhibitors in cancer patients: a retrospective controlled cohort study.. <i>American Journal of Cancer Research</i> , 2021, 11, 6074-6085.	1.4	0
1185	Association of early electrical changes with cardiovascular outcomes in immune checkpoint inhibitor myocarditis. <i>Archives of Cardiovascular Diseases</i> , 2022, 115, 315-330.	0.7	7
1186	Advanced materials for management of immune-related adverse events induced by immune checkpoint inhibitors. <i>Materials and Design</i> , 2022, 219, 110738.	3.3	0
1187	Successful Therapy for Myocarditis Concomitant With Complete Heart Block After Pembrolizumab Treatment for Head and Neck Squamous Cell Carcinoma: A Case Report With Literature Review. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, .	1.1	11
1188	Preclinical Studies of a Novel Human PD-1 B-Cell Peptide Cancer Vaccine PD1-Vaxx From BALB/c Mice to Beagle Dogs and to Non-Human Primates (<i>Cynomolgus</i> Monkeys). <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	11
1189	Cardio-oncology in Austria: cardiotoxicity and surveillance of anti-cancer therapies. <i>Wiener Klinische Wochenschrift</i> , 2022, 134, 654-674.	1.0	7
1190	Cancer Therapy-Related Cardiac Dysfunction in Patients Treated with a Combination of an Immune Checkpoint Inhibitor and Doxorubicin. <i>Cancers</i> , 2022, 14, 2320.	1.7	4
1191	Adverse and unconventional reactions related to immune checkpoint inhibitor therapy for cancer. <i>International Immunopharmacology</i> , 2022, 108, 108803.	1.7	5
1192	The prognostic value of global myocardium strain by CMR-feature tracking in immune checkpoint inhibitor-associated myocarditis. <i>European Radiology</i> , 2022, 32, 7657-7667.	2.3	5
1193	Cancer therapeutics-related cardiovascular dysfunction: Basic mechanisms and clinical manifestation. <i>Journal of Cardiology</i> , 2023, 81, 253-259.	0.8	2
1194	Neurological Manifestations of Myocarditis. <i>Current Neurology and Neuroscience Reports</i> , 2022, , .	2.0	0

#	ARTICLE	IF	CITATIONS
1195	T cell help in the autoreactive germinal center. <i>Scandinavian Journal of Immunology</i> , 2022, 95, e13192.	1.3	4
1196	Vasopressors and Risk of Acute Mesenteric Ischemia: A Worldwide Pharmacovigilance Analysis and Comprehensive Literature Review. <i>Frontiers in Medicine</i> , 2022, 9, .	1.2	4
1197	Cardiotoxicity of Biological Therapies in Cancer Patients: An In-depth Review. <i>Current Cardiology Reviews</i> , 2023, 19, .	0.6	3
1198	Chest Pain in the Cancer Patient. <i>European Cardiology Review</i> , 0, 17, .	0.7	3
1199	Cardiovascular toxic effects of antitumor agents: Pathogenetic mechanisms. <i>Thrombosis Research</i> , 2022, 213, S95-S102.	0.8	9
1200	Routine assessment of cardiotoxicity in patients undergoing long-term immune checkpoint inhibitor therapy. <i>Heart and Vessels</i> , 2022, 37, 1859-1865.	0.5	3
1201	Immune checkpoint inhibitors for solid organ transplant recipients: clinical updates. <i>Korean Journal of Transplantation</i> , 2022, 36, 82-98.	0.0	9
1202	A Prospective Study to Detect Immune Checkpoint Inhibitors Associated With Myocarditis Among Patients Treated for Lung Cancer. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, .	1.1	4
1203	Major Adverse Cardiac Events With Immune Checkpoint Inhibitors: A Pooled Analysis of Trials Sponsored by the National Cancer Instituteâ€™ Cancer Therapy Evaluation Program. <i>Journal of Clinical Oncology</i> , 2022, 40, 3439-3452.	0.8	24
1204	Cardiotoxicity of anthracyclines and targeted anti-HER2/neu therapy in treatment of oncological patients. , 2022, 2, 63-67.		0
1205	Diagnosis and management of cardiomyopathy and heart failure during cancer treatment. , 2023, , 138-145.		0
1206	Arrhythmia and device assessment during cancer treatments. , 2023, , 175-184.		0
1207	Renal and urinary bladder cancer. , 2023, , 327-335.		0
1208	Hepatobiliary carcinomas. , 2023, , 358-365.		0
1209	Head and neck cancers. , 2023, , 376-382.		0
1210	Cancer therapeutic drug guide. , 2023, , 451-506.		0
1211	Plasma exchange for severe immune-related adverse events from checkpoint inhibitors: an early window of opportunity?. <i>Immunotherapy Advances</i> , 2022, 2, .	1.2	15
1212	Immune Checkpoint Inhibitor-Associated Cardiotoxicity in Solid Tumors: Real-World Incidence, Risk Factors, and Prognostic Analysis. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	8

#	ARTICLE	IF	CITATIONS
1213	Mechanisms underlying immune-related adverse events during checkpoint immunotherapy. <i>Clinical Science</i> , 2022, 136, 771-785.	1.8	2
1214	The Dynamic Role of Cardiac Macrophages in Aging and Disease. <i>Current Cardiology Reports</i> , 2022, 24, 925-933.	1.3	5
1215	“Prevention is better than cure” warning for comedications in patients receiving immune check-point inhibitors to avoid acute kidney injury. <i>CKJ: Clinical Kidney Journal</i> , 0, , .	1.4	0
1216	Immune Checkpoint Inhibitor-Associated Myositis. <i>Journal of Clinical Rheumatology</i> , 2022, 28, 367-373.	0.5	8
1217	Role of cardiac <scp>MRI</scp> in the diagnosis of immune checkpoint inhibitor-associated myocarditis. <i>International Journal of Cancer</i> , 2022, 151, 1860-1873.	2.3	19
1219	Cardiovascular toxicities associated with immune checkpoint inhibitors: An updated comprehensive disproportionality analysis of the FDA adverse event reporting system. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 0, , .	0.7	2
1220	Myocardial Dysfunction in Patients with Cancer. <i>Heart Failure Clinics</i> , 2022, 18, 361-374.	1.0	1
1221	PD-1 inhibitor induces myocarditis by reducing regulatory T cells, activating inflammatory responses, promoting myocardial apoptosis and autophagy. <i>Cytokine</i> , 2022, 157, 155932.	1.4	9
1223	Critical insights into cardiotoxicity of anthracyclines. , 2022, , 103-112.		0
1224	ICIs-Related Cardiotoxicity in Different Types of Cancer. <i>Journal of Cardiovascular Development and Disease</i> , 2022, 9, 203.	0.8	11
1225	<scp>AGS</scp> and <scp>NIA</scp> bench-to bedside conference summary: Cancer and cardiovascular disease. <i>Journal of the American Geriatrics Society</i> , 2022, 70, 2764-2774.	1.3	4
1226	(Immune Checkpoint Inhibitor Myocarditis: Current Views on Diagnosis and Treatment). <i>Cor Et Vasa</i> , 2022, 64, 310-315.	0.1	0
1227	Incidence of Cardiovascular Events in Patients Treated With Immune Checkpoint Inhibitors. <i>Journal of Clinical Oncology</i> , 2022, 40, 3430-3438.	0.8	29
1228	Ipilimumab- and nivolumab-induced myocarditis in a patient with metastatic cholangiocarcinoma: a case report. <i>Journal of Medical Case Reports</i> , 2022, 16, .	0.4	4
1229	Multi-organ Immune-Related Adverse Event Is a Risk Factor of Immune Checkpoint Inhibitor-Associated Myocarditis in Cancer Patients: A Multi-center Study. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	9
1230	Acute Myocarditis Following Methimazole: A Case Report. <i>Clinical Therapeutics</i> , 2022, , .	1.1	1
1231	Risk factors and predictors of immune-related adverse events: implications for patients with non-small cell lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 861-874.	1.1	6
1232	The Therapeutic Potential of Carnosine as an Antidote against Drug-Induced Cardiotoxicity and Neurotoxicity: Focus on Nrf2 Pathway. <i>Molecules</i> , 2022, 27, 4452.	1.7	19

#	ARTICLE	IF	CITATIONS
1233	Incidence of immune checkpoint inhibitor mediated cardiovascular toxicity: A systematic review and meta-analysis. <i>European Journal of Clinical Investigation</i> , 2022, 52, .	1.7	7
1234	Ly6C ^{hi} monocytes balance regulatory and cytotoxic CD4 T cell responses to control virus-induced immunopathology. <i>Science Immunology</i> , 2022, 7, .	5.6	7
1235	HBV cccDNA ⁺ Culprit and Stumbling Block for the Hepatitis B Virus Infection: Its Presence in Hepatocytes Perplexed the Possible Mission for a Functional Cure. <i>ACS Omega</i> , 2022, 7, 24066-24081.	1.6	8
1236	PD1 Deficiency Modifies Cardiac Immunity during Baseline Conditions and in Reperfused Acute Myocardial Infarction. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7533.	1.8	5
1237	Imaging Mass Cytometry Analysis of immune Checkpoint Inhibitor-Related Pneumonitis: A Case Report. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
1238	TNF- α Inhibitors and Other Biologic Agents for the Treatment of Immune Checkpoint Inhibitor-Induced Myocarditis. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	11
1239	Diretriz de Miocardites da Sociedade Brasileira de Cardiologia \hat{a} 2022. <i>Arquivos Brasileiros De Cardiologia</i> , 2022, 119, 143-211.	0.3	14
1240	Newer Cancer Therapies and Perioperative Implications. , 2023, , 56-69.		0
1241	Cardiac Remodelling Following Cancer Therapy: A Review. <i>Cardiovascular Toxicology</i> , 2022, 22, 771-786.	1.1	8
1242	Right ventricular and atrial strain in patients with advanced melanoma undergoing immune checkpoint inhibitor therapy. <i>ESC Heart Failure</i> , 2022, 9, 3533-3542.	1.4	3
1243	Identification of Pathogenic Immune Cell Subsets Associated With Checkpoint Inhibitor-Induced Myocarditis. <i>Circulation</i> , 2022, 146, 316-335.	1.6	43
1244	Imaging features of toxicities associated with immune checkpoint inhibitors. <i>European Journal of Radiology Open</i> , 2022, 9, 100434.	0.7	6
1245	An Immune Checkpoint Inhibitor Heart: How CD45RA ⁺ Effector Memory CD8 ⁺ T Cells (Temra) Are Implicated in Immune Checkpoint Inhibitor Myocarditis. <i>Circulation</i> , 2022, 146, 336-338.	1.6	0
1246	Cardiotoxicity of anticancer drugs and radiotherapy in patients with hematologic malignancies and solid tumors. <i>Oncogematologiya</i> , 2022, 17, 127-136.	0.1	1
1247	C-reactive protein and immune-related adverse events as prognostic biomarkers in immune checkpoint inhibitor treated metastatic renal cell carcinoma patients. <i>Acta Oncologica</i> , 2022, 61, 1240-1247.	0.8	4
1248	Case report of elevation of high-sensitivity cardiac troponin T in the absence of cardiac involvement in immune checkpoint inhibitor-associated myositis. <i>European Heart Journal - Case Reports</i> , 2022, 6, .	0.3	5
1249	Cardiogenic shock among cancer patients. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	3
1250	Echocardiographic and Cardiac MRI Comparison of Longitudinal Strain and Strain Rate in Cancer Patients Treated with Immune Checkpoint Inhibitors. <i>Journal of Personalized Medicine</i> , 2022, 12, 1332.	1.1	1

#	ARTICLE	IF	CITATIONS
1251	Neural Net Modeling of Checkpoint Inhibitor Related Myocarditis and Steroid Response. <i>Clinical Pharmacology: Advances and Applications</i> , 0, Volume 14, 69-90.	0.8	0
1252	Camrelizumab-Related Lethal Arrhythmias and Myasthenic Crisis in a Patient with Metastatic Thymoma. <i>Case Reports in Cardiology</i> , 2022, 2022, 1-6.	0.1	5
1253	NLRP3-mediated inflammation in cardio-oncology: sterile yet harmful. <i>Translational Research</i> , 2023, 252, 9-20.	2.2	7
1254	Activation of Adaptive and Innate Immune Cells via Localized IL2 Cytokine Factories Eradicates Mesothelioma Tumors. <i>Clinical Cancer Research</i> , 2022, 28, 5121-5135.	3.2	8
1255	Checking ovarian reserves after checkpoint blockade. <i>Nature Cancer</i> , 2022, 3, 907-908.	5.7	3
1256	2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). <i>European Heart Journal Cardiovascular Imaging</i> , 2022, 23, e333-e465.	0.5	97
1257	Prospective screening for myocarditis in cancer patients treated with immune checkpoint inhibitors. <i>Journal of Cardiology</i> , 2023, 81, 63-67.	0.8	8
1258	Coronary artery disease and revascularization associated with immune checkpoint blocker myocarditis: Report from an international registry. <i>European Journal of Cancer</i> , 2022, 177, 197-205.	1.3	8
1259	2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). <i>European Heart Journal</i> , 2022, 43, 4229-4361.	1.0	705
1260	Global research trends on precision cancer medicine-related rashes (2008-2021): A bibliographic study. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
1263	Early evaluation of subclinical cardiotoxicity in patients with lung cancer receiving immune checkpoint inhibitors by cardiovascular magnetic resonance: a prospective observational study. <i>Quantitative Imaging in Medicine and Surgery</i> , 2022, 12, 4771-4785.	1.1	2
1264	T2 and T2âŽ mapping and weighted imaging in cardiac MRI. <i>Magnetic Resonance Imaging</i> , 2022, 93, 15-32.	1.0	3
1265	Pathophysiology of Immune Checkpoint Inhibitor-Induced Myocarditis. <i>Cancers</i> , 2022, 14, 4494.	1.7	16
1266	Fatal toxicity induced by anti-PD-1 immune checkpoint inhibitor in thymic epithelial tumor. <i>Immunotherapy</i> , 2022, 14, 1097-1107.	1.0	3
1267	Tislelizumab-related enteritis successfully treated with adalimumab: A case report. <i>World Journal of Clinical Cases</i> , 0, 10, 10186-10192.	0.3	2
1269	Fulminant Myocarditis for Non-small-cell Carcinoma of the Lung with Nivolumab and Ipilimumab Plus Chemotherapy. <i>Internal Medicine</i> , 2023, 62, 1319-1322.	0.3	3
1270	Rheumatology (Arthritis and Myositis). , 2022, , 301-313.		0
1271	Nephrology (Kidney). , 2022, , 197-214.		0

#	ARTICLE	IF	CITATIONS
1272	Immunotherapy Adverse Events. <i>Current Clinical Pathology</i> , 2022, , 25-30.	0.0	0
1273	Management of Patients with Cardiac Toxicity: The Point of View of the Oncologist. <i>Current Clinical Pathology</i> , 2022, , 91-111.	0.0	0
1274	<i>Cardiology (Heart)</i> . , 2022, , 7-27.		0
1275	Cardiac Risk Factors for Immunotherapy. <i>Current Clinical Pathology</i> , 2022, , 45-50.	0.0	0
1276	Management of Patients with Cardiac Toxicity: The Point of View of the Cardiologist. <i>Current Clinical Pathology</i> , 2022, , 73-89.	0.0	0
1277	Intracellular Cardiac Signaling Pathways Altered by Cancer Therapies. , 2022, , 111-173.		0
1278	Cardiotoxicity associated with immune checkpoint inhibitors: Current status and future challenges. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	13
1279	Immune-Related Uncommon Adverse Events in Patients with Cancer Treated with Immunotherapy. <i>Diagnostics</i> , 2022, 12, 2091.	1.3	5
1280	Cardiovascular complications of immune checkpoint inhibitors for cancer. <i>European Heart Journal</i> , 2022, 43, 4458-4468.	1.0	30
1281	Severe Immune-Related Adverse Events: A Case Series of Patients Needing Hospital Admission in a Spanish Oncology Referral Center and Review of the Literature. <i>Diagnostics</i> , 2022, 12, 2116.	1.3	1
1282	Overcoming the cardiac toxicities of cancer therapy immune checkpoint inhibitors. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	5
1283	Immune Checkpoint Inhibitor-Induced Myositis/Myocarditis with Myasthenia Gravis-like Misleading Presentation: A Case Series in Intensive Care Unit. <i>Journal of Clinical Medicine</i> , 2022, 11, 5611.	1.0	5
1284	Immune Checkpoint Inhibitor-Induced Myocarditis vs. COVID-19 Vaccine-Induced Myocarditisâ€”Same or Different?. <i>Life</i> , 2022, 12, 1366.	1.1	2
1285	Immune checkpoint inhibitor-induced myocarditis. , 2022, 2, 35-43.		1
1286	Immune checkpoint inhibitors â€œ the revolutionary cancer immunotherapy comes with a cardiotoxic price. <i>Trends in Cardiovascular Medicine</i> , 2024, 34, 71-77.	2.3	6
1287	The role of non-coding RNAs in myocarditis: a narrative review. <i>Annals of Translational Medicine</i> , 2022, 10, 1022-1022.	0.7	0
1289	Immune checkpoint inhibitor therapy increases systemic SDF-1, cardiac DAMPs Fibronectin-EDA, S100/Calgranulin, galectine-3, and NLRP3-MyD88-chemokine pathways. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	20
1290	Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: A Systematic Review. <i>International Journal of Molecular Sciences</i> , 2022, 23, 10948.	1.8	8

#	ARTICLE	IF	CITATIONS
1291	Drug allergy: A 2022 practice parameter update. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 150, 1333-1393.	1.5	131
1292	PD-1 inhibitor therapy causes multisystem immune adverse reactions: a case report and literature review. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
1293	Myocarditis Induced by Immunotherapy in Metastatic Melanoma: Review of Literature and Current Guidelines. <i>Journal of Clinical Medicine</i> , 2022, 11, 5182.	1.0	2
1294	Cardiotoxicity induced by immune checkpoint inhibitor: The complete insight into mechanisms, monitoring, diagnosis, and treatment. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	4
1295	Case Report: Treatment for steroid-refractory immune-related myocarditis with tofacitinib. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	7
1296	Which cardiac parameters best predict the cardiovascular outcomes among patients with anti-PD-1 immunotherapy-induced myocardial injury?. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	1
1297	Immune-Checkpoint Inhibitor (ICI) Resumption After Severe Graft injury in a Heart Transplant Recipient with Nivolumab-Sensitive Metastatic Melanoma and Renal Cell Carcinoma. <i>Journal of Heart and Lung Transplantation</i> , 2022, , .	0.3	1
1298	Diagnosis and management of immune checkpoint inhibitor-associated acute kidney injury. <i>Nature Reviews Nephrology</i> , 2022, 18, 794-805.	4.1	20
1299	Immune checkpoint inhibitor induced myocarditis, myasthenia gravis, and myositis: A case series. <i>Cancer Medicine</i> , 0, , .	1.3	6
1300	Research focus and theme trend on fulminant myocarditis: A bibliometric analysis. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	1
1301	A model-informed approach to assess the risk of immune checkpoint inhibitor-induced autoimmune myocarditis. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	2
1302	Cardiac computed tomographic imaging in cardio-oncology: An expert consensus document of the Society of Cardiovascular Computed Tomography (SCCT). Endorsed by the International Cardio-Oncology Society (ICOS). <i>Journal of Cardiovascular Computed Tomography</i> , 2023, 17, 66-83.	0.7	21
1303	Meeting the Challenges of Myocarditis: New Opportunities for Prevention, Detection, and Intervention: A Report from the 2021 National Heart, Lung, and Blood Institute Workshop. <i>Journal of Clinical Medicine</i> , 2022, 11, 5721.	1.0	3
1304	Current Molecular Combination Therapies Used for the Treatment of Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2022, 23, 11046.	1.8	19
1305	The role of immune checkpoints in cardiovascular disease. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	10
1306	Immune-checkpoint inhibitor use in patients with cancer and pre-existing autoimmune diseases. <i>Nature Reviews Rheumatology</i> , 2022, 18, 641-656.	3.5	37
1307	Diagnosis and Differential Diagnosis of Fulminant Myocarditis. , 2022, , 197-206.		0
1308	Etiology and Pathogenesis of Fulminant Myocarditis. , 2022, , 27-42.		0

#	ARTICLE	IF	CITATIONS
1309	Pathophysiology and Mechanisms of Fulminant Myocarditis. , 2022, , 43-64.		0
1310	What Causes Death in Esophageal Cancer Patients Other Than the Cancer Itself: A Large Population-Based Analysis. Journal of Cancer, 2022, 13, 3485-3494.	1.2	2
1311	Targeting Inflammation in the Diagnosis, Management, and Prevention of Cardiovascular Diseases. Global Heart, 2022, 17, .	0.9	5
1312	Neurological adverse events of immune checkpoint blockade: from pathophysiology to treatment. Current Opinion in Neurology, 2022, 35, 814-822.	1.8	4
1313	Teriprizumab-induced myocarditis in a patient with cholangiocarcinoma: a case report. Journal of International Medical Research, 2022, 50, 030006052211332.	0.4	2
1314	The incidence and risk of cardiovascular events associated with immune checkpoint inhibitors in Asian populations. Japanese Journal of Clinical Oncology, 2022, 52, 1389-1398.	0.6	11
1316	Quantitation of cardiac troponin I in cancer patients treated with immune checkpoint inhibitors: a case-control study. Clinical Chemistry and Laboratory Medicine, 2022, .	1.4	0
1317	Rechallenging nivolumab following immune checkpoint inhibitor-induced pericarditis. Baylor University Medical Center Proceedings, 0, , 1-2.	0.2	0
1319	Cardiac Biomarkers for the Detection and Management of Cancer Therapy-Related Cardiovascular Toxicity. Journal of Cardiovascular Development and Disease, 2022, 9, 372.	0.8	6
1321	A case of lymphocytic myocarditis in a patient treated with an immune checkpoint inhibitor, a recent class of chemotherapy agents. Revista Portuguesa De Cardiologia, 2022, , .	0.2	3
1322	Immune Checkpoint Inhibitors Do Not Increase Short-Term Risk of Hypertension in Cancer Patients: a Systematic Literature Review and Meta-Analysis. Hypertension, 2022, 79, 2611-2621.	1.3	16
1323	Electrocardiographic Features of Immune Checkpoint Inhibitor-Associated Myocarditis. Current Problems in Cardiology, 2023, 48, 101478.	1.1	10
1324	Underreporting of Major Cardiac Adverse Events With Immune Checkpoint Inhibitors in Clinical Trials: Importance of Postmarketing Pharmacovigilance Surveys. Journal of Clinical Oncology, 2023, 41, 1154-1156.	0.8	2
1325	Immune Checkpoint Inhibitors Related to Cardiotoxicity. Journal of Cardiovascular Development and Disease, 2022, 9, 378.	0.8	3
1326	Association between immune-mediated adverse events and efficacy in metastatic non-small-cell lung cancer patients treated with durvalumab and tremelimumab. Frontiers in Immunology, 0, 13, .	2.2	1
1327	Applying quantitative CMR parameters for detecting myocardial lesion in immune checkpoint inhibitors-associated myocarditis. European Journal of Radiology, 2022, 156, 110558.	1.2	0
1328	Hormonal therapies up-regulate MANF and overcome female susceptibility to immune checkpoint inhibitor myocarditis. Science Translational Medicine, 2022, 14, .	5.8	13
1329	Cardiotoxicity Induced by Immune Checkpoint Inhibitors: What a Cardio-Oncology Team Should Know and Do. Cancers, 2022, 14, 5403.	1.7	7

#	ARTICLE	IF	CITATIONS
1330	Immune checkpoint inhibitor monotherapy is associated with less cardiac toxicity than combination therapy. PLoS ONE, 2022, 17, e0272022.	1.1	4
1331	Immunotherapy in gynecologic malignancies. , 2023, , 506-520.e7.		0
1332	Prevalence and characteristics of immune checkpoint inhibitor-related myocardial damage: A prospective observational study. PLoS ONE, 2022, 17, e0275865.	1.1	4
1333	T cells specific for Î±-myosin drive immunotherapy-related myocarditis. Nature, 2022, 611, 818-826.	13.7	100
1334	Transthyretin Cardiac Amyloidosis Mimicking Immune Checkpoint-Induced Myocarditis in a Patient Treated with Atezolizumab and Bevacizumab for Advanced Hepatocellular Carcinoma: A Case Report. Case Reports in Oncology, 0, , 967-973.	0.3	0
1335	Myocardial Protection and Current Cancer Therapy: Two Opposite Targets with Inevitable Cost. International Journal of Molecular Sciences, 2022, 23, 14121.	1.8	4
1336	Characterization of immune checkpoint inhibitor-induced cardiotoxicity reveals interleukin-17A as a driver of cardiac dysfunction after anti-PD-1 treatment. British Journal of Pharmacology, 2023, 180, 740-761.	2.7	17
1337	Cardiac arrhythmias associated with immune checkpoint inhibitors: A comprehensive disproportionality analysis of the FDA adverse event reporting system. Frontiers in Pharmacology, 0, 13, .	1.6	3
1339	Cardiac myosin-specific autoimmune T cells contribute to immune-checkpoint-inhibitor-associated myocarditis. Cell Reports, 2022, 41, 111611.	2.9	28
1340	Myocarditis and myositis/myasthenia gravis overlap syndrome induced by immune checkpoint inhibitor followed by esophageal hiatal hernia: A case report and review of the literature. Frontiers in Medicine, 0, 9, .	1.2	5
1341	A Retrospective, Single-Institution Experience of Bullous Pemphigoid as an Adverse Effect of Immune Checkpoint Inhibitors. Cancers, 2022, 14, 5451.	1.7	14
1342	Immune checkpoint inhibitor-related adverse cardiac events in patients with lung cancer: a systematic review and meta-analysis. Cancer Cell International, 2022, 22, .	1.8	5
1343	The Effect of PD-1 Inhibitor Combined with Irradiation on HMGB1-Associated Inflammatory Cytokines and Myocardial Injury. Journal of Inflammation Research, 0, Volume 15, 6357-6371.	1.6	3
1344	Immune checkpoint inhibitor-related myositis and myocarditis with multiple myositis-specific/associated antibodies. Journal of the Neurological Sciences, 2023, 444, 120528.	0.3	3
1345	Hematologic and Oncologic Emergencies. Critical Care Nursing Quarterly, 2023, 46, 100-113.	0.4	0
1346	Current studies and future promises of PD-1 signal inhibitors in cervical cancer therapy. Biomedicine and Pharmacotherapy, 2023, 157, 114057.	2.5	5
1347	Activation of B cells in Tertiary Lymphoid Structures in cancer: Anti-tumor or anti-self?. Seminars in Immunology, 2023, 65, 101703.	2.7	11
1348	Pacemakers and methylprednisolone pulse therapy in immune-related myocarditis concomitant with complete heart block. Open Medicine (Poland), 2022, 17, 2109-2116.	0.6	6

#	ARTICLE	IF	CITATIONS
1349	The spectrum of cardiovascular complications related to immune-checkpoint inhibitor treatment. <i>Cardio-Oncology</i> , 2022, 8, .	0.8	8
1350	The Flip of the Coin of Personalized Cancer Immunotherapy: A Focused Review on Rare Immune Checkpoint Related Adverse Effects. , 0, , .		0
1351	Multisystem immune-related adverse events due to toripalimab: Two cases-based review. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	3
1352	Severe cardiotoxicity in 2 patients with thymoma receiving immune checkpoint inhibitor therapy: A case report. <i>Medicine (United States)</i> , 2022, 101, e31873.	0.4	4
1353	Glomerular diseases after immune checkpoint inhibitors use: What do We know so far?. <i>Renal Failure</i> , 2022, 44, 2058-2067.	0.8	1
1354	Immunogenomic correlates of immune-related adverse events for anti-“programmed cell death 1 therapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
1355	Immunotherapeutic strategies to induce inflection in the immune response: therapy for cancer and COVID-19. <i>Biotechnology and Genetic Engineering Reviews</i> , 0, , 1-40.	2.4	5
1356	Multiple Immunotherapy-Related Cardiovascular Sequelae. <i>CJC Open</i> , 2023, 5, 170-172.	0.7	1
1357	Acetylcholine receptor binding antibody-associated myasthenia gravis, myocarditis, and rhabdomyolysis induced by tislelizumab in a patient with colon cancer: A case report and literature review. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
1358	Anti-PD-1 immune-related adverse events are associated with high therapeutic antibody fixation on T cells. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
1359	Fulminant Cardiotoxicity in a Patient With Cardiac Lymphoma Treated With CAR-T Cells. <i>JACC: CardioOncology</i> , 2022, 4, 708-712.	1.7	2
1360	Comparative risk of acute kidney injury among cancer patients treated with immune checkpoint inhibitors. <i>Cancer Communications</i> , 2023, 43, 214-224.	3.7	5
1361	Cancer Immunotherapy Beyond Checkpoint Blockade. <i>JACC: CardioOncology</i> , 2022, 4, 563-578.	1.7	1
1363	Assessing the risk of cardiovascular events in patients receiving immune checkpoint inhibitors. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	2
1364	Immune Checkpoint Inhibitor Myocarditis and Cellular Rejection in Orthotopic Heart Transplant Recipients. <i>JACC: CardioOncology</i> , 2022, 4, 717-721.	1.7	0
1365	Longitudinal Strain and Troponin I Elevation in Patients Undergoing Immune Checkpoint Inhibitor Therapy. <i>JACC: CardioOncology</i> , 2022, 4, 673-685.	1.7	10
1366	Treatment of rheumatic adverse events of cancer immunotherapy. <i>Best Practice and Research in Clinical Rheumatology</i> , 2022, 36, 101805.	1.4	9
1367	Immune checkpoint inhibitors: acute and chronic cardiovascular complications. <i>Nature Reviews Cardiology</i> , 2023, 20, 73-74.	6.1	3

#	ARTICLE	IF	CITATIONS
1368	Unchecked autoreactive CD8+ T cells wreak havoc in cancer immunotherapy. , 2022, 1, 1111-1113.		2
1369	Immune-related adverse events: A bibliometric analysis. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	10
1370	Biomarkers for Immune Checkpoint Inhibitor-Induced Myocarditis. <i>JACC: CardioOncology</i> , 2022, 4, 701-703.	1.7	1
1371	Late-Onset Immunotherapy-Induced Myocarditis 2 Years After Checkpoint Inhibitor Initiation. <i>JACC: CardioOncology</i> , 2022, 4, 727-730.	1.7	6
1372	The Role of Single-Cell Profiling and Deep Immunophenotyping in Understanding Immune Therapy Cardiotoxicity. <i>JACC: CardioOncology</i> , 2022, 4, 629-634.	1.7	1
1373	Checkpoint inhibitor immune-related adverse events: A focused review on autoantibodies and B cells as biomarkers, advancements and future possibilities. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
1374	Positron emission tomography molecular imaging to monitor anti-tumor systemic response for immune checkpoint inhibitor therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2023, 50, 1671-1688.	3.3	2
1375	Association of immune-related adverse events with the outcomes of immune checkpoint inhibitors in patients with dMMR/MSI-H metastatic colorectal cancer. , 2023, 11, e005493.		3
1376	Immune checkpoint inhibitor-induced myocarditis and myositis in liver cancer patients: A case report and literature review. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
1377	The potential of auto-antigen-guided treatment of immune checkpoint inhibitor-mediated myocarditis. <i>Med</i> , 2023, 4, 13-14.	2.2	0
1378	Corticosteroids and Cancer Immunotherapy. <i>Clinical Cancer Research</i> , 2023, 29, 2580-2587.	3.2	8
1379	Application of Immune Checkpoint Inhibitors in Gynecological Cancers: What Do Gynecologists Need to Know before Using Immune Checkpoint Inhibitors?. <i>International Journal of Molecular Sciences</i> , 2023, 24, 974.	1.8	3
1380	Immunopathogenesis of Immune Checkpoint Inhibitor Induced Myocarditis: Insights from Experimental Models and Treatment Implications. <i>Biomedicines</i> , 2023, 11, 107.	1.4	4
1381	Incidence of adverse cardiovascular events associated with immune checkpoint inhibitors and risk factors for left ventricular dysfunction: A single-center prospective clinical study. <i>Frontiers in Cardiovascular Medicine</i> , 0, 10, .	1.1	6
1382	Cardiotoxicity of Anti-Cancer Radiation Therapy: a Focus on Heart Failure. <i>Current Heart Failure Reports</i> , 2023, 20, 44-55.	1.3	1
1383	A bibliometric analysis of research progress on pharmacovigilance and cancer from 2002 to 2021. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	2
1384	A Patent Review on Cardiotoxicity of Anticancerous Drugs. <i>Cardiovascular and Hematological Agents in Medicinal Chemistry</i> , 2024, 22, 28-39.	0.4	1
1385	Immune Checkpoint Inhibitor-Induced Primary Hyperparathyroidism in a Small-Cell Lung Cancer Patient: A Case Report. <i>Medicina (Lithuania)</i> , 2023, 59, 215.	0.8	2

#	ARTICLE	IF	CITATIONS
1386	Fulminant Myocarditis Complicated with Immune Checkpoint Inhibitor in Patients with Thymoma: Report of Three Cases. <i>International Journal of Cardiovascular Practice</i> , 2023, 7, .	0.2	0
1387	Soluble and cell-based markers of immune checkpoint inhibitor-associated nephritis. , 2023, 11, e006222.		9
1389	Immune Checkpoint Inhibitors in Solid Organ Transplant Recipients With Advanced Skin Cancersâ€”Emerging Strategies for Clinical Management. <i>Transplantation</i> , 2023, 107, 1452-1462.	0.5	7
1390	Immune-related giant cell myocarditis after immune checkpoint inhibitor therapy in a patient with urothelial carcinoma and myasthenia gravis. <i>Journal of Cancer Research and Practice</i> , 2023, 10, 31.	0.2	1
1391	Cardiovascular, Renal and Pulmonary Toxicity of Immune Checkpoint Inhibitors in Cancer: What the GP Should Know. <i>Praxis</i> , 2023, 112, 160-171.	0.2	1
1392	Germline genetic variants are associated with development of insulin-dependent diabetes in cancer patients treated with immune checkpoint inhibitors. , 2023, 11, e006570.		8
1393	Cardiovascular Effects of Immune Checkpoint Inhibitors: More Than Just Myocarditis. <i>Current Oncology Reports</i> , 2023, 25, 743-751.	1.8	2
1394	Cardiotoxicity, Cardioprotection, and Prognosis in Survivors of Anticancer Treatment Undergoing Cardiac Surgery: Unmet Needs. <i>Cancers</i> , 2023, 15, 2224.	1.7	2
1395	Clinical characteristics and management of immune checkpoint inhibitor-related cardiotoxicity: A single-center experience. <i>Frontiers in Cardiovascular Medicine</i> , 0, 10, .	1.1	2
1396	Combination immunomodulation for immune-checkpoint-inhibitor-associated myocarditis. <i>Nature Reviews Clinical Oncology</i> , 2023, 20, 427-428.	12.5	3
1397	Altered plasma exosome miRNAs and novel potential biomarkers in pediatric fulminant myocarditis. <i>Genomics</i> , 2023, 115, 110622.	1.3	1
1398	Combined radiation- and immune checkpoint-inhibitor-induced pneumonitis â€” The challenge to predict and detect overlapping immune-related adverse effects from evolving laboratory biomarkers and clinical imaging. <i>Neoplasia</i> , 2023, 39, 100892.	2.3	1
1400	Implication of the Gut Microbiome and Microbial-Derived Metabolites in Immune-Related Adverse Events: Emergence of Novel Biomarkers for Cancer Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2769.	1.8	7
1401	TCR sequencing: applications in immuno-oncology research. <i>Immuno-Oncology Technology</i> , 2023, 17, 100373.	0.2	3
1402	Myocardial Milieu Favors Local Differentiation of Regulatory T Cells. <i>Circulation Research</i> , 2023, 132, 565-582.	2.0	12
1403	Autoantibody profiles in patients with immune checkpoint inhibitor-induced neurological immune related adverse events. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	11
1404	Autoantibodies involved in primary and secondary adrenal insufficiency following treatment with immune checkpoint inhibitors. <i>Immuno-Oncology Technology</i> , 2023, 17, 100374.	0.2	4
1405	Neuromuscular and cardiac adverse events associated with immune checkpoint inhibitors: pooled analysis of individual cases from multiple institutions and literature. <i>ESMO Open</i> , 2023, 8, 100791.	2.0	3

#	ARTICLE	IF	CITATIONS
1406	Autoantibodies Drive Heart Damage Caused by Concomitant Radiation and PD-1 Blockade. <i>Cancer Immunology Research</i> , 2023, 11, 546-555.	1.6	2
1407	Transcriptomic profiling reveals distinct subsets of immune checkpoint inhibitor induced myositis. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, 829-836.	0.5	14
1408	The mechanism and treatment of targeted anti-tumour drugs induced cardiotoxicity. <i>International Immunopharmacology</i> , 2023, 117, 109895.	1.7	3
1409	Advances in immune checkpoint inhibitors induced-cardiotoxicity. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	2
1410	Abatacept/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis. <i>Cancer Discovery</i> , 2023, 13, 1100-1115.	7.7	40
1411	Phase I Study of a Multivalent WT1 Peptide Vaccine (Galipepimut-S) in Combination with Nivolumab in Patients with WT1-Expressing Ovarian Cancer in Second or Third Remission. <i>Cancers</i> , 2023, 15, 1458.	1.7	3
1412	Soluble CTLA-4 mutants ameliorate immune-related adverse events but preserve efficacy of CTLA-4 and PD-1 targeted immunotherapy. <i>Science Translational Medicine</i> , 2023, 15, .	5.8	4
1413	The interplay between the microbiome and colonic immune system in checkpoint inhibitor therapy. , 0, 2, .		0
1414	Eosinophil and IFN- γ associated with immune-related adverse events as prognostic markers in patients with non-small cell lung cancer treated with immunotherapy. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	7
1415	Current landscape and tailored management of immune-related adverse events. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	1
1416	A retrospective cohort study on the cardiotoxicity incidence rates of immune checkpoint inhibitors for oncology patients. <i>Journal of the Chinese Medical Association</i> , 2023, 86, 499-505.	0.6	8
1417	Emerging trends and hotspots evolution in cardiotoxicity: A bibliometric and knowledge-Map analysis From 2010 to 2022. <i>Frontiers in Cardiovascular Medicine</i> , 0, 10, .	1.1	1
1418	Case report: combination of immune-related thrombocytopenia and myocarditis in Δ° patient treated with immune checkpoint inhibitors for non-small cell lung cancer. <i>Malignant Tumours</i> , 2023, 13, 24-29.	0.1	0
1419	Acute myocarditis with transient myocardial thickening in two oncologic patients treated with anti-CD2 immunotherapy. <i>ESC Heart Failure</i> , 2023, 10, 2090-2093.	1.4	3
1420	Coronary artery disease-associated immune gene RBP1 and its pan-cancer analysis. <i>Frontiers in Cardiovascular Medicine</i> , 0, 10, .	1.1	1
1421	Cardiotoxicity: Importance of biomarkers. <i>Arhiv Za Farmaciju</i> , 2023, 73, 1-16.	0.2	0
1422	Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy. <i>Cancer Cell</i> , 2023, 41, 450-465.	7.7	60
1424	Rheumatic Immune-Related Adverse Events due to Immune Checkpoint Inhibitors – A 2023 Update. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5643.	1.8	7

#	ARTICLE	IF	CITATIONS
1425	Pearls for practice from the 2022 joint task force drug allergy practice parameter. <i>Current Opinion in Pediatrics</i> , 0, Publish Ahead of Print, .	1.0	1
1426	Immune Checkpoint Inhibitor Associated Myocarditis and Cardiomyopathy: A Translational Review. <i>Biology</i> , 2023, 12, 472.	1.3	2
1427	Refractory right ventricular myocarditis induced by immune checkpoint inhibitor despite therapy cessation and immune suppression. <i>Cardio-Oncology</i> , 2023, 9, .	0.8	1
1428	Myocarditis and myasthenia gravis induced by immune checkpoint inhibitor in a patient with relapsed thymoma: A case report. <i>Clinical Case Reports (discontinued)</i> , 2023, 11, .	0.2	1
1429	Myocarditis: causes, mechanisms, and evolving therapies. <i>Expert Opinion on Therapeutic Targets</i> , 2023, 27, 225-238.	1.5	4
1430	Immune checkpoint inhibitors break whose heart? Perspectives from cardio-immuno-oncology. <i>Genes and Diseases</i> , 2024, 11, 807-818.	1.5	4
1431	Clinicopathological classification of immune checkpoint inhibitor-associated myocarditis: possible refinement by measuring macrophage abundance. <i>Cardio-Oncology</i> , 2023, 9, .	0.8	1
1432	Immune Checkpoint Inhibitors-Related Myocarditis: A Review of Reported Clinical Cases. <i>Diagnostics</i> , 2023, 13, 1243.	1.3	9
1433	Toxicitate a cardiacă a inhibitorilor punctelor de control (IPC) utilizate în imunoterapia cancerului. <i>Oncolog-Hematolog Ro</i> , 2023, 1, 23.	0.0	0
1434	Predictive value of CXCL10 for the occurrence of immune-related adverse events in patient with renal cell carcinoma. <i>Microbiology and Immunology</i> , 0, , .	0.7	1
1435	Effects of periodontitis on cancer outcomes in the era of immunotherapy. <i>The Lancet Healthy Longevity</i> , 2023, 4, e166-e175.	2.0	2
1436	Immunopathogenesis and immunomodulatory therapy for myocarditis. <i>Science China Life Sciences</i> , 2023, 66, 2112-2137.	2.3	5
1437	Role of advanced cardiovascular imaging in chemotherapy-induced cardiotoxicity. <i>Heliyon</i> , 2023, 9, e15226.	1.4	3
1439	Value of troponin T versus I in the diagnosis of immune checkpoint inhibitor-related myocarditis and myositis: rechallenge?. <i>ESC Heart Failure</i> , 2023, 10, 2680-2685.	1.4	6
1440	A case of subclinical immune checkpoint inhibitor-associated myocarditis in non-small cell lung cancer. <i>BMC Pulmonary Medicine</i> , 2023, 23, .	0.8	3
1441	Immune checkpoint inhibitor sintilimab-induced lethal myocarditis overlapping with myasthenia gravis in thymoma patient: A case report. <i>Medicine (United States)</i> , 2023, 102, e33550.	0.4	1
1442	Cardiotoxicity of lung cancer-related immunotherapy versus chemotherapy: a systematic review and network meta-analysis of randomized controlled trials. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
1443	Immune Checkpoint Inhibitor-Mediated Cardiovascular Disease: The Dark Side of the Monoclonal Antibody Therapy against Cancer. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2023, 23, .	0.6	1

#	ARTICLE	IF	CITATIONS
1444	PD-1/PD-L1 inhibitors-associated cardiac adverse events: a retrospective and real-world study based on the FDA Adverse Event Reporting System (FAERS). <i>Expert Opinion on Drug Safety</i> , 2024, 23, 257-267.	1.0	0
1445	ICU admission for solid cancer patients treated with immune checkpoint inhibitors. <i>Annals of Intensive Care</i> , 2023, 13, .	2.2	4
1446	Early evaluation of severe immune checkpoint inhibitor-associated myocarditis: a real-world clinical practice. <i>Journal of Cancer Research and Clinical Oncology</i> , 0, , .	1.2	0
1447	Risk Factors for Immune Checkpoint Inhibitor-Mediated Cardiovascular Toxicities. <i>Current Oncology Reports</i> , 2023, 25, 753-763.	1.8	3
1448	Hepatocellular carcinoma (HCC) immunotherapy by anti-PD-1 monoclonal antibodies: A rapidly evolving strategy. <i>Pathology Research and Practice</i> , 2023, 247, 154473.	1.0	1
1449	Immune checkpoint inhibitor-associated myocarditis: from pathophysiology to rechallenge of therapy— a narrative review. <i>Future Cardiology</i> , 2023, 19, 91-103.	0.5	6
1450	Evaluating the effect of PD-1 inhibitors on left ventricular function in lung cancer with noninvasive myocardial work. <i>Quantitative Imaging in Medicine and Surgery</i> , 2023, .	1.1	1
1465	Cardiovascular toxicity of checkpoint inhibitors: review of associated toxicity and design of the Spanish Immunotherapy Registry of Cardiovascular Toxicity. <i>Clinical and Translational Oncology</i> , 2023, 25, 3073-3085.	1.2	2
1482	Cardiovascular Toxicity of Immune Checkpoint Inhibitors: A Guide for Clinicians. <i>Drug Safety</i> , 2023, 46, 819-833.	1.4	2
1488	Immune checkpoint biology in health & disease: Immune checkpoint biology and autoimmunity in cancer patients. <i>International Review of Cell and Molecular Biology</i> , 2024, , 181-206.	1.6	0
1509	Perikardierkrankungen. <i>Springer Reference Medizin</i> , 2023, , 1-13.	0.0	0
1511	Akkermansia muciniphila: a potential booster to improve the effectiveness of cancer immunotherapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 13477-13494.	1.2	2
1527	Role of echocardiography in patients treated with immune checkpoints inhibitors. <i>Journal of Echocardiography</i> , 0, , .	0.4	0
1535	Advances of autoimmune rheumatic diseases related to malignant tumors. <i>Inflammation Research</i> , 0, , .	1.6	0
1550	Case Report: A Presentation of Early-Onset Immune-Mediated Bullous Pemphigoid in a Patient with Urothelial Cancer. <i>Current Oncology</i> , 2023, 30, 7802-7809.	0.9	1
1571	<i>Pediatric Cardio-Oncology</i> . , 2023, , 1-18.		0
1578	Natural cationic polymer-derived injectable hydrogels for targeted chemotherapy. <i>Materials Advances</i> , 2023, 4, 6064-6091.	2.6	1
1582	Nanotechnology Potent Photothermal and Photodynamic Immunotherapies of Cancer. <i>Journal of Medical and Biological Engineering</i> , 0, , .	1.0	0

#	ARTICLE	IF	CITATIONS
1604	Immune Checkpoint Inhibition. , 2024, , 1-91.		0
1608	Perikarderkrankungen. Springer Reference Medizin, 2023, , 409-421.	0.0	0
1615	New Concepts in Cardio-Oncology. Cancer Treatment and Research, 2023, , 303-341.	0.2	0
1629	The cardiac-related adverse events of PD-1/PD-L1 immunotherapy in advanced or metastatic lung cancer: a RCT-based meta-analysis. Supportive Care in Cancer, 2024, 32, .	1.0	0
1635	Case Report: Temporary pacing using active fixation lead and invasive electrophysiology studies for immune checkpoint inhibitor associated reversible advanced atrioventricular block. Frontiers in Cardiovascular Medicine, 0, 11, .	1.1	0
1639	Chinese Society of Cardiology guidelines on the diagnosis and treatment of adult fulminant myocarditis. Science China Life Sciences, 0, , .	2.3	0
1642	Clinical and translational attributes of immune-related adverse events. Nature Cancer, 0, , .	5.7	0
1663	Case report: A case of metastatic BRAFV600-mutated melanoma with heart failure treated with immune checkpoint inhibitors and BRAF/MEK inhibitors. Frontiers in Oncology, 0, 14, .	1.3	0